Longitudinal investigation of vaccine specific antibody levels and cellular markers of adaptive immune responses in HIV Exposed Uninfected (HEU) and Unexposed (UE) infants by Naidoo, Shalena
  
LONGITUDINAL INVESTIGATION OF VACCINE SPECIFIC 
ANTIBODY LEVELS AND CELLULAR MARKERS OF ADAPTIVE 
IMMUNE RESPONSES IN HIV EXPOSED UNINFECTED (HEU) 
AND UNEXPOSED (UE) INFANTS 
by  
Shalena Naidoo 
 
 
Thesis presented in fulfilment of the requirements for the degree Master of Science 
in Medical Science at the University of Stellenbosch 
 
 
Supervisor 
Dr Corena de Beer 
 
Co-supervisors 
 Dr Monika Esser 
Dr Hayley Ipp 
 
Faculty of Health Sciences 
Department of Pathology 
Division of Medical Microbiology and Immunology 
 
March 2012
i 
 
DECLARATION 
 
By submitting this thesis/dissertation, I declare that the entirety of the work contained 
therein is my own, original work, that I am the sole author thereof (save to the extent 
explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch 
University will not infringe any third party rights and that I have not previously in its 
entirety or in part submitted it for obtaining any qualification. 
 
______________________ 
Signature 
 
 
 
 
______________________ 
Shalena Naidoo 
 
 
 
 
09 December 2011 
Date 
 
 
Copyright © 2011 University of Stellenbosch 
 
All rights reserved 
 
Stellenbosch University  http://scholar.sun.ac.za
ii 
 
SUMMARY 
Background: In South Africa alone, 30% of women of child-bearing age are infected with 
HIV. With the increasing focus and success of prevention of mother-to-child transmission 
(PMTCT) programmes, an estimated 300 000 infants are born exposed to HIV every year. 
The underlying impact of in utero HIV exposure on infant immune health has not been 
extensively characterised. Clinical follow-up of these HIV-exposed uninfected (HEU) infants 
reveals increased infectious morbidity and mortality compared to their unexposed (UE) 
counterparts. 
Objectives: (i) To evaluate and characterise adaptive immune properties by measuring 
vaccine-specific antibody levels in children from 2 weeks to 2 years of age in the presence 
and absence of maternal HIV infection. (ii) To investigate specific cellular markers of immune 
activation, immune regulation, apoptosis and B cell memory on T and B cell populations in 
HEU and UE children measured at 18 and 24 months of age.  
Methods: This sub-investigation formed part of a collaborative pilot study between the 
universities of British Columbia (Vancouver, Canada) and Stellenbosch. A total of 95 HIV-
positive and HIV-negative mothers were recruited after delivery at Tygerberg Hospital, and 
signed informed consent for their infants to be included in the study. Of these infants, only 27 
HEU and 30 UE infants were eventually enrolled and followed up at various time points, 
starting at two weeks of age. Four of these infants were confirmed to be HIV-positive at 2 
weeks and clinically followed up according to the protocol, but were excluded from statistical 
data analyses.  
Blood was collected at 2, 6 and 12 weeks and again at 6, 12, 18 and 24 months of age. 
Quantitative IgG-specific antibodies to Haemophilus influenzae B (Hib), Bordetella pertussis, 
tetanus and pneumococcus were measured at each time point, using commercially available 
ELISA (Enzyme-Linked ImmunoSorbent) kits. Cellular markers of immune activation, 
immune regulation, apoptosis and memory were measured in various populations of T and B 
cells at 18 and 24 months only, by using four-colour flow cytometry and validated whole-
blood staining methods. In addition, a functional assay was developed to evaluate cell 
susceptibility to apoptosis (spontaneously) by measuring the expression of Annexin V on 
both CD4+ T and CD20+ B cells after 16 and 24-hour incubation periods.  
The statistical analysis of the antibody data was conducted by repeated-measures ANOVA 
(i.e. analysis of variance), using a mixed-model approach. Differences in the expression of 
the two groups’ cellular markers were compared by employing one-way ANOVA. An F test p 
value (which assumes normality) was reported, while the non-parametric Mann-Whitney U 
test served as confirmatory tool. Repeated-measures ANOVA was used for the evaluation of 
the functional spontaneous apoptosis assay at three time points (ex vivo, 16 and 24 hours) 
on the 18-month samples, while one-way ANOVA was used for the 24-month samples. 
Results: The HEU group (n = 23) displayed significantly lower levels of antibodies to 
pertussis (20.80 vs 28.01 Food and Drug Administration [FDA] U/ml; p = 0.0237), tetanus 
(0.08 vs 0.53 IU/ml; p < 0.001) and pneumococcus (31.67 vs 80.77 mg/l; p = 0.003) than the 
UE group (n = 23) at 2 weeks of age. No statistical differences were noted for Hib antibody 
levels between the two groups at this time point. At 6 weeks of age, HEU infants displayed 
lower mean levels of all antibodies measured; however, these differences did not reach 
statistical significance.  
Following vaccination, compared to UE controls, the HEU group presented with statistically 
significantly higher antibody levels to pertussis at 6 months (155.49 vs 63.729 FDA U/ml; 
p = 0.0013), 12 months (26.54 vs 8.50 FDA U/ml; p < 0.001) and 18 months of age (1658.94 
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vs 793.03 FDA U/ml; p = 0.0362). A significant difference in tetanus antibody levels between 
the two groups was only evident at 24 months, with the HEU group displaying higher levels 
(3.28 vs 1.70 IU/ml; p = 0.018) than the UE group. No differences were observed between 
the two groups following vaccination for Hib.  
At 18 and 24 months, the HEU group showed increased expression of cellular markers of 
immune activation (CD69 and CD40L) on CD4+ T cells compared to UE controls. The two 
groups showed similar expression of the cellular marker of activation CD38 on CD8+ T cells. 
The HEU group displayed significantly higher levels of CD127, the interleukin (IL) 7 receptor, 
on CD4+ T cells compared to UE controls at 18 months of age. The HEU group also showed 
increased expression of cellular markers of apoptosis on both CD4+ T and CD8+ T cells. No 
statistical significance was noted for the expression of Fas on CD4+ T cells at 18 and 24 
months of age. However, at 24 months, the HEU group showed significantly increased 
expression of FasL on both CD4+ T and CD8+ T cells. During cell culture experiments, the 
HEU group displayed increased susceptibility to spontaneous apoptosis shown by increased 
Annexin V expression on CD4+ T cells after a 16-hour incubation period at both 18 and 24 
months. At 18 and 24 months, no difference was noted in the two groups’ immune regulation 
as measured by the expression of CTLA-4.  
The HEU group displayed increased levels of the cellular markers of immune activation 
CD80 on CD20+ B cells at 18 and 24 months of age. The HEU group also showed 
significantly increased levels of CD69 on CD19+ B cells at 24 months. No statistical 
significance was reached for the expression of CD62L and CD10 at either 18 or 24 months. 
Although the HEU group displayed increased levels of apoptosis (Fas) on CD20+ B cells, no 
statistical significance was reached at 18 or 24 months of age. In addition, the HEU group 
showed no difference in the expression of programmed death 1 (PD-1) at 18 and 24 months. 
HEU and UE groups showed similar expression of Annexin V after 16 hours of incubation in 
the 18 and 24-month samples. The expression of the biomarker of B cell memory CD27 on 
CD20+ B and CD19+ B cells was comparable between the two groups at both time points.  
Conclusion: At 2 and 6 weeks, lower mean antibody responses in HEU infants suggest 
poor placental transfer due to maternal HIV infection, while increased responses to specific 
antibodies may reflect an exaggerated immune response to immunisation. These robust 
responses may be due to the lack of competition with maternal antibodies, or may be 
ascribed to indirect stimulation of B cells via the activation of T cells.  
A hyper-inflammatory state is an imminent danger, with increased expression of cellular 
markers of immune activation and apoptosis that may be consistent with early HIV exposure 
that persists following infancy. These observations may serve as contributing factors to the 
extensively documented increased susceptibility to infections in the HEU population. 
Although these findings are consistent with a primed immune system, larger studies are 
required to confirm these observations in relation to clinical outcomes and to assess further 
whether these differences persist in later years. 
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OPSOMMING 
Agtergrond: In Suid-Afrika alleen het 30% van vroue van ŉ vrugbare leeftyd MIV. Met die 
toenemende fokus en sukses van programme vir die voorkoming van moeder-na-kind-
oordrag (sogenaamde PMTCT-programme) word ongeveer 300 000 babas jaarliks aan MIV 
blootgestel. Die onderliggende impak van intra-uteriene MIV-blootstelling op ŉ baba se 
immuunstelsel is nog nie omvattend beskryf nie. Kliniese opvolgondersoeke van hierdie 
MIV-blootgestelde dog onbesmette babas (sogenaamde HEU’s) dui op ŉ hoër siekte- en 
sterftesyfer weens infeksies as hul nieblootgestelde eweknieë (sogenaamde UE’s). 
Doelstellings: (i) Om kinders met MIV-positiewe en MIV-negatiewe moeders se aangepaste 
(verworwe) immuuneienskappe te beoordeel en te beskryf deur hulle vaksienspesifieke 
teenliggaamvlakke vanaf die ouderdom van twee weke tot twee jaar te meet. (ii) Om 
ondersoek in te stel na bepaalde sellulêre merkers van immuunaktivering, 
immuunregulering, apoptose en B-selgeheue by die T- en B-selgroepe van sowel HEU’s as 
UE’s op die ouderdom van 18 en 24 maande. 
Metodes: Hierdie subondersoek het deel uitgemaak van ŉ samewerkende loodsondersoek 
tussen die universiteite van Brits-Columbië (Vancouver, Kanada) en Stellenbosch. Altesaam 
95 MIV-positiewe en MIV-negatiewe moeders is gewerf nadat hulle by Tygerberghospitaal 
geboorte geskenk het, en het ingeligte toestemming verleen dat hul babas by die studie 
ingesluit kon word. Van dié babas is slegs 27 HEU’s en 30 UE’s uiteindelik in die studie 
opgeneem en in verskillende stadia vanaf die ouderdom van twee weke opgevolg. Vier van 
die babas is op twee weke as MIV-positief bevestig en volgens die protokol klinies opgevolg, 
maar is van die statistiese dataontleding uitgesluit. 
Bloedmonsters is op twee, ses en 12 weke en weer op ses, 12, 18 en 24 maande geneem. 
Kwantitatiewe IgG-spesifieke teenliggame teen Haemophilus influenzae B (Hib), Bordetella 
pertussis, tetanus en pneumokokkus is telkens met behulp van kommersieel verkrygbare 
ELISA- (“Enzyme-Linked ImmunoSorbent”-)stelle bepaal. Sellulêre merkers van 
immuunaktivering, immuunregulering, apoptose en geheue is op slegs 18 en 24 maande by 
verskillende populasies T- en B-selle deur middel van ŉ vierkleurvloeisitometrie en geldig 
verklaarde volbloedkleuringsmetodes bepaal. Voorts is ŉ funksionele toets ontwikkel om 
selvatbaarheid vir apoptose te bepaal deur die ekspressie van Annexin V op sowel CD4+ T- 
as CD20+ B-selle ná 16 en 24 uur van inkubasie te meet. 
Die statistiese ontleding van die teenliggaamdata is met behulp van herhaaldemetings-
ANOVA (d.w.s. afwykingsontleding) volgens ŉ gemengdemodel-benadering gedoen. 
Verskille in die twee groepe se sellulêre merkervlakke is deur middel van eenrigting-ANOVA 
vergelyk. ŉ F-toets-p-waarde (wat normaliteit veronderstel) is bereken, terwyl die 
nieparametriese Mann-Whitney-U-toets as bevestigende instrument gedien het. Vir die 18 
maande-monsters is herhaaldemetings-ANOVA gebruik om die funksionele toets vir 
spontane apoptose in drie stadia (ex vivo, op 16 uur en op 24 uur) te beoordeel. Vir die 24 
maande-monsters is eenrigting-ANOVA gebruik. 
Resultate: Op die ouderdom van twee weke het die groep HEU’s (n = 23) aansienlik laer 
teenliggaamvlakke teen kinkhoes (20.80 vs 28.01 Food and Drug Administration [FDA] U/ml; 
p = 0.0237), tetanus (0.08 vs 0.53 U/ml; p < 0.001) en pneumokokkus (31.67 vs 80.77 mg/l, 
p = 0.003) as die UE-groep (n = 23) getoon. In dié stadium is geen statistiese verskille in 
Hib-teenliggaamvlakke tussen die twee groepe opgemerk nie. Op ses weke het die groep 
HEU’s laer gemiddelde vlakke van ál die betrokke teenliggame getoon, hoewel hierdie 
verskille nie statisties beduidend was nie. 
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In vergelyking met die UE-kontrolegroep het die groep HEU’s ná inenting statisties 
beduidend hoër teenliggaamvlakke teen kinkhoes getoon op ses maande (155.49 vs 63.729 
FDA U/ml; p = 0.0013), 12 maande (26.54 vs 8.50 FDA U/ml; p < 0.001) én 18 maande 
(1658.94 vs 793.03 FDA U/ml; p = 0.0362). ŉ Beduidende verskil in die twee groepe se 
tetanus-teenliggaamvlakke het eers op 24 maande geblyk, met die groep HEU’s s’n hoër 
(3.28 vs 1.70 IE/ml; p = 0.018) as die UE’s s’n. Ná inenting teen Hib is geen verskille tussen 
die twee groepe waargeneem nie. 
Op 18 en 24 maande het die HEU’s verhoogde ekspressie van sellulêre merkers van 
immuunaktivering (CD69 en CD40L) op CD4+ T-selle getoon in vergelyking met die UE-
kontrolegroep. Soortgelyke vlakke van die sellulêre merker van aktivering CD38 is ook op 
die CD8+ T-selle van die twee groepe opgemerk. Op 18 maande het die HEU-groep ŉ 
beduidend verhoogde ekspressie van CD127, die IL-7-reseptor, op CD4+ T-selle getoon in 
vergelyking met die UE-kontrolegroep. Die HEU groep het ook verhoogde ekspressie van 
sellulêre merkers van apoptose op sowel CD4+ T- as CD8+ T-selle getoon. FAS-ekspressie 
op CD4+ T-selle op 18 en 24 maande was nie statisties beduidend nie, hoewel die HEU-
groep op 24 maande beduidend verhoogde ekspressie van FasL op CD4+ T- sowel as 
CD8+ T-selle getoon het. In selkwekingseksperimente het die HEU-groep ŉ verhoogde 
vatbaarheid vir apoptose getoon na aanleiding van die ekspressie van Annexin V op CD4+ 
T-selle ná 16 uur van inkubasie op sowel 18 as 24 maande. Op 18 en 24 maande was 
immuunregulering, aan die hand van die ekspressie van CTLA-4, bykans dieselfde by albei 
groepe. 
Op sowel 18 as 24 maande toon die HEU’s verhoogde ekspressie van die sellulêre merker 
van immuunaktivering CD80 op CD20+ B-selle. Op 24 maande het die HEU’s ook aansienlik 
hoër vlakke van CD69 by CD19+ B selle getoon. Op nóg 18 nóg 24 maande was die 
ekspressie van CD62L en CD10 statisties beduidend. Hoewel verhoogde vlakke van 
apoptose (Fas) by CD20+ B-selle by die HEU-groep opgemerk is, was dit nie statisties 
beduidend op 18 óf 24 maande nie. Daarbenewens was daar ook geen verskil in die 
ekspressie van geprogrammeerde seldood 1 (PD-1) op 18 en 24 maande nie. Op 18 en 24 
maande het die HEU’s en UE’s ŉ soortgelyke ekspressie van Annexin V ná 16 uur van 
inkubasie getoon. Op sowel 18 as 24 maande was die twee groepe se ekspressie van die 
biomerker van B-selgeheue CD27 op CD20+ B- en CD19+ B-selle vergelykbaar. 
Gevolgtrekking: Op twee en ses weke dui laer gemiddelde teenliggaamreaksies by HEU’s 
op swak plasentale oordrag weens die moeder se MIV-infeksie, terwyl verhoogde reaksies 
op bepaalde teenliggame weer op oordrewe immuunreaksie op inenting dui. Hierdie 
robuuste reaksie kan toegeskryf word aan die gebrek aan mededinging met die moeder se 
teenliggame, of kan deur indirekte stimulasie van die B-selle via die aktivering van die T-
selle veroorsaak word. 
ŉ Hiperinflammatoriese toestand is ŉ dreigende gevaar, met verhoogde ekspressie van 
sellulêre merkers van immuunaktivering en apoptose wat met vroeë MIV-blootstelling met ŉ 
latere nawerking verbind kan word. Hierdie waarnemings kan bydraende faktore wees tot 
HEU’s se goed gedokumenteerde verhoogde vatbaarheid vir infeksies. Hoewel hierdie 
bevindings met ŉ geaktiveerde immuunstelsel strook, moet groter studies dit aan die hand 
van kliniese uitkomste bevestig en ook bepaal of hierdie verskille in later jare voortduur. 
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“Do all you can with what you have, in the time you have, in the 
place you are…” 
 
Nkosi Johnson 
(1989-2001) 
International AIDS Conference in Durban, South Africa, July 9, 2000 
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CHAPTER 1 
INTRODUCTION 
 
In 2010, approximately 21 000 children under the age of 5 years died each day. Sub-
Saharan Africa currently experiences the highest rates of child mortality, where 1 in every 8 
children dies before their fifth birthday. Here, compared to the developed world, childhood 
mortality is about 17 times greater (UNICEF, 2011). 
In the year 2000, the top five causes of death in children under the age of 5 years featured 
HIV/AIDS in first place, followed by low birth weight, diarrhoeal diseases, lower respiratory 
tract infections and malnutrition (Bradshaw et al., 2003). In 2009, approximately 5.6 million 
people were living with HIV/AIDS in South Africa which is believed to be more than in any 
other country (UNAIDS, 2010).  About 1 in 3 women between the ages of 25 and 29 were at 
increased risk for infection in 2008 (Shisana et al., 2009). UNAIDS (2010) reported that in 
East and Southern Africa about 68% of pregnant women living with HIV were receiving 
antiretroviral (ARV) treatment for the prevention of HIV transmission to their infants.   
The risk of transmitting HIV from an infected mother to her infant is around 30% in the 
absence of PMTCT programmes. However, with comprehensive interventions, the rate of 
infection is decreased to less than 5% (De Cock et al., 2000). With improved access to ARV 
therapy and PMTCT programmes, 300 000 infants are born annually HIV exposed but 
remain HIV uninfected (HEU) (Bobat et al., 1996). 
Despite their HIV negative status, documentation is accumulating on increased infectious 
morbidity and mortality in this group of infants, consequently classifying them as a vulnerable 
population (Marinda et al., 2007, Filteau, 2009, Kuhn et al., 2007, Thea et al., 1993).  
Compared to their unexposed (UE) counterparts, HEU infants show a greater mortality rate 
(Newell et al., 2004). In addition, a number of studies have observed increased events of 
severe infections in HEU infants such as lower respiratory tract infections, meningitis, acute 
bronchiolitis, cytomegalovirus (CMV) as well as increased incidence of group B 
Streptococcal infection (Slogrove et al., 2009, McNally et al., 2007, Mussi-Pinhata et al., 
2010, Bates et al., 2008, Epalza et al., 2010). Furthermore, haematological abnormalities 
have been reported due to ARV exposure during foetal development as well as early 
infancy, therefore further highlighting the need for clinical follow-up during both pregnancy 
and early infancy (El Beitune and Duarte, 2006).  
The reasons for the increased incidence of morbidity and mortality in HEU infants have not 
yet been defined clearly; however, they are believed to be multi-factorial. Contributing factors 
include low birth weight, reduced breastfeeding, ARV exposure, poor growth and nutrition, 
maternal disease severity, decreased acquisition of maternal antibodies and inadequate 
infant care (Filteau, 2009).  
Several immune abnormalities have been described in infants and children born to HIV 
positive mothers. Differences in the proportions of T cell populations, as well as reduced 
CD4/CD8 ratios and decreased CD8+ naïve T cell percentages have been observed (Clerici 
et al., 2000). Other studies have documented lower progenitor cells and decreased thymus 
outputs (Nielsen et al., 2001). 
During in utero development the growing foetus comes into contact with HIV viral particles. 
These particles serve as inducers of increased levels of immune activation, as well as 
apoptosis (Nielsen et al., 2001, Miyamoto et al., 2010). Increased levels of CD40L on 
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activated lymphocytes have been reported (Romano et al., 2006), as well as increased B cell 
apoptosis (Miyamoto et al., 2010). 
Furthermore, the persistence of immune abnormalities due to HIV and ARV exposure 
beyond infancy and differences in even HEU adolescents have been documented (Miyamoto 
et al., 2010, Clerici et al., 2000). However, due to fact that HIV mainly uses CD4+ T 
lymphocytes as an entry point to invasion of the immune system, research has concentrated 
more on evaluating abnormalities of the T cell compartment and less on dysfunctions of B 
lymphocyte sub-populations (Clerici et al., 2000).  
A number of B cell abnormalities have been documented with HIV infection, some of which 
include hypergammaglobulinemia, polyclonal activation, as well as autoimmunity (De Milito, 
2004). Abnormal levels of IgG that persist in HEU infants from birth until 24 months of age 
suggest an altered humoral immune response (Bunders et al., 2010).  
Vaccination is considered the most cost effective tool for preventing disease in the 
population at large; however, only a few studies have addressed the impact of HIV exposure 
on infant vaccination response (Abramczuk et al., 2011, Jones et al., 2011, Madhi et al., 
2005). Currently HIV exposed infants receive the same vaccine schedule as the unexposed. 
Considering that their immune system develops in a different antigenic environment due to 
maternal HIV infection, it merits further investigation to evaluate HEU vaccination responses.  
The above studies have shown that HEU infants mount significantly different responses to 
certain vaccines. In comparison to UE controls, the response to vaccination is more robust 
and is believed to be a result of reduced passive specific maternal antibody levels at birth, 
thus allowing for less antibody interference (Madhi et al., 2005, Jones et al., 2011). Although 
these studies highlight significant differences and trends in vaccine specific responses in 
HEU infants, they have mainly evaluated responses to primary vaccination and not of follow-
up immunisation through longitudinal studies. In addition, potential immunological 
differences, such as lymphocyte functionality as reasons for weak or heightened responses 
to certain vaccines need to be investigated (Abramczuk et al., 2011). 
In an attempt to address the immunological differences that exist within HEU and UE infants 
as potential contributing factors to the increased events of morbidity and mortality, we 
evaluated and described specific properties of the adaptive immune system. Vaccine 
specific IgG levels in HEU infants and UE controls were investigated as part of a longitudinal 
study from 2 weeks to 2 years of age. We hypothesised that infants born to HIV positive 
mothers respond differently to specific vaccinations of the scheduled Expanded Programme 
on Immunisation of South Africa (EPI-SA), due to increased antigenic exposure, decreased 
maternal antibody levels and differs according to the type of immunology required to mount 
responses to certain vaccines. 
We further evaluated aspects of immune activation, regulation and apoptosis on both T and 
B cells by measuring the expression of various cellular markers of immune activation at 18 
and 24 months of age at a time of observed decrease of vulnerability to infection (after the 
first 6 months). We also evaluated the expression of a cellular marker of B cell memory.  
We hypothesised that HEU infants display increased levels of immune activation and 
apoptosis due to increased antigenic and ARV exposure on both T and B cell components of 
the adaptive immune system that may persist into late infancy potentially indicating long-
term immunological differences. In addition, we hypothesised that HEU infants present with 
decreased levels of B cell memory as a result of increased apoptosis.  
This study will therefore add valuable insight and baseline knowledge of the longitudinal 
vaccine specific antibody response of HEU infants that will serve as groundwork for larger 
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cohort studies. Furthermore, this study will address the long-term effects of HIV exposure on 
immune health and provide evidence that will coerce the need to enhance follow-up clinical 
evaluation of HEU infants.  
A detailed understanding of mechanisms that account for the increased incidence of 
infectious morbidity and mortality in HEU infants is still missing. Therefore addressing 
potential immune mechanisms to structure appropriate strategies to improve the quality of 
life in the growing HEU population is relevant to the South African setting, a country with one 
of the most severe burdens related to the HIV pandemic.  
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2.1 OVERVIEW OF THE IMMUNE SYSTEM 
Our immune systems are constantly challenged with infectious agents (pathogens) that may 
lead to disease and if not effectively controlled, may result in death. The ability of the human 
body to respond to infection and maintain resistance to infectious diseases is termed 
immunity. The synchronized reaction of cells, tissues and organs to the invasion of 
pathogenic elements is defined as the immune response. Therefore, the principle function of 
the immune system is to prevent and eliminate established infections, thereby preventing 
illness and fatality (Abbas and Lichtman, 2006-2007) 
The defence mechanisms of the host comprises of two types of immunity: (1) Innate and (2) 
Adaptive. Innate immunity is the first protective mechanism against infections and the 
adaptive is described as a rather slow, but more specific and specialised response to 
infection (Abbas and Lichtman, 2006-2007). The specific properties of each of these immune 
compartments will be further described below with specific focus on the adaptive arm of the 
immune system. 
2.1.1. Innate immunity 
Innate immunity, also known as natural or native immunity, forms part of the early barriers of 
protection. Mechanisms of this type of protection detect and destroy pathogens rapidly and 
do not rely on clonal expansion of antigen-specific lymphocytes (adaptive immunity) (Murphy 
et al., 2008).  
The innate immune system serves well in warning the adaptive immune arm of the invasion 
of pathogens, thereby provoking the initiation of effective immune responses. Innate immune 
responses provide secondary signals for the activation of cells of the adaptive immune 
system, such as B and T lymphocytes (Murphy et al., 2008).  
Native immunity plays a key role in controlling infection whilst the adaptive immune arm 
prepares for defence. Most organisms have evolved to overcome the defences of early 
immunity, therefore prompting the need for specialised defences. The difference in adaptive 
compared to innate immunity lies in its specificity in antigen recognition. 
2.1.2. Adaptive immunity 
Adaptive immune responses develop over the life course of an individual in response to 
infections with specific pathogens. In contrast to innate immune responses, adaptive 
immunity is more specific and results in the generation of immunological long-term memory 
that offers protection against re-infection. Adaptive immune responses are classified as a 
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more specialised response to infection, thus making any human more vulnerable to disease 
if they have defects in this immune compartment (Alberts et al., 2002). 
Another specialised feature of adaptive immunity is its ability to avoid damaging responses 
against host molecules. In the event that this mechanisms fails, autoimmune diseases will 
occur which may lead to death (Alberts et al., 2002). 
The main properties that contribute to the specialisation of adaptive immunity is listed and 
described in Table 2-1.  
Table 2- 1: Properties of adaptive immunity (Abbas and Lichtman, 2006-2007) 
PROPERTY SIGNIFICANCE FOR IMMUNITY TO MICROBES 
Specificity 
Capable of recognising and responding to various types of 
microorganisms 
Memory Ability to improve response to recurrent or persistent infections 
Clonal Expansion Possess the capacity to compete with rapidly proliferating microbes 
Specialisation 
Responses to distinct microbes are optimized for defence against these 
microbes 
Non-reactivity to self Prevents injurious immune responses against host cells and tissues 
  
2.1.2.1 Cells involved in Adaptive immunity 
Lymphocytes form the basis of adaptive immunity. They play a significant role in defining the 
adaptive immune response and occur in large numbers in the blood and lymph. A large 
portion of lymphocytes are found in lymphoid organs, such as the thymus, lymph nodes and 
spleen (Alberts et al., 2002)  
T and B lymphocytes are the two types of cells that contribute to defining the role of adaptive 
immunity in specificity and memory. T cells develop from the thymus and B cells from the 
bone marrow. However, both these cells are believed to develop from the same common 
lymphoid progenitor cells, which in turn are derived from haemopoietic stem cells that give 
rise to blood cells, such as red and white blood cell types (Alberts et al., 2002).  
In the presence of an antigen, T and B cells become activated, where after they proliferate 
and mature into effector cells. Effector B cells produce molecules called antibodies, which 
then mature into plasma cells. Effector T cells on the other hand, produce a diversity of 
cytokines, which serve as signalling proteins that act as cell mediators. T cells are divided 
into three main classes. The first is cytotoxic T lymphocytes (CTL), which are involved in the 
direct killing of infected host cells. The second class of T cells are T helper (Th) cells, which 
are involved in the activation of cells such as macrophages, dendritic cells (DCs) and B cells. 
Th cell activation occurs via the secretion of cytokines and the presentation of co-stimulatory 
proteins on their surface. The third T cell class are T regulatory (Tregs) or suppressor cells, 
which make use of similar strategies of Th cells and are involved in the control and 
regulation of the immune response (Alberts et al., 2002).  
Th cells are also known as CD4+ T cells. They interact with the major histocompatibility 
complex (MHC) II molecules on antigen presenting cells (APCs), such as DCs, 
macrophages and even B cells. There are two main types of Th cells. The first is Th1 cells, 
which are mainly involved in mediating inflammatory immune responses, and the second is 
Th2 cells, which play a key role in humoral immunity through the activation of B cells (Abbas 
and Lichtman, 2006-2007).  
Cytotoxic T cells express CD8 molecules on their surfaces and are thus referred to as CD8+ 
T cells. These cell types bind to MHC type I molecules that present peptides from 
intracellular organisms, such as viruses, and results in the activation and killing action of 
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CD8+ T cells. The killing action by CTLs results in the release of various toxic molecules, 
such as perforin and granzymes, which induce the process of cell death or apoptosis. In 
addition, CTLs could also induce another pathway that occurs through the expression of Fas 
Ligand (FasL) on the surface of the CTLs, that interacts with Fas on the surface of the target 
cells, ultimately inducing apoptosis (Abbas and Lichtman, 2006-2007). 
There are two forms of adaptive immunity; i.e. cell-mediated immunity and humoral 
immunity. Both forms are mediated by various cells and molecules and are intended to 
provide defence against intra- and extracellular pathogens respectively (Abbas and 
Lichtman, 2006-2007). Each of these responses will be described below.  
2.1.2.2 Cell-mediated immunity 
The role of cell-mediated immunity is to respond to intracellular microorganisms. This type of 
immunity is mediated by T lymphocytes.  
Activation of T lymphocytes by recognition of MHC associated peptides 
The T cell receptor (TCR) is comprised of an α and β chain, which are involved in antigen 
recognition. These receptors recognise displayed peptides and residues located around the 
peptide-binding cleft of MHC molecules located around the peptide-binding cleft. Antigens of 
protein nature from the extracellular environment are taken up into vesicles by APCs, which 
process them into peptides, which are then displayed by MHC class II complexes. Antigens 
that are present within the cytoplasm are processed and displayed by MHC class I 
molecules (Abbas and Lichtman, 2006-2007).  
Each mature MHC restricted T cell expresses either CD4 or CD8 molecules called co-
receptors, as they function with the TCR to bind to MHC molecules. During this time, the 
TCR recognises the MHC complexes that are bound to peptides. CD4+ T cells recognise 
extracellular microbial antigens displayed on MHC class II and CD8+ T cells recognise 
peptides from intracellular microbes displayed by MHC class I molecules (Abbas and 
Lichtman, 2006-2007).  
T cell activation through co-stimulation 
Well-defined co-stimulators of T cells are proteins known as CD80 (B7-1) and CD86 (B7-2) 
which are primarily expressed on professional APCs and whose expression is increased 
during the encounters of APC molecules with microbes. These proteins are recognised by a 
receptor expressed on T cells, called CD28. Signals that are provided by CD28, allow the 
binding of B7 proteins on APCs to T cells. This binding provides signals through the binding 
of T cells and co-receptors to MHC complexes on APCs. The CD28-mediated signals are 
key signals for initiating responses of naïve T cells. In addition, another set of molecules that 
provide increased co-stimulatory signals for T cells are CD40 Ligand (CD40L) that bind to 
CD40 on APCs. This binding stimulates or activates the APCs to express more B7 co-
stimulation and secrete cytokines, such as IL-12, which further enhance T cell differentiation 
(Abbas and Lichtman, 2006-2007).  
On the other hand, CD8+ T cells recognise antigen peptides from cytoplasmic proteins, such 
as viral proteins, in any nucleated cell. CD8+ cytotoxic lymphocytes in certain viral infections 
require the activation of CD4+ helper cells. During these types of infection, infected cells are 
taken up by specific APCs, called DCs, after which viral antigens are then “cross-presented”. 
The same APCs may present viral antigens from the cytosol in MHC I classes. In addition, 
CD4+ T cells may produce cytokines that assist in activating CD8+ T cells that lead to their 
clonal expansion and differentiation into effector and memory CTLs. This type of event may 
explain the defective CTL responses in individuals infected with HIV that result in the 
Stellenbosch University  http://scholar.sun.ac.za
8 
 
destruction of CD4+ T cells and not necessarily the CD8+ T cells. However, other viral 
infections do not seem to require CD4+ T cell assistance (Abbas and Lichtman, 2006-2007).  
The role of cytokines in T cell mediated immunity 
The secretion of various cytokines with diverse functions is mainly produced by CD4+ T cells 
that occur in response to antigens and co-stimulation. These molecules are a large set of 
proteins that function as mediators of immunity and inflammation. Following activation of 
CD4+ T cells, the first cytokine to be produced is IL-2. This cytokine upregulates the ability of 
T cells to increase in numbers and respond to IL-2 by regulating the expression of the IL-2 
receptor. In addition, the key action of IL-2 is to stimulate the proliferation of T cells; 
therefore it is often termed the T cell growth factor (Abbas and Lichtman, 2006-2007). 
However, in comparison to CD4+ T cells, CD8+ T lymphocytes do not produce IL-2 in 
response to antigen stimulation. It is believed that antigen recognition drives the proliferation 
of CD8+ T cells without the requirement of IL-2 (Abbas and Lichtman, 2006-2007).  
Th1 and Th2 cells 
CD4+ helper T cells differentiate into subsets of effector cells that produce distinct sets of 
cytokines that possess various functions. These subsets are divided into Th1 and Th2. 
Th1 cells are mainly involved in mediating inflammatory immune responses via the activation 
of macrophages. The most important cytokine produced by this subset is IFNγ, which serves 
as a potent stimulator of macrophages. In addition, it is also involved in the production of 
antibody isotypes that promote phagocytosis of microbes, as these antibodies bind to Fc 
receptors of phagocytes and activate complement. Furthermore, interferon gamma (IFNγ) 
also stimulates the expression of MHC II molecules and B7 co-stimulators on APCs, thus 
leading to the amplification of T cell responses. Another important cytokine produced by Th1 
cells is the tumour necrosis factor alpha (TNFα) (Abbas and Lichtman, 2006-2007).  
Th2 cells are primarily involved in humoral immunity through the activation of B lymphocytes. 
Cytokines such as IL-10 produced by Th2 cells are involved in the inhibition of 
macrophages. In addition, cytokines such as IL-4 and IL-10 are involved in the 
regulation/suppression of Th1 cell types (Abbas and Lichtman, 2006-2007). 
2.1.2.3 Humoral immunity 
Humoral immunity is mediated by antibodies and function in the elimination of extracellular 
microbes. Humoral immunity is important in defending the host against bacterial capsules 
rich in polysaccharides and lipids (Murphy et al., 2008).  
Introduction to Antibodies 
Antibodies are produced by B lymphocytes and serve as the main mediators of humoral 
immunity through neutralisation and destruction of extracellular microbes (Murphy et al., 
2008).  
The antibody molecule is Y-shaped and found in the components of blood or plasma, as well 
as extracellular fluid. It is composed of two regions: the constant region that holds one of five 
biochemically distinguishable forms, and the variable region that is composed of an unlimited 
variety of different amino acid sequences that vary in structure and allow for antibodies to 
bind to a wide range of antigens (Murphy et al., 2008).  
The binding specificity of the antibody is determined by the variable regions. In an antibody 
molecule there are two identical variable regions that has two identical antigen binding sites 
(Fab region). The constant region contributes to determining the effector function of the 
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antibody molecule that defines how the antibody will destroy the antigen once bound (Fc 
region). In addition, the antibody molecule is composed of two identical heavy and light 
chains, which both contribute to the variable and constant region, thus allowing the molecule 
to have a twofold axis of symmetry. The heavy and light chains of the variable regions 
combine to form the antigen-binding specificity of the antibody molecule (Murphy et al., 
2008).  
Antibody function 
Antibodies can participate in host defence in three main ways: neutralisation, opsonisation 
and complement activation. In addition to the above listed properties, antibodies also serve a 
fourth function which is its participation in the process of dependent cellular cytotoxicity 
where NK cells bind Fc receptors resulting in cell lysis and eventual phagocytosis. 
Antibodies are produced after the stimulation of B lymphocytes by antigens in the peripheral 
lymphocyte organs. B lymphocytes stimulated by antigen then differentiate into antibody 
secreting cells to produce antibodies of different heavy chain classes or isotypes. Isotypes 
then enter the blood and progress towards the sites of infection, as well as the mucosal 
sections, to prevent infection by microbes that enter through the epithelia. This function of 
antibodies allows them to fight infection throughout the body. Some antigen-stimulated B 
lymphocytes differentiate into memory cells that do not secrete antibodies but wait for 
antigen. When encountering these antigens, memory cells subsequently differentiate into 
antibody producing cells, thus providing a large release of antibodies that are more effective 
in fighting infection. These properties of antibodies are utilised during the development of 
vaccines and aims to stimulate the development of long-lived antibody secreting cells and 
memory (Abbas and Lichtman, 2006-2007). 
Immunoglobulin isotopes 
There are a total of five known classes of antibodies, immunoglobulin (Ig) A, IgD, IgE, IgG 
and IgM, each of them possessing their own class of heavy chains (α, δ, ε, γ and µ) 
respectively. IgG and IgA isotypes have various subclasses e.g. IgG1-4 that differ in heavy 
chains. The differing heavy chains give a distinctive conformation to the hinge and tail 
regions of the antibodies so that each class and subclass is unique (Alberts et al., 2002).  
IgG is the main class of immunoglobulin in the blood. It is classified as a four chain monomer 
and is produced in large quantities during secondary antibody responses. The tail of the IgG 
molecules also binds to specific receptors expressed on macrophages and neutrophils by 
means of Fc receptors and in addition, is involved in the activation of the complement 
system (Alberts et al., 2002). 
Antibody responses to the first encounter with the antigen are termed the primary immune 
response. The second response to the same antigen is called the secondary immune 
response. Primary and secondary immune responses differ quantitatively and qualitatively. 
The antibody concentration during the primary response is much smaller than after repeated 
exposure (e.g. immunisation). During secondary responses with protein antigens, an 
increase in heavy chain class switching along with affinity maturation is achieved. This is due 
to the increase in T lymphocyte help. The secondary exposure to antigens results in 
improved capacity of antibodies to bind and neutralise microbial elements (Abbas and 
Lichtman, 2006-2007).  
The course of an antibody response is depicted in Figure 2-1 below: 
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Figure 2- 1: Graphical representation of primary and secondary antibody responses. The secondary 
response caused by exposure to the same antigen is specific, thus highlighting the specificity of the 
adaptive immune system. The response to the second exposure is much faster and more efficient at 
eliminating the pathogen (Alberts et al., 2002). 
Antibody response to T-independent antigens 
Antigens, such as polysaccharides, lipids and other non protein antigens, cannot bind to 
MHC molecules and therefore cannot be seen by T cells. These types of antigens elicit 
immune responses without assistance by T cells (Abbas and Lichtman, 2006-2007).  
Defence against bacteria that contain polysaccharide-rich capsules is mainly mediated by 
antibodies through the process of phagocytosis. Polysaccharide and lipid antigens are 
believed to contain an arrangement of the same epitopes, which are able to cross-link many 
antigen receptors on a specific B cell (Abbas and Lichtman, 2006-2007).  
The activation of B cells occurs through the clustering of the B cell receptor (BCR) and their 
related signalling molecules. Ig receptor-mediated signal transduction cross-linking occurs 
when two or more antigen molecules accumulate or when repeating epitopes of one antigen 
molecule bind to adjacent Ig molecules in the membrane of a B cell. This often occurs in the 
case of polysaccharides, lipids and other non protein antigens that contain similar epitopes 
that can bind to many Ig receptors at once. Receptors are non-covalently attached to 
proteins, called Igα and Igβ, which form the BCR complex. Cross-linking of receptors 
induces B cell signalling and activation of transcription factors that result in the proliferation 
and differentiation of B cells (Abbas and Lichtman, 2006-2007).  
Antibody responses to T-dependent antigens 
Conversely, antigens, such as proteins, are recognised by Th cells, which play a key role in 
driving B cell activation, as well as heavy chain class switching and affinity maturation. 
Without T cell help, protein antigens produce weak antibody responses (Abbas and 
Lichtman, 2006-2007).  
This process starts with the activation of T cells via antigen recognition and co-stimulation of 
APCs, preferentially by protein antigens that are administered with adjuvants. Antigens that 
stimulate CD4+ Th cells are produced from extracellular microorganisms that are displayed 
on MHC II molecules on APCs. This process occurs in the cell rich zones of peripheral 
lymphoid tissues. CD4 T cells that recognise these antigens then differentiate into effector 
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cells that produce cytokines derived from Th1 and Th2 subsets. During this time, some T 
cells move toward the lymphoid follicles and the antigen-stimulated B and T cells move 
toward each other. Subsequent to B and T cells encountering each other at the edges of 
lymphoid follicles, B lymphocytes with bound protein antigen endocytose these antigens in 
endosomal vesicles and display MHC class II-associated peptides, which are recognised by 
CD4+ T cells (Abbas and Lichtman, 2006-2007).  
CD40L on activated Th cells binds to CD40 on B cells and this result in signals that 
encourage the B cells to proliferate and secrete antibodies. In addition, Th cells also produce 
cytokines that bind to cytokine receptors on B lymphocytes and stimulate Ig production.   
T cells also assist with signals that are required to stimulate heavy chain class switching and 
affinity maturation (Abbas and Lichtman, 2006-2007). 
The adaptive immune system is designed to fight off infection and allow for the maintenance 
of good health. However, the immune system is often challenged by pathogens that have 
developed a number of mechanisms to overcome the protective mechanisms of immunity; 
one such pathogen is HIV. 
2.2 THE HIV PANDEMIC 
2.2.1 The global status of the HIV/AIDS pandemic 
Nearly four decades after the first encounters with HIV, UNAIDS reports a reverse in the 
increase in HIV trends since 1999, which was thought to be the pinnacle years of the HIV 
epidemic. The number of new HIV infections per year has stabilised and deaths due to AIDS 
related diseases have decreased mainly due to increased access to antiretroviral (ARV) 
therapy (ART). An estimated 2.6 million new infections was documented in 2009, which has 
decreased by 19% since 1999 were 3.1 million new infections occurred. Despite these 
positive advancements towards limiting the spread of HIV, the number of individuals living 
with the disease is still relatively high and at the end of 2009 the number of infections stood 
at 33.3 million globally. In this same year, a total of 1.8 million deaths was reported 
(UNAIDS, 2010).  
2.2.2 HIV pandemic in Sub-Saharan Africa 
Sub-Saharan Africa continues to bear the greatest burden of the HIV/AIDS global pandemic. 
Currently it is host to 68% of the global total of infections of which 22.5 million people were 
living with HIV in 2009. In this region, countries such as South Africa, Ethiopia, Nigeria, 
Zambia and Zimbabwe are mainly affected by the pandemic. Southern Africa alone 
accounted for 34% of all HIV infection cases where an estimated total of 11 million people 
were living with the virus (UNAIDS, 2010).  
2.2.3 HIV pandemic in South Africa  
In South Africa an estimated 5.6 million people were living with HIV in 2009, classifying this 
country as the largest host of the HIV/AIDS pandemic. More recent statistics show an 
increase in the number of people living with HIV from 4.21 million in 2001 to 5.38 million in 
2011. South Africa has an HIV prevalence of 10.5% of which 16.6% of the adult population 
between the ages of 15-49 are infected (StatsSA, 2011).  
Furthermore, UNAIDS reports South Africa as being one of the few countries where an 
increase rise in mother and child mortality has been observed since the 1990s. AIDS is 
largely responsible for maternal mortality in South Africa and it also accounts for 35% of all 
deaths in children under the age of 5 years. Despite a decline in the prevalence of HIV, the 
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number of children orphaned by AIDS has risen and South Africa is currently as one of the 6 
countries that has collectively contributed to 9 million HIV/AIDS orphans (UNAIDS, 2010).  
2.2.4 HIV infection in women and children  
HIV continues to contribute to the increased maternal and child mortality figures. In Sub-
Saharan Africa, females between the ages of 15-24 are eight times more likely than men to 
be HIV positive (UNAIDS, 2010).  
In 2009, 370 000 children contracted HIV during the perinatal and breastfeeding period and 
260 000 children younger than 15 years died from HIV related diseases (UNAIDS, 2010). 
Mid-year population statistics for South Africa in 2011 reported 63 600 new HIV infections 
among children between the ages of 0-14 years of age (StatsSA, 2011).  
In 2009, the Department of Health (DOH) of South Africa reported a 29.4% prevalence rate 
in women attending antenatal clinics after conducting a study across the nine provinces. 
They reported the highest prevalence in Kwazulu-Natal (39.5%) followed by Mpumalanga 
(34.7%) with the Northern Cape (17.2%) and Western Cape (16.9%) having the lowest 
number. In 2009, women between the ages of 30-34 presented the highest prevalence at 
antenatal clinics in South Africa (DOH, 2010b) 
Mother-to-child transmission accounts for a large portion of HIV infection in children. With 
increased access to ART and the implementation of vigorous programmes to curb the 
transmission of HIV from mother to child, a decrease in transmission has been reported by 
UNAIDS. The total number of children born infected with HIV has decreased from 500 000 to 
370 000 from 2001 to 2009. This equates to a 24% global decrease in mother-to-child 
transmission in the last 5 years (UNAIDS, 2010).  
2.3 HIV PATHOGENESIS AND IMMUNOLOGICAL ABERRATIONS  
HIV infection leads to immune dysfunction and subsequent depletion. In the past years there 
has been great progress in trying to understand the immunopathogenesis of HIV.  
2.3.1 Structure of HIV  
HIV-1 is a member of the lentivirus (from the Latin lentus, meaning “slow”) subgroup of 
retroviruses and is a family member of the HIV-2 and simian immunodeficiency virus (SIV). 
HIV-2 has been described and predominantly found in West Africa and causes less severe 
disease compared to HIV-1 (Murphy et al., 2008).  
The structure of the HIV-1 particle consists of two identical positive strand ribonucleic acid 
(RNA) copies of the viral genome, which codes for 9 viral genes and is encapsulated by a 
narrowed capsid, consisting of about 2000 copies of the viral protein, p24. The HIV particle 
is essentially spherical and is about 120 nm in diameter. A milieu of viral proteins surrounds 
the capsid, thus maintaining the integrity of the viral particle. A viral envelope surrounds the 
capsid and is composed of layers of phospholipids (Murphy et al., 2008).  
Various viral proteins, such as gag (viral core protein containing p24) and env (envelope 
proteins) consists of a cap comprised of three molecules called glycoprotein (gp) 120, as 
well as a stem consisting of three molecules of gp41 which are embedded in the capsid and 
play a role in anchoring of the viral envelop to the host cell. The HIV-1 genome contains 
additional genes, such as tat (transactivator), rev (the regulator of the virion protein) and nef 
(negative factor), which play a role in virus replication. Infectivity of the virus is further 
promoted by various accessory genes, such as Vif (virion infectivity factor), Vpr (viral protein 
R) and Vpu (Viral protein U) (Murphy et al., 2008). 
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2.3.2 Viral entry and replication 
Cellular tropism is essentially defined as the ability of HIV to enter particular cell types and is 
determined by the expression of specific receptors on the surfaces of those particular cells. 
HIV is known to bind mainly to cells, such as DCs, CD4+ T cells and macrophages. The 
entry of HIV into specific cell types involves a complex of two viral glycoproteins, gp120 and 
gp41, contained on the viral envelope. The portion of the gp120 glycoprotein binds with 
increased affinity to the cell-surface of the CD4 molecules. Prior to the synthesis and entry of 
the virus into the host cell, gp120 must also bind to a co-receptor on the membrane of the 
host cell. There are a number of chemokine receptors for HIV viral entry; the well described 
chemokine co-receptors CC-chemokine receptor 5 (CCR5), which is mainly expressed on 
DCs and macrophages, or the CXC-chemokine receptor 4 (CXCR4) chemokine, which is 
expressed on activated T cells. Binding of gp120 to gp41 subsequently results in the 
integration of the viral envelope with the cell plasma membrane, thus allowing the viral 
genome including associated proteins to enter the cell cytoplasm (Murphy et al., 2008). 
During the infection of a host cell, the RNA genome of the virus is reverse transcribed into 
copy deoxyribonucleic acid (DNA) (cDNA) by viral encoded reverse transcriptase. Viral 
integrase allows for viral cDNA to be integrated into the host’s genome. The copy of cDNA is 
then referred to the as the provirus. HIV can establish a latent infection during which the 
provirus remains dormant, which have been observed to occur in memory CD+ T cells and 
macrophages, thus serving as important reservoirs of infection (Murphy et al., 2008). 
2.3.3 The immune response following HIV infection 
Upon HIV infection, both innate and adaptive immune systems respond by controlling HIV 
viral replication; nonetheless, a number of immune dysfunctions result in HIV-infected 
individuals. A number of viral strategies for overcoming the hosts immune control 
mechanism have been identified. Immune responses, such as phagocytosis, are simply not 
efficient; however, both cell-mediated and humoral immunity play central roles in controlling 
infection. In untreated individuals, viral replication is not completely controlled, thus leading 
to increased viraemia, disease progression and ultimately the development of AIDS (Murphy 
et al., 2008). 
HIV infection generates an immune response that controls the virus, but is unable to 
eradicate the disease. During the asymptomatic phase there are very low concentrations of 
HIV in the peripheral blood due to the persistent replication of virus in the lymphoid tissues. 
CD4+ T cell counts gradually decline and CTLs remain relatively high, however eventually 
become exhausted and lose their function resulting in increased concentrations of HIV in the 
peripheral blood. The host develops antibodies to the envelop protein (env) and the core 
protein (p24) (humoral immune response), which assist in trying to control and eliminate 
infection (Murphy et al., 2008).  
During the acute phase of viral infection, both adults and children present with increased 
levels of viraemia within 2 months of infection. The acute phases however, differ in adults 
and children with regards to the initial responses. Where adults experience a “brief burst” of 
high plasma viraemia, which is controlled by both cellular and humoral immunity, the levels 
of plasma viraemia in children lasts for much longer. The number of CD4+ T cells generated 
increases drastically to compensate for lost cells. These cells however, become new targets 
for viral replication and destruction. The lack of CTL functionality in infants, may explain the 
increased viraemia during the first stages of infection (Leal et al., 2007).  
2.3.4 Immune activation of T cells and chronic infection  
It has been documented that HIV infection not only contributes to immunodeficiency, but also 
results in dramatic immune activation, which serves as one of the underlying mechanisms of 
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immune dysfunction. The exact mechanisms for T cell activation is still unclear, but is 
believed to be a major contributor to HIV pathogenesis. HIV pathogenesis is achieved when 
the virus depletes all CD4+ T cell populations, which is believed to occur within the first few 
weeks of infection (Hunt, 2007, Cohen et al., 2008) 
The review by Hunt (2007) highlights the potential mechanisms that may outline the reasons 
for T cell activation other than via the recognition of HIV antigens, which is believed to 
account for a relatively small portion of the T cell repertoire. Suggestions by evaluation of in 
vitro studies, implicate the binding of gp120 to CD4 or co-receptors of the molecule, thus 
inducing activation without direct infection. In addition, bystander T cells may be become 
activated by infected macrophages through the nef accessory protein. In addition, the 
regulatory T cells that play a key role in controlling T cell activation may be affected during 
HIV infection, rendering it unable to serve its function. T cell activation may also be triggered 
by constant activation of the innate immune system that produces inflammatory cytokines, 
which in turn triggers the constant stimulation of T cells (Hunt, 2007). 
An overtly active immune system represents a prime feature of chronic immune activation. 
Studies have hallmarked the relationship between CD4+ T cell activation and subsequent 
depletion, which contributes to disease progression and continuous viral replication.  
Activation of both CD4+ and CD8+ T cells express a number of surface activation markers, 
such as CD38 and human leukocyte antigen (HLA)-DR. The expression of CD38 on CD8+ T 
cells is classified as the most well described surrogate marker of immune activation and 
disease progression in HIV. It is even considered a better predictor than CD4+ T cell counts 
and HIV RNA levels (Giorgi et al., 1999, Giorgi et al., 2002). 
CD69 is described as an early marker of immune activation of T cells. The expression of this 
protein molecule acts as a co-stimulatory molecule for T cell activation and proliferation. A 
study by Nielsen et al (2008) showed a correlation between lymphocyte proliferation and 
expression of CD69 in a group of HIV positive individuals (Nielsen et al., 1998). Other 
studies have indicated impairment in the expression of CD69 in patients with advanced 
stages of HIV. These patients do not respond with an increase expression of CD69 upon 
stimulation with an antigen such as Staphylococcus enterotoxin B (Pitsios et al., 2008). 
Continuous activation of T cells causes the exhaustion and loss of both naïve and memory T 
cell pools, thus resulting in T cell homeostasis that leads to T cell depletion (Hazenberg et 
al., 2003). A commonly described reason for T cell depletion during immune activation 
events is apoptosis.  
2.3.5 Increased apoptosis during HIV infection 
Introduction to apoptosis 
Apoptosis or cell death is described as a normal physiological process that contributes to the 
maturation and maintenance of tissue homeostasis. The process is characterised by a 
number of morphological and biochemical features, such as loss of cell structure, chromatin 
condensation and breakdown of cell DNA. Apoptosis plays important roles during other 
physiological processes, such as the development of embryos and vascular systems, as well 
as during the modification of cells and tissues (Wyllie et al., 1984).  
Apoptosis also plays a crucial role in adaptive immune responses, such as the development 
of lymphocytes. Through the process of apoptosis, autoimmunity is prevented by negatively 
selecting those cells that do not bind correctly to appropriate structures (e.g. if a T cell binds 
too strongly to an MHC molecule). Apoptosis is responsible for the termination of an immune 
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response by deleting self-reactive T cell clones and by the elimination of malignant and virus 
infected cells (Sloand et al., 1997). 
During apoptotic events, a number of changes occur in the cell membranes of apoptotic 
cells. The loss of phospholipid asymmetry allows for the exposure of phophatidylserine (PS), 
which then translocates to the outer cell membrane during the process of apoptosis. Annexin 
V is believed to be an early marker of apoptosis, which binds to PS with high affinity due its 
calcium dependent phospholipid-binding nature and remains bound throughout the process 
of apoptosis. Therefore, by the use of flow cytometry and the conjugation of the Annexin V 
protein to a fluorescent dye, cells that are undergoing apoptosis can be detected (Fadok et 
al., 1992, Vermes et al., 1995, Zhang et al., 1997).  
Apoptosis during HIV infection 
The depletion of T lymphocytes in HIV infection is believed to be due to the processes of 
apoptosis or induced cell death. Studies have described an increased level of spontaneous 
apoptosis of HIV infected and uninfected lymphocytes as a result of increased immune 
activation (Sloand et al., 1997). 
A number of studies have described T cell loss during HIV infection as either a direct 
destruction by the virus or through the defective depletion of T cells during HIV progression 
phases (Stan et al., 2008, Yue et al., 2005). It has also been documented that a large 
number of cells that undergo apoptosis are uninfected (Vassena et al., 2007). Furthermore, 
by use of appropriate scientific models, researchers were able to study the influence of 
apoptosis on the dynamics of HIV infection, which was observed to play a key role in 
immunological failure (Mhawej et al., 2009). 
Banda et al (1992) has proposed that the initiation of apoptosis occurs when gp120 cross-
links with the CD4 receptor (Banda et al., 1992). Other studies have proposed that upon this 
cross-linking reaction, the upregulation of Fas occurs due to increased expression of IFNγ 
and TNFα (Oyaizu et al., 1994). In addition, other viral proteins, such as tat, have been 
documented to increase the levels of cell apoptosis (Alimonti et al., 2003). Some studies 
have even proposed that infected APCs, such as macrophages, are involved in directing the 
apoptosis of CD4+T cells (Badley et al., 1996).  
During HIV infection it is the Fas/FasL system which mediates T cell apoptosis. Fas or CD95 
is a cell receptor that belongs to the TNF family. The Fas protein is expressed on activated 
mature lymphocytes, but do not occur on resting naïve T cells. Fas contain so-called death 
domains in its cytoplasmic tail, which are responsible for the activation of caspases involved 
in initiating the apoptotic process (Murphy et al., 2008, Sloand et al., 1997). 
Elevated levels of Fas have been reported in HIV infected individuals and have been 
observed to play a role in increased disease progression (Poonia et al., 2009) 
2.3.6 Other T cell abnormalities associated with HIV infection 
In addition to the loss if CD4+ T cells along with the loss of CTLs, HIV infection is also 
associated with impaired thymic output, thus leading to impaired naïve T cell pools (Gaulton, 
1998). IL-7 is a pleiotropic cytokine that plays a key role in controlling T cell homeostasis, 
enhancing CTL function and increasing T cell survival. The IL-7 receptor complexes (IL-7R), 
consists of two subunits; one of them being the IL-7Rα chain (CD127) which is expressed on 
a number of cells including naïve and memory T cells and the other a common-γ chain 
receptor that is shared on a variety of cytokines. Disruption of the IL-7 signalling pathway 
thus results in impaired immunity (Fry et al., 2001, Fry and Mackall, 2002, Hofmeister et al., 
1999). Studies have documented a decrease in CD127 expression on CD8+ T and CD4+ T 
cells, thus playing a role in disease progression amongst HIV positive individuals (Young 
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and Angel, 2011). The same study found that HIV infection modifies the pathway of IL-7 
signalling, thus leading to a blockage in thymopoiesis and the “arrest” of T cell development. 
The study further concluded that the blocking mechanisms play no role in the expression of 
CD127. In contrast, other studies have found decreased expression of CD127 on CD8 T 
cells, which resulted in increased apoptosis of the same cell type (CD8 T cells), thus leading 
to chronic HIV infection. It was also found during in vitro studies, that with addition of IL-7, 
the expression of CD127 was restored and a decrease in apoptosis was noted. This study 
further highlighted the use of IL-7 as immunotherapy in HIV infected patients (Zhang et al., 
2009). 
T cell responses are modulated through the balance of both co-stimulatory, as well as co-
inhibitory signals that result in signalling molecules that play key roles in the regulation of T 
cell activation and tolerance. For example, pathways such as the B7:CD28 family that 
produce signals to activate and halt T cell responses, thus serve important roles in creating 
immune tolerance and preventing autoimmunity (Kaufmann and Walker, 2009). CD28 is the 
co-stimulatory molecule, whereas CTLA-4 and PD-1 serve as inhibitory molecules/T cell 
regulation. CD28 and CTLA-4 are known to share the same ligands, i.e. B7-1 (CD80) and 
B7-2 (CD86) and PD-1 interacts with B7-H1 (PD-L1) and B7-DC (PD-L2). During the 
recognition of MHC peptides by TCR, which serves as signal 1, and CD80 and CD86 by 
CD28, which serves as signal 2, activation, proliferation, differentiation and the production of 
cytokines occur. Following the TCR signal, PD-1 and CTLA-4 expression occurs. The 
binding of the TCR to one of these receptors leads to the arrest of the cell cycle, thereby 
terminating the T cell activation pathways (Kaufmann and Walker, 2009).  
In HIV infection, the increased expression of PD-1 on HIV specific CTLs had been 
associated with CTL dysfunction. Cells with increased expression of PD-1 displayed 
impaired proliferating responses to the related antigen during in vitro studies. PD-1 
expression was also associated with increased viral loads and disease progression, thus 
upon the receipt of ART resulted in a decrease in PD-1 expression (Petrovas et al., 2006, 
Day et al., 2006, Trautmann et al., 2006). Studies have also shown a direct relationship 
between the expression of PD-1 and increased apoptosis. CTLs that expressed PD-1 were 
observed to be more vulnerable to undergoing both spontaneous, as well as Fas mediated 
apoptosis (Petrovas et al., 2006). 
The expression of CTLA-4 on the cell surface is induced after TCR signalling processes and 
consecutively presented on CD4+ FOXP3+ Treg cells. Naturally occurring FOXP3+ 
regulates Treg expression of CTLA-4 and dominantly controls T cell self tolerance. Blockage 
of CTLA-4 thus results in the abortion of Treg activity during both in vitro and in vivo studies. 
In addition, CTLA-4 absence such as lymphoproliferative diseases can be controlled by 
providing CTLA-4 sufficient T cells thus suggesting functional defects in Tregs in the 
absence of CTLA-4 (Sojka et al., 2009, Jain et al., 2010) 
Various studies have conferred varying roles of CTLA-4 expression on T cells during HIV 
infection. Some studies showed that during progressive disease, overtly increased 
expression of CTLA-4 on CD4 T cells was noted that indirectly correlated with CD4 count 
(Leng et al., 2002). Other studies have shown the expression of CTLA-4 during the acute 
HIV infection stage (Zaunders et al., 2006). In addition, a study by Kaufmann et al (2007) 
showed that CTLA-4 expression was shown to occur during various stages of HIV infection, 
except in individuals who had the ability to maintain virological control (without ART) 
(Kaufmann et al., 2007).  
CD40 ligand is mostly expressed on activated CD4+ T cells and plays a role in B-cell 
proliferation and Ig class switching. The interaction of CD40 with CD40L is also responsible 
for the ignition of the immune response (Romano et al., 2006). Soluble CD40L levels have 
been found to be increased in HIV-infected patients that have undergone successful ART 
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(Sipsas et al., 2002) and other studies have verified a long-lasting effect of ART on the 
maintenance of total lymphocyte counts (Bunders et al., 2005a). The positive features of 
ARV drugs are not only to reduce viral replication, but also to promote viral immunity.  Other 
studies have found similar findings in both HIV and non-HIV cases where other anti-virals 
were administered (Sipsas et al., 2002). In addition, treatment with nucleoside analogues 
was also found to increase the expression of CD40L (Bergamini et al., 2002).  
The binding of CD40L on activated T cells to the CD40 receptor on B cells leads to the 
increased expression of costimulator molecules, such as CD80 on other APCs (O'Gorman et 
al., 2001). Abnormal expression of CD40 ligand can lead to abnormalities in both the T and 
B cell compartments of the immune system. O’Gorman et al (2001) showed that the levels of 
CD40L were aberrantly lower in a group of HIV infected children when compared to negative 
children born to HIV infected mothers. It is hypothesised that this could be due to the loss of 
a subpopulation of Th cells, which produce CD40L upon stimulation.  
2.3.7 B cell abnormalities during HIV infection  
Despite CD4+ T cells being the primary target for HIV infection, the virus ultimately affects all 
lymphocyte populations (De Milito, 2004). In fact, B cells were the first dysfunctional 
lymphocytes to be described in AIDS patients (Lane et al., 1983). These patients were 
characterised by hypergammaglobulinaemia, polyclonal B cell hyperactivation and poor 
stimulation of B cells in vitro.  
Aberrant hyperactivity of B cells during HIV infection may serve to be of benefit to the virus in 
order to avoid effective anti-viral B cell responses. Although a number of studies have 
extensively addressed the parameters of HIV pathogenesis, the underlying cause of B cell 
activation during infection remains unknown and has contributed to a number of debates in 
research (Haas et al., 2011). 
B cell dysregulation in HIV disease may be a result of irregular immune activation. Features 
of B cell hyperactivation in HIV disease include increased levels of Ig and autoantibodies, 
expansion in B cell areas of lymphoid tissue, increased expression of activation, proliferation 
and terminal differentiation markers on circulating B cells. In addition, activation of B cells 
during HIV infection has been documented to be the cause of B cell lymphomas (Moir and 
Fauci, 2008).  
Whether HIV directly infects B cells are unknown. However, studies have detected viral 
products displayed on the surface of blood and lymph node isolations from infected 
individuals (Moir et al., 2000). The described reason for this observation is linked to the 
interaction of complement-opsonised HIV virions to CD21 receptors expressed on B cells. 
This argument was further supported by evidence from Stoiber et al who delineated the role 
of CD21 receptors in the capture of HIV virions opsonised with complement factors (Stoiber 
et al., 2003).  
The direct effects of HIV on B cells may not be the only phenomenon linked to B cell 
aberration during infection. Other effects may include the indirect stimulation by CD4+ T 
cells (Grossman et al., 2006) or the binding of HIV through a superantigen effect (Berberian 
et al., 1993).  
In addition, Treg abnormalities during HIV infection may result in immune activation as a 
consequence of the development of abnormal T cell subpopulations (Eggena et al., 2005). 
These Treg abnormalities may cause direct B cell dysfunction. Studies by Lim et al (2005) 
explored the effect of Tregs on B cell Ig responses. Tregs may potentially migrate to B cell 
areas of the secondary lymphoid tissues and result in the suppression of T cell-dependent B 
cell IgG response. Researchers reported the presence of FOXP3+ Tregs in T-B areas of the 
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germinal centers which can cause direct suppression of B cell Ig responses. The 
suppression of B cells Ig production by Treg is accompanied by inhibition of Ig class switch 
recombination (Lim et al., 2005). Thus during HIV infection, abnormal functioning of Treg 
cells may result in uncontrolled B cell proliferation. 
A number of changes in B cell subpopulations have been observed during HIV infection. 
CD27 is a commonly defined marker of B cell memory, which has been shown to be 
depleted (De Milito et al., 2001, Nagase et al., 2001). Furthermore, there has also been 
evidence that indicate loss of memory B cells during early ART (Titanji et al., 2005). Other 
subpopulations of B cells, such as CD10 (immature/transitional B cells), are increased with 
increased levels of immune activation (Malaspina et al., 2006).   
As noted with T cell activation, apoptosis occurs along with B cell activation and cell death 
during HIV infection. There are two major pathways described for apoptosis, which include 
(1) the intrinsic pathway triggered by mitochondrial apoptosis, and (2) the extrinsic pathway 
activated by the death receptor (Fas). Immature B cells are more susceptible to following the 
intrinsic pathway for the early deletion of defective B cells, as a result of the low expression 
of Bcl-2, which is often associated with cell survival. Mature or activated B cells are more 
likely to express Fas, which makes them more susceptible to apoptosis via interaction of 
FasL; therefore it makes use of the extrinsic pathway. Fas is considered as the most over-
expressed death receptor on B cells in HIV patients with high viral loads (Moir et al., 2004). 
During HIV infection, both mature and immature B cells are present in high quantities, thus 
making them more susceptible to cell death via either apoptotic pathways (Moir and Fauci, 
2008).  
A major contradiction observed with B cell aberration during HIV infection is the increased 
observation of activation in vivo; however, individuals respond poorly to ex vivo B cell 
stimulation, such as immunisation. This observation therefore highlights the role of viral 
replication as the driving force behind B cell hyperactivation and dysfunctions (De Milito, 
2004). This idea was further supported by studies that have shown the link between HIV 
viraemia and the expansion of terminally differentiated B cells with high levels of Ig that do 
not respond to stimuli and are more susceptible to apoptosis (Moir et al., 2001, Moir et al., 
2004).    
The functionality of B cells can be assessed by evaluating the interaction or co-stimulatory 
effects between CD4+ T cells and B cells. Upon activation by antigen, B cells display antigen 
proteins to CD4+ T cells. As described in previous sections, this occurs via the interactions 
between CD80/CD86 receptors, which are upregulated after B cell activation and interaction 
with CD28 on CD4+ T cells. Studies have shown the inability of activated B cells to provide 
stimulatory signals to CD4+ T cells in HIV infection and in addition, are also associated with 
an impaired interaction between CD40L on T cells and CD40 on B cells (Malaspina et al., 
2003, Moir et al., 2003).  
As previously alluded to, ART does not restore memory B cell pools. Thus, HIV infected 
individuals on ARV therapy may not generate antigen specific B cells after immunisation 
(Malaspina et al., 2005, Titanji et al., 2006). In addition, memory B cell responses that 
require CD4+ T cell assistance may be impaired, thus reducing the generation of antigen 
specific B cells. Hart et al (2007) has demonstrated defective responses to T-cell 
independent vaccines, such as pneumococcal polysaccharides and measles, thus 
increasing susceptibility to pneumococcal disease (Hart et al., 2007). In the paediatric 
population, poor antibody responses have been documented in both T-independent and T-
dependent instances, which explains the increases susceptibility to bacterial infections in this 
population  (Bliss et al., 2008, Obaro, 2004, Dankner et al., 2001, Titanji et al., 2006). 
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2.4  EFFECTIVE INTRODUCTION OF PREVENTION OF MOTHER-TO-CHILD 
TRANSMISSION (PMTCT) PROGRAMMES 
During pregnancy, HIV infected women have a 15-45% chance of transmitting the virus in 
the absence of prophylactic treatment. The UNAIDS (2010) reports that without preventative 
measures, HIV infected women have about a 1 out of 3 chance of transmitting the virus to 
her offspring.  Almost half of the infants infected with HIV from their mothers will die before 
the age of 2 years without effective treatment.  
In order to decrease the rate of transmission from an infected mother to her child, vigorous 
implementation of PMTCT programmes along with increased access to ART has resulted. 
Therefore, with the administration of ART during pregnancy and delivery to both mother and 
infant, the risk of transmitting the virus is decreased to less than 5% (DOH, 2009).   
South Africa, along with Botswana, Namibia and Swaziland, has thus far achieved above 
80% coverage of ART to prevent transmission. Coverage in South Africa and Zambia was 
reported to be around 95%, whereas Chad and the Democratic Republic of Congo (DRC) 
was reported to have coverage of only 6% and 9% respectively (UNAIDS, 2010). 
The national PMTCT programme in South Africa was established and initiated in 2001, 
which was then followed by the initiation of the ART schedule in 2004. The original PMTCT 
programme involved using a single dose nevirapine (NVP) regime, which was then amended 
in 2008 to the use combination/dual therapy and included both AZT and NVP, which was 
recommended by the WHO (DOH, 2009). These initiatives were further enhanced and 
modified to address the increased mortality observed amongst women and children. 
During the course of April 2010, revisions of the programme in keeping with the guidelines of 
the WHO, stipulated that all women with a CD4 cell count less than 350 cells/µl were 
considered eligible for ART. Pregnant women, who tested HIV positive, would receive 
treatment at 14 weeks gestation rather than in the final trimester. Previously, a CD4 count of 
200 cells/µl served as the guideline for initiating therapy in pregnant mothers (DOH, 2010a).  
These changes highlight constant improvements to decrease the spread of HIV from 
infected mothers to infants. In addition, it has been reported that along with a functioning 
health system, PMTCT programmes and interventions may be able to eliminate HIV infection 
in children (Sprague et al., 2010).  
2.5 THE HIV EXPOSED UNINFECTED (HEU) INFANT PROBLEM 
2.5.1 The increasing number of HEU infants  
The number of HIV positive pregnant women continues to grow annually around the globe. 
This growth is attributed to increased access to ART, as well as improved and expanded 
PMTCT services as highlighted in preceding sections, especially in low- and middle-income 
countries combined with revisions of the WHO guidelines (Heidari et al., 2011). As these 
programs are increasingly accessed by pregnant women, the number of children born with 
HIV is decreasing. As a result, the number of infants born exposed to HIV during foetal 
development will increase annually around the world. Out of the 1 million babies born in 
South Africa annually, about 300 000 of these infants are born exposed to HIV (DOH, 2009). 
HEU infants represent 30% of all children born in some areas of South Africa (Shapiro and 
Lockman, 2010). 
Although these HEU children remain HIV negative, there has been constant documentation 
supporting increased infectious morbidity and mortality that highlight the need for extensive 
clinical follow-up (Filteau, 2009, Slogrove et al., 2009). These observations classify HEU 
infants as an increasingly important vulnerable group.  
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The reason for increased morbidity and mortality in the HEU population is yet to be 
delineated; however, it is believed to be multi-factorial. Factors such as low-birth weight, 
poor growth, exposure to ART, inadequate clinical follow-up, reduced breastfeeding, as well 
as immune abnormalities, have all been suggested as contributing risk factors (Figure 2-2) 
(Filteau, 2009). In addition, a review by Filteau (2009) also highlights the limited knowledge 
available on the health of HEU infants from low-socioeconomic backgrounds. Most of the 
current knowledge available on the HEU population is derived from developed countries, 
were issues such as health care, diet, exposure to environmental pathogens and poverty, 
differ drastically to third world countries.  
 
Figure 2- 2: Contributing factors that may account for the increased morbidity and mortality within the 
HEU population (Filteau, 2009). 
2.5.2 Increased mortality in HEU infants 
An increase in mortality has been well-documented in HEU cohorts from both developed and 
developing worlds.  
A pooled analysis of seven MTCT trials of HIV infected women was conducted by Newell et 
al (2004), who observed the mortality rates of 3 468 children that were followed over a 15½ 
month period. The study found strong correlations of infant mortality with maternal death and 
severe maternal immunodeficiency (Newell et al., 2004).  
Studies conducted in the United States of America (USA) show increased mortality in both 
HEU and HIV infected infants in early infancy. They showed that infants born to HIV infected 
mothers have increased risk of death during the first two years of life (Paul et al., 2005). 
Research conducted in Zimbabwe and Malawi showed similar mortality rates for the same 
infant age and further highlighted the impact of HIV exposure on long-term infant health 
(Marinda et al., 2007, Crampin et al., 2003). The latter study also observed that uninfected 
infants born to HIV infected mothers have at least twice the mortality risk than infants born to 
HIV negative mothers. They also showed correlations with HEU mortality and low birth 
weight, low maternal CD4 counts, maternal death and social morbidities, such as low 
household income. Death associated with birth weight was also shown in studies conducted 
in Tanzania (Wei et al., 2004). 
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Similar studies by Zaba et al showed a relationship between maternal death and child death 
in a pooled analysis of three African countries (Tanzania, Uganda and Malawi) (Zaba et al., 
2005).  
In a study conducted in a Ugandan cohort, maternal HIV status along with maternal survival 
seemed to be a common dominator for the outcomes of child mortality (Nakiyingi et al., 
2003). A Zambian study observed that increased mortality amongst HEU infants was 
associated with maternal death occurring within four months of delivery. Interestingly, the 
study observed a reduction in infant mortality with every 100 cell/µl of CD4+ T cell increase 
in the mother after adjusting for haemoglobin levels, birth weight and maternal death factors. 
The risk of death in infants whose mother died within 4 months of delivery was just under 
48% (Kuhn et al., 2005).  
A recent study conducted by Kuhn et al., observed a cumulative mortality rate of just under 
14 % amongst 749 HEU infants who were followed up from 1-24 months of age. They further 
reported early weaning as a high risk for infant mortality in comparison to weaning beyond 
18 months of age. In addition, they noted a greater infant mortality within the first year of life; 
however, the risk associated with weaning had progressed over time. Furthermore, 
researchers found that additional risk factors for child death were related to maternal death, 
limited access to food, as well as households with other children under the age of 5 years of 
age (Kuhn et al., 2010). Shapiro et al  also found an association of early weaning and 
mortality in HEU infants compared to UE counterparts (Shapiro and Lockman, 2010).   
Although there have been a number of studies that have documented increased mortality 
amongst HEU infants, other studies have reported no significant differences between HEU 
and UE infants in Zambia and Malawi (Taha et al., 1999, Sutcliffe et al., 2008).  
In general, the mortality of HEU infants is higher than that of an UE child. The reason behind 
the significant mortality is unclear but seems to be combination of factors that include 
maternal death, weaning, severity of maternal disease as well as low birth weight. 
Observations of many studies prompt the need for extensive clinical follow-up of both mother 
and infant pairs.  
2.5.3 Increased morbidity in HEU children  
A large Zimbabwean study consisting of 14 110 mother-infant pairs enrolled as part of the 
Zimbabwe Vitamin A for mothers and babies (ZVITAMBO) trial cohort reported a significantly 
higher morbidity amongst HEU infants compared to UE counterparts. They reported 
significantly increased levels of lower respiratory tract infections during the first half of 
infancy, which seemed to be transient after the first 6 months. A large proportion of HEU 
infants presented with oral thrush during infancy which seemed to be about 2 to 3 times 
greater compared to UE counterparts. Overall, increased morbidity was more profound in 
HEU infants whose mothers presented with more severe HIV disease. A significantly higher 
morbidity rate was noted in infants whose mothers had a CD4 cell count below 800 cells/µl 
(Koyanagi et al., 2011).  
A study conducted in Latin America and the Caribbean Countries found common infections 
related to skin or mucous membranes and upper and lower respiratory tract infections. A 
total of 17.5% of infants in this study were hospitalised with infection mostly related to lower 
respiratory tract diseases. In addition, this study also noted an association with maternal 
disease severity and HEU morbidity (Mussi-Pinhata et al., 2007). 
Kuhn et al also observed increased morbidity in a cohort of Zambian HEU infants also 
associated with severity of maternal HIV disease. This study observed increased 
hospitalisations related to pneumonia and/or sepsis, diarrhoea, as well as malaria. 
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Hospitalisations were also associated with low maternal CD4 count, as well as the lack of 
breastfeeding (Kuhn et al., 2005)  
A number of studies have documented increased cases of pneumonia amongst children 
born to HIV positive mothers. A South African study documented increased disease severity 
in 8 HEU infants, most notably to infections such as Pneumocystis jiroveci pneumonia, 
Pseudomonas sepsis and CMV colitis (Slogrove et al., 2009). Similarly other studies have 
also documented increased events of the opportunistic infection, Pneumocystis jiroveci 
pneumonia in HEU infants (Heresi et al., 1997, McNally et al., 2007).  
Earlier studies have documented an increased incidence of diarrhoeal disease in HEU 
children, which was observed to be twice as high when compared to UE infants (Thea et al., 
1993). Mussi-Pinhata et al had documented an increase in lower respiratory tract infections 
amongst HEU infants. Acute bronchiolitis in the first 6 months was reported as a common 
infection amongst this group. In addition, this study also found an association between low 
maternal and infant CD4 counts as a risk factor for lower respiratory tract infections (Mussi-
Pinhata et al., 2010).  
HEU infants in addition are also at increased risk of exposure to infections related to parental 
illness, such as tuberculosis. This may often be the case in high prevalence settings (Cotton 
et al., 2008). They may also be exposed to other viral infections during intrauterine 
development, such as CMV, which is a common infection in immunodeficient patients (Bates 
et al., 2008). In addition, due to the lack of breastfeeding, these infants may also be at 
greater susceptibility to dietary pathogens thus leading to enteric diseases.   
Due to low birth weight and increased morbidity amongst HEU infants, abnormal growth 
parameters have been documented. Growth is characterised as a potential indicator of 
overall infant and child health. During the first half of infancy, HEU infants of the DRC have 
shown similar weights, but different lengths. However, no association between maternal HIV 
infection and growth was found (Bailey et al., 1999). In contrast, a Zambian study observed 
both lower weight and length (after adjusting for gestational age) in HEU infants in the first 6 
weeks of life (Makasa et al., 2007). 
The European Collaborative study (2003) however, showed increased weight for body max 
index in HEU children, which may be a result of being formula fed. However, it seems as 
though HEU children from African descent tend to show a less rapid catch up growth 
compared to European cohorts (European-Collaborative-Study, 2003). The consequences of 
poor growth in these infants is yet be delineated and whether there may be an association 
with poor health, obesity and chronic ailments (Filteau, 2009).  
2.5.4 Effects of exposure to ART 
There have been a number of documented effects of ART exposure during foetal and infant 
development. Mitochondrial dysfunction has been reported as a common side effect of ART 
in HEU infants (Noguera et al., 2004). In contrast, the European Collaborative study (2005), 
found an association of ART and anaemia in the early life of HEU infants; but found no 
verification of ART associated mitochondrial abnormalities (European-Collaborative-Study, 
2005).  
Other studies have found relationships of ART exposure with abnormal T lymphocyte 
counts, as well as CTL counts in HEU children that persisted from infancy until 8 years of life 
(Bunders et al., 2005b). ART has also been linked with abnormal neutrophil and red blood 
cell counts in the HEU populations (Pacheco et al., 2006, Feiterna-Sperling et al., 2007). 
Other effects of include decreased birth weights as noted in Thai infants; which seemed to 
decreased over time (Briand et al., 2006) 
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Although the effects of ART should be carefully examined, the benefits of therapy far 
outweigh its side-effects, which seem to be transient. Severe clinical outcomes have been 
documented in HEU infants who have not been exposed to ART, thus indicating that its 
effects are not the only “alarm” for the poor health of HEU cohorts.  
2.6 IMMUNE ABNORMALITIES IN HEU INFANTS 
Despite an HIV negative status, HEU infants display a number of immune abnormalities that 
may represent the effects of early HIV exposure. These immune abnormalities may serve as 
contributing factors for the increased morbidity and mortality observed in these infants and 
children.  
As previously outlined in this review, a number of multifaceted patterns in the changes of the 
immune system are associated with HIV infection. These changes include alterations in T 
and B cell populations, increases in CTLs, changes in cytokine profiles and major B 
lymphocyte defects. 
During foetal development, the growing foetus of an HIV positive mother comes into contact 
with HIV particles and proteins. HIV-specific cellular immune responses have been reported 
in more than one-third of HEU infants evaluated by Kuhn et al (Kuhn et al., 2002). The 
earliest of studies have even documented HIV specific lymphocyte proliferation following 
stimulation with HIV proteins (Borkowsky et al., 1990) and other studies have shown CTL 
responses to HIV epitopes (Rowland-Jones et al., 1993, Aldhous et al., 1994). In addition, 
investigations have reported memory Th cell responses to HIV peptides at birth (Kuhn et al., 
2001b, Clerici et al., 1993, Wasik et al., 1999).  
A study by Vázquez Pérez et al (2006) observed HIV-1 DNA in peripheral blood 
mononuclear cells (PBMC) from HIV exposed non-breastfed children at 3 months of age. 
The evidence of this study has prompted researchers to evaluate whether these findings 
may be associated with increased protection against HIV, which may explain HIV specific 
immune responses, but no infection (Vázquez Pérez et al., 2006).  
Evidence for immune activation and inflammation has also been documented. Studies by 
Khun et al (2001a) investigated the relationship between Th1 and Th2 cytokine production in 
cord blood leukocytes in both HIV infected and uninfected mothers. Infant cytokine levels 
were measured at birth and at 6 months of age. They showed that exposure to HIV in utero 
was associated with a greater increase of Th1 cytokines (IFNγ) than Th2 (IL-10) in cord 
blood cells of HEU infants than UE infants thus reflecting exposure to an inflamed 
environment (Kuhn et al., 2001a). Similarly, more recent studies have shown decreased 
production in the levels of IL-4 and IL-7 in cord blood mononuclear cells of HEU newborns, 
but increased levels of IL-10 and IFNγ. Furthermore, they found that the expression of IFNγ 
and TNFα were higher in the supernatant of HIV positive mothers (Borges-Almeida et al., 
2011).  
A study by Schramm et al (2006), evaluated a host of plasma markers, such as neoptrin, β2-
microglobulin and soluble L-selectin in order to evaluate the level of immune activation in 
HEU infants in the presence and absence of a single-dose NVP administered to the mother 
at the onset of labour. They found that increased immune activation that did not result in HIV 
infection, was associated with exposure to HIV during foetal development, regardless of 
NVP exposure. In addition, they found that infants who were exposed to NVP displayed even 
higher levels of immune activation in cord blood samples. The outcome of this study 
suggested that NVP may synergise with HIV-1, thus resulting in an environment that 
endorses HIV-1 replication (Schramm et al., 2006).  
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In addition to showing increased levels of pro-inflammatory cytokine and plasma markers, a 
number of changes in the peripheral blood counts of CD4+ and CD8+ T lymphocytes have 
been documented in HEU individuals (Blanche et al., 1999, Clerici et al., 2000, Pacheco et 
al., 2006). Nielsen et al reported a reduction in the number of naïve CD4+ T cells, which they 
then concluded could have been a result of fewer progenitor cells and decreased thymus 
output (Nielsen et al., 2001). Other researchers have also highlighted changes in T cell 
populations that may result in abnormal responses to vaccines (Clerici et al., 2000, Bunders 
et al., 2005a, Ono et al., 2008). A large cohort study conducted in Kenya found significant 
differences in CD8+ T cells in HEU infants that persisted until 1 year of age (Embree et al., 
2001). In addition, an Italian study found that these abnormities continued in HEU children 
until 8 years of age (Clerici et al., 2000).  
A study by Economides et al (1998) was the first to measure and compare the levels of 
apoptosis in CD4+ and CD8+ T cells of HIV infected and HEU newborns. They found that 
HEU newborns showed significantly more apoptosis after one day of in vitro culture than 
those obtained from UE newborns (Economides et al., 1998). Studies have suggested that 
apoptosis may be as a result of immune activation (Hosaka et al., 2000). In the HIV 
population, a strong correlation was observed between apoptosis and inflammation, rather 
than severity of disease. Studies of HIV infected adults and children show an impact of 
apoptosis on bystander cells not infected with HIV (Finkel et al., 1995). In addition other 
studies have found increased apoptosis despite immune activation (Miyamoto et al., 2010). 
Although very few studies have documented increased apoptosis in the HEU population, it 
may be worth evaluating considering increasing documentation of early immune activation.  
HIV mainly uses CD4+ T lymphocytes as an entry point to invade the immune system. 
Studies have been concentrating on evaluating abnormalities of the T cell compartment with 
less emphasis on dysfunctions on the B lymphocyte abnormalities (Clerici et al., 2000). A 
study by Bunders et al (2010) showed persistent hypergammaglubulinaemia in children born 
to HIV positive mothers. They further showed that abnormal levels of IgG persisted in HEU 
children until 24 months of age, thus suggesting an altered humoral immune response 
(Bunders et al., 2010). Furthermore, studies have documented exaggerated responses to 
primary vaccination with bacterial pathogens (Jones et al., 2011). A recent study by Borges-
Almeida et al (2011) found increased levels of B cells (CD19/CD5+) in cord blood of HEU 
newborns (Borges-Almeida et al., 2011). These studies therefore define the increasing 
evidence of B cell abnormalities that is associated with in utero HIV exposure; these studies 
further prompt the need to further evaluation.  
The causes for the documented immune abnormalities found in the HEU cohort is yet to be 
delineated, however many of these abnormalities seem to be linked to HIV exposure, as 
they represent responses to HIV or exposure to an immunologically inflamed milieu. 
However, other maternal factors associated with HIV may also serve as mediators of 
immune dysfunction in HEU infants.  
2.7 EARLY PREVENTION OF INFECTION (MATERNAL ANTIBODIES) 
2.7.1 Role of maternal antibodies 
During the first phases of growth and development, the neonatal immune system is relatively 
incompetent in fighting disease. This implies that innate mechanisms inherited during foetal 
development, play a key role in protecting the neonate against potential pathogens. This 
protection is offered by maternal antibodies, which are transferred from the mother to her 
infant. The protective role of maternal antibodies was first defined in 1846, by observing the 
protective capacity of antibodies in infants born to mothers who survived measles infection 
during an outbreak in Faroe Islands (Englund, 2007). 
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Placental transfer generally occurs during the first trimester and between 28-32 weeks 
gestation, were IgG levels in the foetus rises to about 50% of that of the mother (Malek, 
2003). By 40 weeks, foetal IgG concentrations are higher than that of the mother (Englund, 
2007). A healthy, full term neonate produces about 5% of adult levels of IgG including 20% 
of IgM and IgA at birth (de Moraes-Pinto et al., 1998). 
Some researchers consider the acquisition of maternal immunological memory as one of the 
fundamental elements required for the survival of newborns (Zinkernagel, 2001). The 
importance of maternal antibodies in protecting neonates is highlighted in infants diagnosed 
with agammaglobulinaemia, which is characterised by the inability to produce Ig. These 
infants are protected against infection in the first 3 to 12 months of life. Subsequent to the 
decay in maternal antibodies, infants are considered vulnerable to infectious diseases.  
It is therefore essential that infants receive adequate levels that will confer protection against 
specific pathogens during their vulnerable period before receiving prescribed vaccinations 
(Mackay, 2006). The amount of antibodies transferred from the mother to the infant 
determines the length of its protection, as well as the response to vaccination, which will be 
described and discussed in subsequent sections (de Moraes-Pinto et al., 1998, Farquhar 
and John-Stewart, 2003). 
2.7.2 Mechanism of transfer of maternal antibodies 
The transport of antibodies across the placenta is an active, selective and intracellular 
process. Only certain IgG subclasses (preferentially IgG1 and IgG3) are passed from mother 
to foetus through the placenta and transfer begins at around 17 weeks. This occurs through 
the contact of maternal blood with cells of the placenta that contain Fc receptors. These Fc 
receptors bind IgG molecules circulating through the blood which then serve as direct 
passages to the foetus. Antibody molecules that are attached to the receptors are taken up 
by placental cells through a process called receptor-mediated endocytosis. Following this, 
they are subsequently transported across the cell in vesicles, which are then released into 
the foetal blood by exocytosis. Other antibody subclasses or isotypes are unable to be 
transferred due to the structural inability to bind specific Fc receptors. IgG is also secreted 
into breast milk, which also offers protection against mucosal pathogens (Alberts et al., 
2002, Englund, 2007). 
There are a number of factors that influence the effective transfer of maternal antibodies, 
some of which include placental abnormalities, total IgG concentration in maternal blood, 
vaccine-antigen type, gestational age of infant, as well as time duration of maternal 
vaccination and delivery (van den Berg et al., 2010, Englund, 2007). 
2.7.3 Influence of maternal antibodies on infant immune responses 
Many infants still have relatively high levels of maternal antibodies at the initiation of primary 
immunisation. Studies have alluded to the interference of pre-existing maternal antibodies on 
vaccination responses. The extent of this effect varies with the type of vaccine antigen 
(Glezen, 2003).  
A number of studies have observed lower than expected responses for vaccines in the 
presence of high maternal antibodies. Research into the effects of maternal antibodies on 
the infant’s immune response showed a decrease of 25-56% in antibody levels to whole cell 
pertussis due to the presence of pre-existing antibodies. However, the same observation 
was not consistent with the administration of an acellular pertussis vaccine (Englund et al., 
1995a). 
Other earlier studies have also documented lower than expected responses to both 
inactivated and oral live polio vaccines given at birth. The response was further decreased in 
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infants who were breastfed (Warren et al., 1964, Simoes et al., 1985). However, adequate 
responses were noted after immunisation at 2 months of age.  
A study by Bjorkholm et al (1995) evaluated infant responses to diphtheria toxoid after 
maternal vaccination given during pregnancy. Vaccination was given at 3, 5 and 12 months 
of age and serum was collected at 3, 7 and 18 months. They found that infants with pre-
existing antibody levels greater than 0.1 IU/ml had decreased responses to primary 
vaccination. However, after the second dose given at 12 months of age, similar antibody 
responses were observed between infants with low and high pre-existing antibodies 
(Bjorkholm et al., 1995). In another study that evaluated infant response to combination 
vaccines with Hib and tetanus after maternal immunisation with tetanus toxoid during 
pregnancy, found that Hib levels were unaffected however, tetanus antibody responses were 
reduced. Subsequently, the response to secondary vaccine doses was adequate (Nohynek 
et al., 1999). These studies therefore imply that passively acquired antibodies play a role in 
suppressing the antibody response to immunisation during early infancy, but do not influence 
the response to booster vaccination.  
 
Although antibody transfer occurs from mother to infant, there is no evidence that supports 
the transfer of cellular immunity. The priming of neonatal T lymphocytes when evaluating 
vaccination with tetanus toxoids or influenzae vaccines (T cell dependent response) is not 
observed (Englund, 2007). 
 
Figure 2- 3: Diagrammatic representation of the expected influence of maternal antibodies on 
vaccination responses in infants (Siegrist, 2003) 
 
The mechanism where maternal antibodies interfere with the infants’ immune response to 
vaccination is still unclear. However, it is believed to be epitope specific, mainly affecting B 
cell responses. It may be related to the maternal antibody to vaccine antigen ratio during the 
time of immunisation, which may result in epitope masking. Epitope masking refers to the 
concept whereby maternal antibodies disguise vaccine antigenic epitopes, therefore 
preventing the binding of infant B cells to these epitopes. In addition, it is suggested that a 
potential means of avoiding such immunological conditions would be to increase the dose of 
vaccine antigens, thereby increasing the abundance of antigenic epitopes that will allow 
sufficient binding of infant B cells (Figure 2-3) (Siegrist, 2003).  
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A diagrammatic representation depicting maternal antibody interference is shown in Figure 
2-4.  
 
Figure 2- 4: Diagrammatic representation of the dual effect of maternal antibodies on infant 
responses to vaccines. The presence of maternal antibodies inhibits B cell responses to masked 
epitopes, but do not affect the generation of memory B cells. Maternal antibodies also play a role in 
increasing T cell responses by enhancing antigen capture and presentation (Lambert et al., 2005).  
2.7.4 Maternal antibody levels in HEU infants  
In previous sections of this literature review, we have alluded to the increased morbidity and 
mortality that exist within the HEU population. Although the reasons for this increased 
vulnerability is considered multifactorial, maternal antibodies or the deficiency thereof, may 
serve as contributing factors.  
It has been speculated that HIV impairs the transport of IgG from an infected mother to her 
foetus (de Moraes-Pinto et al., 1998, Farquhar and John-Stewart, 2003). Therefore, an infant 
born to an HIV positive mother may be deprived from early protection against disease. In 
addition, the effective transfer of maternal antibodies is influenced by the integrity of the 
placenta. Diseases, such as malaria and HIV, have negative impacts on the transfer. In the 
case of malaria, studies have shown impairment in the Fc receptors (Englund, 2007). 
Increased concentrations of HIV specific antibodies present in maternal blood during the 
final trimester may also obstruct Fc receptors, thus inhibiting the active transport antibodies 
(Farquhar et al., 2005). 
Jones et al (2011) observed significantly decreased levels of maternal antibodies to 
pertussis, tetanus, Hib and pneumococcus in HEU compared to UE infants at birth. In 
addition, they found that compared to HIV negative women, HIV positive women had 
significantly lower levels of antibodies to Hib and pneumococcus. However, the levels to 
tetanus and pertussis were similar between both maternal groups (Jones et al., 2011). 
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Similarly, a Malawian study investigating the influence of maternal HIV infection on the 
transfer of specific IgG antibodies to Streptococcus pneumoniae, showed a low 
transplacental antibody transfer (a reduction of 86%) in HEU infants.  The presence of IgG 
antibodies to the tetanus toxoid and measles, however, was not reduced (de Moraes-Pinto 
et al., 1998, Farquhar and John-Stewart, 2003).  
Similar findings have also been related to viral antibodies. A Zambian study showed that 
infants born to HIV positive women had lower antibody levels to measles than infants born to 
HIV negative women. Levels were even lower in infants infected with HIV. This suggests that 
prior to vaccination, HEU and HIV infected infants are at a larger risk for contracting measles 
(Scott et al., 2005). The findings of this study was also supported by other investigations in 
Kenya and Brazil, that showed a decrease of measles antibodies in cord blood samples of 
infants from HIV positive women (Scott et al., 2005, de Moraes-Pinto et al., 1993). In 
addition, another study by Scott et al (2007) showed that infants born to HIV-1 infected 
women were less likely to have maternally derived antibodies that would be functional in 
neutralising the measles virus. Due to this increased risk, they suggested that children 
receive measles vaccination before the scheduled time of 9 months (Scott et al., 2007). 
A Kenyan showed that maternal HIV infection was associated with a 52% reduction of 
tetanus antibodies in infants after compensating for maternal vaccination. They also found 
that 5.3% of the mothers and 7.8% of the newborns were seronegative to tetanus. The study 
concluded that HIV interferes with the transfer of maternal antibodies, thus resulting in the 
insufficient transfer of maternal antibodies (Cumberland et al., 2007). 
It is unclear whether HIV viral load may interfere with the mechanism of transfer. Although 
Jones et al (2011) found a 23% reduction in the placental transfer for Hib, 40% for pertussis 
and 27% for tetanus, there was no association between maternal CD4 count or HIV viral 
load and placental transfer. This goes in contrast to a study by Farquhar et al (Farquhar et 
al., 2005), who showed a positive correlation with maternal viral load and reduced transfer of 
maternal antibodies. 
Other studies have shown that mothers with a higher total IgG concentration transferred 
lower levels of antibodies to their infants (Hartter et al., 2000). This was confirmed in a 
Malawian study that showed that maternal HIV infection and hypergammagobulinaemia 
were associated with a reduction in the transfer of IgG antibodies to S. pneumoniae (de 
Moraes-Pinto et al., 1996). Hypergammaglobulinaemia is often associated with HIV infection 
and Hartter et al (2000) has proposed that during hypergammaglobulinaemia, IgG antibodies 
compete for available receptors. They also observed that despite German mothers having 
only half the IgG concentration of that of Nigerian women, they still transferred a higher 
amount of measles antibody to their foetuses. The increased total IgG observed in Nigerian 
women may be indicative of constant antigenic stimulation thus resulting in limited passive 
transfer of antibodies to their infants. 
2.8 VACCINATION IN PREVENTING DISEASE 
2.8.1 History of vaccination  
The period before vaccination led to a number of feared epidemics around the world. Millions 
of people died from diseases of which held very little understanding (Baker, 2010). The 
genesis of vaccination, and more importantly the field of immunology, developed along with 
the emergence and discovery of smallpox, which was suspected to emerge after 10 000 BC 
and claimed the lives of millions of people around the world. The origin of smallpox is 
unknown, however is believed to have been an animal poxvirus that had undergone 
mutations for transmission to humans (Parrino and Graham, 2006).  
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The mortality rate of pathogenic smallpox was around 30%. Following exposure to this 
pathogen, the incubation period lasted for about 10-12 days after which time individuals 
would show no symptoms of infection. The incubation phase was then followed by a pre-
eruptive phase that resulted in fever, headache, nausea and vomiting. Individuals would 
thereafter develop characteristic rashes that progress into vesicles and pustules within a 
week, which was then followed by the formation of a scab. Those individuals who developed 
scares after surviving smallpox were observed to be immune to re-infection. The concept of 
variolation was then explored and attempts were made to expose individuals to smallpox 
matter by means of inoculating them with smallpox pus or scabs. Through the process of 
developing milder forms of the disease, protection against smallpox infection was 
demonstrated (Parrino and Graham, 2006). 
The start of the vaccine era began with Edward Jenner in 1796 when he developed a 
vaccine against smallpox by inoculating a young boy with material from a cowpox lesion 
from the hand of a milkmaid. Upon second exposure to the pathogen, the boy showed 
protection against infection. Jenner’s work was widely regarded as the foundation of 
immunology despite the origins of variolation starting in India and China (Baker, 2010, 
Riedel, 2005).  
It was around 1979 that the World Health Organisation (WHO) sanctioned the eradication of 
smallpox. Since this milestone, the aim was to eradicate poliomyelitis and measles 
infections, thus significantly contributing to the reduction in various disease burdens caused 
by infectious diseases. These objectives have led to the successful implementation of 
immunisation programmes, as well as a number of public health interventions (Baker, 2010). 
2.8.2 Importance of vaccination in preventing disease 
In 2008, approximately 8 million children died before the age of 5 years around the world. Of 
these, 6 million (68%) were the result of infectious diseases and about 41% of these deaths 
occurred in neonates (Black et al., 2010). In 2002, the WHO reported that an estimated 14% 
(1.4 million) of deaths could have been prevented by the administration of routine 
vaccinations (WHO, 2002). 
The introduction of vaccination has had great impact on global health. Some of the 
successes of vaccination include a decrease in polio cases (300 000 cases in 1980 to only 
2 000 cases in 2002), the eradication of neonatal tetanus and a decrease in measles deaths 
since 1974 (Bloom et al., 2005). 
Vaccination has a major impact on limiting mortality and is often referred to as the most cost-
effective and the most powerful, high impact public health tool that contributes to saving 
millions of lives each year. The eradication of a number of diseases has emphasised the 
global action against fighting disease (Jamison et al., 2006). 
The importance of vaccination therefore lies in its ability to prevent and eradicate diseases, 
thus decreasing the number of unwanted deaths and contributing to improving the life of 
many individuals.  
2.8.3 The Expanded Programme on Immunisation (EPI) 
The WHO created the EPI in 1974, which aimed to make immunisation available to every 
child by 1990. At this time, less than 5% of children in developing countries were receiving 
immunisations. Children under the age of 1 year were being vaccinated against 6 killer 
diseases, which included tuberculosis, diphtheria, tetanus, pertussis, polio and measles. By 
1988, yellow fever was added to the immunisation programme in countries with high 
prevalence and the introduction of hepatitis B (Hep b) followed in 1992. By 1990, about 80% 
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of children under the age of 1 year were vaccinated, which resulted in a the prevention of 3 
million deaths each year (Jamison et al., 2006). 
2.8.4. EPI-SA 
In 1995, the EPI-SA was introduced and primarily covered the six killer diseases listed 
above. Since then, a number of advancements have been made to the schedule, which had 
a major impact on the disease burden of South Africa. The introduction of combination 
vaccines have allowed for better administration and success of implementing larger 
coverage. A number of milestones have been reached in the history of the EPI-SA vaccine 
programme. The introduction of Hep B and Hib vaccines in 1995 and 1999 were one of the 
first important highlights of the programme. The year 2002 marked the elimination of 
neonatal tetanus in 2002 and in 2006, a declaration of being polio-free was put forward. 
More recent advancements include the introduction of the conjugated pneumococcal and 
rotavirus vaccines in 2009 as well as the change from whole cell to acellular pertussis and 
the implementation of a Hib booster at 18 months of age (Baker, 2010).  
The EPI-SA is viewed as the leader of introducing new vaccines into the programme. In 
2003, South Africa individually financed the implementation of Hib into the schedule 
(Ngcobo, 2008). 
The mission of the EPI-SA is ultimately “to reach and protect all targeted children in South 
Africa with safe high quality vaccines that are delivered to the recipient with recent 
technology whilst promoting and developing local capacity and skills” (Ngcobo, 2008). 
The current vaccine schedule for South African infants and children is listed in Table 2-2. 
Table 2- 2: EPI-SA Revised Childhood Immunisation Schedule from April 2009 
(http://www.doh.gov.za/docs/epi-f.html). 
Age of Child Vaccines Required 
At Birth 
OPV (0) Oral Polio Vaccine  
BCG Bacillus Calmette Guerin 
Anti-tuberculosis Vaccine  
6 Weeks 
OPV (1) Oral Polio Vaccine  
RV (1) Rotavirus Vaccine 
DTaP-IPV//Hib (1) Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio 
Vaccine, Haemophilus influenzae type B Combined 
Hep B (1) Hepatitis B Vaccine 
PCV7 (1) Pneumococcal Conjugated Vaccine 
10 Weeks 
DTaP-IPV//Hib (2) Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio 
Vaccine, Haemophilus influenzae type B Combined 
Hep B (2) Hepatitis B Vaccine 
14 Weeks 
RV (2) Rotavirus Vaccine* 
DTaP-IPV//Hib (3) Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio 
Vaccine, Haemophilus influenzae type B Combined 
Hep B (3) Hepatitis B Vaccine 
PCV7 (2) Pneumococcal Conjugated Vaccine 
9 Months 
Measles Vaccine (1) 
PCV7 (3) Pneumococcal Conjugated Vaccine 
18 Months 
DTaP-IPV//Hib (4) Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio 
Vaccine, Haemophilus influenzae type B Combined 
Measles Vaccine (2) 
6 Years Td Vaccine Tetanus and reduced strength of Diphtheria vaccine 
12 Years Td Vaccine Tetanus and reduced strength of Diphtheria vaccine 
* Rotavirus Vaccine should NOT be administered after 24 months 
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Although a number of positive outcomes have been experienced with eradicating diseases 
and preventing a large proportion of deaths, child mortality is still relatively high. One of the 
Millennium Development Goals (MDGs) is to reduce child mortality by two thirds by 2015 
(Duclos et al., 2009). A number of challenges still stand in the way of achieving this goal. 
The challenges that face South Africa highlighted by Ngcobo (2008), state that there is a 
great need to maintain the achievements made in the control of disease through vaccination. 
The second challenge highlights the need for the incorporation of EPI with other child 
survival strategies, such as Infant and Child Nutrition and Comprehensive Care, 
Management and Treatment Services (CCMTS) for children infected with HIV. Lastly, 
attention on incorporating the support of nations and provincial districts, as well as health 
professionals, is required to further improve and strategise programmes. 
2.9 IMMUNOLOGY OF VACCINATION 
The immunology following vaccination is defined by the process of stimulating a protective 
adaptive immune response against infection of microorganisms by exposing an individual to 
a weakened form or component of the pathogen (Abbas and Lichtman, 2006-2007). 
2.9.1 Requirements for an effective vaccine 
Vaccine efficacy is defined by the generation of a qualitative antibody response. In addition, 
the vaccine should offer long-term protection against re-infection by the pathogen and result 
in the generation of immunological memory. These factors together serve as critical 
parameters of long-term vaccine efficacy (Siegrist, 2008).  
Both T and B cells play essential roles in the developing effective immune responses to 
vaccines. Although B cells are commonly thought to dominate the role in vaccine efficacy, T 
cells are critical for the development of high-affinity antibodies and immune memory. More 
importantly, the optimisation of immunisation strategies lies in the identification of immune 
correlates of protection (Siegrist, 2008, Bojak et al., 2002, Igietseme et al., 2004). 
The type of infecting organism determines the efficiency of a successful vaccine. 
Extracellular organisms for example require antibodies to provide the important mode of 
defences in comparison to infection with intracellular organisms were an effective CD8 T-
lymphocyte response is required (Murphy et al., 2008). 
2.9.2 Effectors of vaccine responses 
The main effectors of vaccine immunity are antibodies or Ig, which are produced by B 
lymphocytes. Antibodies essentially bind to the pathogens and promote its destruction via 
various mechanisms, such as neutralisation, opsonophagocytosis or activation of the 
complement cascade. The other effectors involved in vaccine induced immunity include 
those of cytotoxic CD8+ T lymphocytes that are mainly involved in killing intracellular 
pathogens. These effector cells work either by direct killing action through the release of 
perforin or granzymes, or through the release of antimicrobial cell-communicators, cytokines. 
As illustrated in Figure 2-5 below, both these cells type responses are generated and 
maintained by signals of CD4+ T helper cells, which are divided into Th1 and Th2 cells. Th1 
cells produce cytokines, such as IFNγ, TNFα and β and IL-2, which support the activation of 
B cells, macrophages and cytotoxic T cells. On the other hand, Th2 cells produce cytokines, 
such as IL-4, IL-5 and IL-10 that promote the activation and differentiation of B cells only, 
thereby promoting the generation of humoral immune responses (Murphy et al., 2008).  
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Figure 2- 5: Illustration of the immune response after introduction of vaccination as proposed by 
(Bojak et al., 2002). T cell vaccines, such as live viral vectors, induce MHC class I processing and T-
independent vaccines, such as subunit vaccines, induce MHC class II responses. 
 
The type of vaccine administered determines the type of immune response that ultimately 
determines the level of protection offered by the specific vaccines. For example, S. 
pneumoniae and H. influenzae unconjugated polysaccharide vaccines evoke B cell 
responses without T cell assistance (T independent responses), although emerging research 
promotes the role of CD4 T cell help (Malley et al., 2005). T cell dependent immune 
responses are achieved by toxoid, protein and live attenuated viral vaccine types, which tend 
to induce both high affinity antibodies, as well as immune memory (Siegrist, 2008). Most of 
the current vaccines mediate protective immunity through the induction of vaccine specific 
antibodies (Hanekom, 2005). 
Polysaccharide vaccines are classified as long chains of sugar molecules that comprise of 
the surface capsule of specific bacteria. The immune response to a pure polysaccharide 
vaccine such as pneumococcus and Hib (no longer available) are characterised as T cell 
independent. These types of vaccines are not consistently immunogenic in children under 
the age of 2 years which may be related to their immaturity of their immune system. Unlike 
inactivated protein vaccines that result in the increase of antibody levels after each booster 
dose, polysaccharide vaccines do not cause increase in antibody levels. In addition, the 
antibodies induced by polysaccharide vaccines have decreased functionality due to the 
majority of antibodies produced are IgM and very little IgG (Siegrist, 2008 and Siegrist, 
2003).  
In order to increase the immunogenicity of polysaccharide vaccines, vaccines are combined 
to protein molecules in during a chemical process termed conjugation. Conjugated vaccines 
therefore alter the immune response from T-cell independent to T-cell dependent thus 
invoking a more immunogenic response upon boosting. Conjugated vaccines such as 
pneumococcus and Hib are further described below (Siegrist, 2008 and Siegrist, 2003). 
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The immunological process for the production of antibodies via both T-independent and T-
dependent mechanisms have been explained in preceding sections of this review.  
2.9.3 The role of adjuvants 
Adjuvants play an important role in vaccine design with the aim of eliciting an adequate and 
protective immune response. This role of adjuvants is highlighted by the importance of co-
stimulation required for T cell activation. Antigens of protein nature produce T-independent 
immune responses. However, improved immunity by evoking T cell dependent responses, 
antigens can be administered along with adjuvants that allow for the activation of 
macrophages, as well as other APCs. These substances aid the expression of co-
stimulators on APCs, which are also stimulated to produce a host of cytokines that function 
in activating T cells. In most instances1, adjuvants represent products of microbial 
components or alternatively, substances that imitate microbial elements. Essentially, 
adjuvants imitate pathogens by altering inactive protein antigens (Abbas and Lichtman, 
2006-2007). Current adjuvants include a variety of formulations including cell wall 
components, alum and carbomers (Garlapati et al., 2009). 
2.9.4 Generation of immunological memory  
The most enviable aim of any vaccination is the generation of long-lasting protection through 
immunological memory. Following the primary immune response, lymphocytes proliferate 
and undergo phenotypic changes. Memory cells are both quantitatively and qualitatively 
different from cells that have not yet encountered antigen and thus contain extended 
replicates of lymphocytes with differing functionality (Beverley and Maini, 2000).  
The differentiation of memory B cells mainly occurs on the outside of the lymphoid follicles. 
Affinity maturation and heavy chain class switching occur in the germinal centres. After 
exiting the germinal centres, B cells differentiate into memory cells that migrate through the 
blood towards the extrafollicular areas of the spleen and nodes. It is here that they rest and 
await exposure to their specific antigens. After secondary exposure to antigens, these 
memory B cells proliferate and further differentiate into plasma cells, thus secreting large 
quantities of high affinity antibodies. These antibodies are then detected in serum/plasma 
within a few days (Siegrist, 2008).  
2.9.5 Correlates of protection 
Correlates of protection in vaccine-induced immunity is specifically important not only for 
basic research, but for linking immunity with protection. These factors provide insight into the 
reliability of vaccine production, susceptibility to infection within individuals and communities 
and in addition serve well in the certification of efficacy trials. A correlate defined by Plotkin is 
“an immune response that is responsible for a statistically interrelated protection” (Plotkin, 
2010).  
The important characteristic of determining correlates of protection is to firstly define 
protection. It is also important to note that the mechanism of protection offered by 
vaccination may vary by the mechanism required to respond to infection. In addition, the 
ideal way of evaluating correlates of protection involve the assessment of longitudinal 
studies with the evaluation of the outcome being those who get the disease (Plotkin, 2010).   
Correlates may differ both in quantity and quality and in addition, may depend on the 
objective related to the type of infection it is to prevent. Most vaccines are mediated by 
antibodies of which correlates of protection may relate to functionality and specific levels. In 
addition, immune memory is also defined as a critical correlate of protection (Plotkin, 2010).  
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The correlates of protection for various vaccines will be discussed in subsequent sections of 
this review.  
2.10 SELECTED VACCINES OF THE EPI 
This section of the review will evaluate and describe four important vaccine elements that 
form part of the EPI-SA schedule: pertussis, tetanus, Hib and PCV7. These vaccine antigens 
also formed the basis of this investigation. 
Three of the four vaccine antigens listed above are currently routinely administered as part 
of a 5-in-1 combination vaccine, Pentaxim™ (Sanofi Pasteur) that provides immunisation 
against diphtheria, tetanus, pertussis, poliomyelitis and Hib. The vaccine is administered at 
6, 10 and 14 weeks and a booster dose is given at 18 months of age.  Pentaxim™ was first 
licensed in Sweden during 1997 and is at present in use in over 100 countries (Plotkin et al., 
2011). The vaccine is currently given to infants as part of the South African vaccine 
schedule.  
The components and relative quantity of the Pentaxim™ vaccine is listed in Table 2-3 below 
(Plotkin et al., 2011) 
 Table 2- 3: Xomponents and relative quantity of Pentaxim™  
Component per 0.5ml dose Quantity 
Diphtheria toxoid 
Tetanus toxoid 
Bordetella pertussis antigens: 
Toxoid 
Filamentous haemagglutinin 
Inactivated poliomyelitis virus type 1 
Inactivated poliomyelitis virus type 2 
Inactivated poliomyelitis virus type 3 
Haemophilus influenzae type b polysaccharide 
conjugated with tetanus protein (PRP-T) 
Aluminum hydroxide (adjuvant) 
30 IU
a 
40 IU
a 
 
25 µg 
25 µg 
40 DU
b 
8.0 DU
b 
32 DU
b 
10 µg 
 
0.3 mg 
  aInternational Units bD-antigen levels 
A number of studies have evaluated the efficacy, immunogenicity and safety of the 
Pentaxim™ vaccine (Plotkin et al., 2011). Several clinical trials have verified immunogenicity 
and seroconversion after administration of the primary vaccine dosages. In addition, studies 
have shown protective levels one month following primary vaccination to all vaccine 
antigens. Seroprotective levels ranged from 92.3-100% for diphtheria, tetanus and 
polyribosyl ribitol phosphate (PRP) antibodies and for pertussis, seroprotective levels ranged 
from 83.9-100%. Furthermore, these levels were comparable to antibody responses produce 
upon separately administered vaccines (Plotkin et al., 2011). 
A recent study conducted in South Africa assessed these aspects after the administration of 
the primary vaccine dose as part of the EPI-SA vaccine schedule at 6, 10 and 14 weeks of 
age. The study showed increased immunogenicity for all vaccine antigens measured. 
Following the last dosage about 95% of participants showed an anti-PRP level greater than 
or equal to 0.15 µg/ml with a mean level of 2.0 µg/ml. The response to pertussis antigens 
were 97.5%, which represented a 4 fold increase in antibody concentration  and a 100% 
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seroconversion rate for tetanus (≥0.01 IU/ml) was also noted. In addition, other vaccine 
types, diphtheria and polio also showed high immunogenicity. The latter study was 
comparable with a reference study conducted in France using a vaccine regimen of dosages 
administered at 2, 3 and 4 or 2, 4 and 6 months (Madhi et al., 2011). 
The four pathogens alluded earlier, namely, pertussis, tetanus, Hib and pneumococcus will 
be further discussed in this section.  
2.10.1 Pertussis 
Pertussis is considered one of the 10 leading causes of childhood deaths globally. Each year 
an estimated 290 000 deaths occur primarily in non-vaccinated children (WHO, 2002, 
Pereira et al., 2010). For four decades there has been a gradual decline in the number of 
pertussis cases globally. However, there has been concern regarding the increase in 
pertussis incidence, particularly in the adolescent and adult populations. While the trend has 
not been documented in South Africa, these groups of individuals in the developed world 
serve as potential hosts that may contribute to the spread of disease, particularly to the 
unimmunised community (Madide, 2006, Pereira et al., 2010). 
Bordetella pertussis is a Gram-negative coccobacillus that contains many virulent factors 
that contribute to infecting its host by means of attachment to ciliated respiratory epithelium 
and use of filamentous haemagglutinin. After attachment it then produces and releases 
toxins (tracheal cytotoxin). The pertussis toxins play a crucial role in the dysfunction of 
epithelial cells by preventing clearance of debris through altering the movement of cilia. This 
organism is classified as an acute, extremely contagious respiratory disease. Subsequent to 
the incubation period which ranges from about 3 to 12 days, patients present with clinically 
defined symptoms such as a cough lasting for about 2 weeks, vomiting and whooping. 
Diagnosis is made by laboratory confirmed cell culture, PCR or positive paired serology 
(Madide, 2006). 
In South Africa the efficacy of both whole-cell and acellular pertussis vaccines have been 
shown to be in the ranges of 83-98%. However, it is mentioned that the extent of the immune 
response to pertussis is proportionate to the number of doses administered (SAVIC, 2009b). 
A study by Tejiokem et al (2009) showed that after 3 doses of a whole-cell pertussis vaccine 
only 19.2% of HIV positive children and 48% of HEU children possessed detectable 
antibodies. The initial antibody response was much lower in HIV-infected infants than HEU 
infants; however, it is unclear whether HIV-infected children may be at risk of severe or more 
frequent pertussis disease relative to HEU infants (Tejiokem et al., 2009). 
Defining correlates of protection to pertussis is relatively complex, as in addition to the 
pertussis toxin, the vaccine contains one or more attachment factors which may confer 
additional protection. Thus, correct correlates of protection would need to be determined by 
antibody levels against the pertussis toxin, as well as haemagglutinins. The exact  antibody 
levels to each of these are arguable (Plotkin, 2010). Furthermore, it has been suggested that 
protection induced against pertussis may depend on a number of immunological factors 
relating to the humoral and cell-mediated response. Bearing in mind the decay of maternal 
antibodies, a definitive vaccine response represents a 4-fold increase in antibody 
concentration between the pre- and post-vaccination samples (Godfroid et al., 2004). 
Similarly, Capeding, et al (2008) described pertussis seroconversion as a 4-fold increase in 
antibody titres that occurred in 95.3% of their study population (Capeding et al., 2008).  
2.10.2 Tetanus 
Clostridium tetani is a Gram-positive, rod shaped, anaerobic bacterium, which is generally 
present in soil. Tetanus infection occurs by the bacterial release of exotoxins 
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(tetanospasmin), which then results in painful muscular spasms due to its effect on the 
central nervous system. The disease is not contagious, but is acquired when the individual, 
who may have open wounds or cuts, comes into contact with infectious substances 
(released spores). Several complications result from tetanus infection, some of which include 
respiratory failure, cardiovascular instability, as well as renal failure (Poudel et al., 2009).  
In 2010, there were an estimated 9 683 reported tetanus cases globally and in 2008, 61 000 
estimated deaths occurred in children under the age of 5 years (WHO, 2002). Although 
tetanus is considered a relatively rare disease in developed countries, incidence in 
developing worlds contribute to a large number of deaths. In 1998, the WHO estimated 410 
000 deaths due to tetanus, of which 409 000 occurred in developing countries, where 
immunisation is less widespread (Aristegui et al., 2003, WHO, 2002, Poudel et al., 2009). 
The occurrence of tetanus in neonates is most often a result of contamination of the 
umbilical cord or in the case where mothers did not have sufficient antibodies to passively 
transfer in order to confer protection in the infant.  
Correlates of protection against tetanus have been well defined. A level of 0.01ug/ml confers 
sufficient protection and a level greater than 0.1 µg/ml is associated with complete protection 
against tetanus. Tetanus diseases have been reported to occur despite having sufficient 
antibody concentrations, which is believed to be a result of insufficient diffusion into sites of 
toxin production (Plotkin, 2010).  
2.10.3 Hib 
Haemophilus influenzae b is a Gram negative encapsulated coccobacillus that is believed to 
be the leading cause of bacterial pneumoniae and meningitis in children under the age of 5 
years. Disease usually occurs in unvaccinated individuals and includes other clinical 
outcomes, such as septicaemia, cellulitis and epiglottitis (Mangtani et al., 2010). 
About 8.1 million serious events and 371 00 deaths occur due to Hib disease every year. In 
addition, 8 100 deaths occur in HIV infected children (Watt et al., 2009).  
In 1994, Hussey et al observed that 65.5% of invasive Hib disease occurred in children less 
than 5 years of age and that 1 in every 250 children contracted Hib within the first year of life 
(Hussey et al., 1994). It was this epidemiological study that prompted the introduction of the 
Hib vaccine into the EPI, making South Africa the first African country to introduce Hib into 
the immunisation schedule of infants. Following the implementation of this vaccine, the 
number of Hib related cases decreased (Baker, 2010).  
In 2010, a total of 82 cases of Hib were reported amongst children less than 5 years of age. 
According to the Group for Enteric Respiratory and Meningeal disease Surveillance in South 
Africa (GERMS-SA) audit (GERMS-SA, 2010), a total of 91 Hib disease cases were reported 
in South Africa, of which the Western Cape represented the third highest (21 cases). The 
highest incidence was in the Eastern Cape, followed by Gauteng.  
Vaccine efficacy rates for the Hib conjugate vaccine in South Africa ranges from 90-100% 
and immunogenicity is said to differ according to the type of carrier proteins they contain. Hib 
conjugated vaccines are however documented to be effective from 6 weeks of age (SAVIC, 
2009a). Hib conjugate vaccines have also shown to be greatly effective in preventing about 
25% of radiographically confirmed pneumonia (Trotter et al., 2008). Following the 
implantation of the vaccine in 1999, the number of Hib cases declined by an estimated 65% 
in children younger than 1 year of age (von Gottberg et al., 2006) 
HIV-infected individuals have a 6-8 fold increased risk of invasive Hib disease. A study by 
Jeena (2008) found that the initial immunological response to vaccination in HIV-infected 
individuals was 54%, compared to 90% in uninfected infants.  They further found a 
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sequential loss of memory by 15 months of age (Jeena, 2008). Madhi et al (2005) 
investigated both the quantity and quality (bactericidal activity and avidity) of Hib conjugate 
vaccine in both HIV-infected and uninfected infants. The study concluded that only a few HIV 
positive infants were unlikely to have antibody concentrations above the indicated protective 
levels, when compared to uninfected infants. In addition, a limited proportion of HIV infected 
infants had antibody levels considered to be functional. The concentration of antibody 
required for 50% killing of Hib bacteria, through bactericidal activity, was much higher in HIV 
infected infants. The risk for vaccine failure was much higher for HIV infected infants than 
HIV uninfected infants (Madhi et al., 2005). Mangtani et al (2010) therefore recommended 
booster doses in HIV infected infants after 2 years of age (Mangtani et al., 2010). 
Correlates of protection for anti-capsular antibodies are best defined by the 
opsonophagocytic (OPA) or bactericidal activity of antibodies. However, the relative binding 
of antibodies serve as useful surrogates and are routinely used to identify protection. Plotkin  
(2010) suggests that an antibody level of 0.15 µg/ml is most likely to offer protection against 
bacteraemia (Plotkin, 2010).  
2.10.4 PCV 
Streptococcus pneumoniae or pneumococcus is a Gram-positive, catalase negative coccus 
that is characterised into more than 90 serotypes and are responsible for a large portion of 
bacterial meningitis, bacteraemia and otitis media (Zar et al., 2001). Pneumococcal diseases 
account for an estimated 700 000 to 1 million child deaths each year globally. During 2000, 
an estimated 14.4 million severe pneumococcal disease events were reported. In the same 
year, an estimated total of 826 000 deaths in children between 1 and 59 months of age 
occurred. Of this estimated total, 91 000 were HIV positive and 735 000 were HIV negative. 
About 61% of all HIV negative child deaths occurred in ten African and Asian countries 
(O'Brien et al., 2009). Furthermore, the highest mortality rates occurred in sub-Saharan 
Africa and south Asia. In African HIV-infected children, the risk of dealing with invasive 
pneumococcal disease (IPD) is 40 fold greater (Madhi et al., 2000). These estimates not 
only highlight the significant burden of pneumococcal disease in children and the HIV 
infected population, but illustrate the need for effective vaccination to prevent morbidity and 
mortality. 
Pneumococcal conjugate vaccines (PCV) have been shown to be effective in both HIV 
infected and uninfected children. Trials conducted in South Africa and the United States of 
America (USA) showed an overall reduction of 83-94% of vaccine serotype specific IPD in 
uninfected children. Although lower than in HIV uninfected children, PCV was shown to have 
a 54% efficacy in preventing serotype specific IPD in HIV infected children not receiving ART 
(Klugman et al., 2003, Black et al., 2000). Two randomised placebo control trials 
documented the evaluation of PCV9-CRM in South Africa and Gambia. The South African 
trial conducted from 1998 to 2001 demonstrated the efficacy against pneumococcal disease 
in both HIV infected (65% efficacy) and uninfected children (83% efficacy) (Klugman et al., 
2003). 
PCV7 (Prevnar
®, Pfizer, previously Wyeth Pharmaceuticals) was registered in South Africa 
during 2005 and was initially only available through the private health-sector. The vaccine 
was made available to the public sector during 2008 and formed part of the routine infant 
immunisation schedule in one health district (Ukhahlamba district) in the Eastern Cape. The 
latter locality served as a region for piloting the implementation of the vaccine through 
conducting fridge space audits, training of nurses and evaluating the availability of cold chain 
accessibility. Prevnar® was available nationally in April 2009 and the date of execution 
differed between geographical areas. Children born after 15 Feb 2009 that were 6 weeks of 
age on 1 April 2009 could receive Prevnar®. There were no catch-up programmes during 
2008 and 2009. Prevnar® includes 7 serotypes (4, 6B, 9B, 9V, 18C, 19F and 23F) that cause 
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70% of all childhood IPD in South Africa (von Gottberg et al., 2007, von Gottberg, 2010). 
Prevnar13® (Pfizer) has already been rolled-out during early 2011 and includes 13 serotypes 
namely, 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23 F) which are documented to 
contain 83% of the serotypes known to cause IPD in children (von Gottberg, 2010). 
PCV7 consists of a solution of the capsular antigens of S. pneumoniae serotypes 4 (2 µg), 6B 
(4 µg), 9V (2 µg), 18C (2 µg), 19F (2 µg) and 23F (2 µg). Each serotype is individually 
conjugated to the diphtheria protein CRM197 (non-toxic variant of diphtheria toxin) (20 µg), 
which is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium 
diphtheria strain C7 (β197). The formulation also consists of 0.125 mg of aluminum per 
0.6 ml dose as aluminum phosphate adjuvant (information obtained from package insert). 
In South Africa, PCV7 was introduced in the routine infant immunisation programme as a 2-
dose primary series at 6 and 14 weeks of age and a booster dose at 9 months of age. 
Generally, children younger than 2 years of age do not respond relatively well to vaccines of 
capsular polysaccharide nature. These polysaccharides are therefore conjugated to carrier 
proteins that thus lead to T-cell dependent immune activation which results in the induction 
of high-quality antibodies and subsequent immunological memory (Trotter et al., 2008). In 
addition, conjugate vaccines are important for inducing mucosal immunity which is defined 
as their ability to prevent new acquisition of nasopharyngeal serotypes (von Gottberg, 2010). 
The WHO has proposed a protective concentration of IgG anticapsular polysaccharide 
antibodies of ≥ 0.35 µg/ml measured by ELISA one month after primary immunisation. 
Further studies have indicated that this level is suitable for the level of protection conferred in 
a larger population rather than individual immunity (Siber et al., 2007). 
2.13 RESEARCH HYPOTHESIS  
Primary Hypothesis 
HEU infants demonstrate an altered adaptive immune response in early infancy which 
persists into childhood. Aberrations of this type of immunity are related to in utero HIV 
exposure and result in increased morbidity and mortality.  
Secondary Hypotheses 
 Baseline antibody levels prior to specific EPI vaccination in HEU and UE infants at 2 
and 6 weeks of age show significant differences between the two groups reflecting 
differences in passively acquired maternal antibodies. These represent an inability of 
the HIV positive mother to transfer sufficient antibodies to her infant which results in 
increased infectious morbidity during infancy.  
 Specific antibody levels after routine scheduled vaccination of HEU compared to UE 
infants differ significantly and these differences may be related to HIV exposure and 
the consequence of impaired transfer of maternal antibodies.  
 Due to increased antigenic exposure during foetal development and early infancy, 
HEU infants’ upregulate the expression of various cellular markers of immune 
activation, regulation and cell death (apoptosis). The elevated expression of these 
cellular markers is present on both T and B cells of the adaptive immune system 
measured at 18 and 24 months of age.  
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 HEU infants display decreased expression of the cellular marker of B cell memory as 
a result of early HIV exposure. The deficient memory B cell responses are linked to 
variations in antibody levels to vaccination.  
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CHAPTER 3 
AIMS AND OBJECTIVES 
 
3.1 PRIMARY AIM OF STUDY 
The primary aim of this study was to evaluate specific characteristics of the adaptive arm of 
the immune system in HEU infants in comparison to an UE control group 
3.2 OBJECTIVES OF STUDY  
3.2.1 Primary objectives 
a) To assess the IgG levels to specific vaccines (i.e. pertussis, tetanus, Hib and PCV7) 
as administered according to the Expanded Programme on Immunisation of South 
Africa (EPI-SA) from 2 weeks to 2 years of age and document differences in the 
antibody profiles of infants born to HIV positive mothers to those born to HIV negative 
mothers. 
b) To evaluate the effects of HIV exposure on the upregulation of specific cellular 
markers of immune activation, regulation and apoptosis in HEU and UE groups at 18 
and 24 months of age  
3.2.2 Secondary objectives 
a) To investigate the possible role of in utero HIV exposure on acquisition of maternal 
antibody levels by observing the specific antibody levels of infants at 2 and 6 weeks 
of age before the receipt of their primary vaccination 
b) To investigate possible differences or trends that may exist between the HEU and UE 
control groups with regards to specified vaccine antibodies at 12 weeks and 6, 12, 18 
and 24 months of age 
c) To evaluate the effects of HIV exposure on immune activation by investigating 
various cellular markers on both T and B lymphocytes in both HEU and UE control 
groups at 18 and 24 months of age subsequent to the vulnerable period (first 6 
months of life) of susceptibility to infections 
d) To evaluate the effects of maternal HIV infection, antiretroviral exposure (mother and 
infant) and immune activation on the degree of cell death (apoptosis) in the HEU 
group compared to the UE group by investigating specific cellular markers on both T 
and B lymphocytes at 18 and 24 months of age after the vulnerable period of 
susceptibility to infections. 
e) To evaluate immune regulatory properties of both T and B lymphocytes by evaluating 
the expression of specific cellular markers, such as CTLA-4 and PD-1, at 18 and 24 
months of age in both the HEU and UE control infant groups 
f) To assess B cell memory by evaluating the expression of memory marker CD27 at 
18 and 24 months of age in both the HEU and UE control  groups 
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g) To address potential aberrant immunological mechanisms in the adaptive immune 
compartment of the HEU compared to UE control groups that may elucidate the 
potential reasons for the increased morbidity and mortality observed in the HEU 
population 
h) To generate hypotheses for a larger cohort study with the above data 
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4.1 OVERVIEW OF STUDY OUTLINE 
4.1.1 Study Design 
This was a prospective comparative study aimed at observing specific characteristics of the 
adaptive immune response in infants born to HIV positive mothers. This investigation 
(Project Number N08/09/262) formed part of a larger pilot study (Project Number 
N08/10/289) of which probable innate abnormalities in HEU and unexposed (UE) controls 
were investigated. This multi-collaborative pilot study was also aimed at investigating a 
potential difference for a range of immunological, social, nutritional and clinical parameters 
between these infant groups from birth to 2 years of age. 
In this sub-study we observed IgG antibody responses in the two infant groups (HEU and 
UE) to routine vaccinations as part of the EPI in South Africa at community clinics within the 
Western Cape region. Specific antibody levels at 2, 6, 12 weeks and 6, 12, 18 and 24 
months of age were investigated in HEU and UE infant groups respectively. Specific 
antibody levels to pertussis, tetanus, Hib and pneumococcal capsular polysaccharide (PCP) 
were determined at the various time points.  The UE group served to define the normal 
ranges within the specified age clusters to which the exposed group were compared and 
documented for any differences. 
Antibody levels at 2 and 6 weeks in both infant groups represented the presumed transfer of 
maternal antibodies. Infants received routine vaccines as outlined in the EPI schedule (Table 
2-2). At birth infants received a dose of the oral polio vaccine (OPV) (Sanofi Pasteur, Lyon, 
France), as well as the Bacillus Calmette Guérin (BCG; Danish strain 1331, Statens Serum 
Institute) vaccine. At 6, 10 and 14 weeks and 18 months of age, infants were given a vaccine 
combination consisting of diphtheria, tetanus toxoid, pertussis and Hib (DTP-Hib; Sanofi 
Pasteur), as well as Hepatitis (Hep) B (Heber Biotec, Havana, Cuba) and OPV. Changes to 
the EPI schedule occurred from July 2009 and included the replacement of DTP-Hib with 
diphtheria, tetanus toxoid and acellular pertussis (aP) vaccine combined with inactivated 
polio and Hib (DTaP-IPV/Hib; Sanofi Pasteur). Additions to the schedule included two new 
vaccines viz. the pneumococcal 7-valent (PCV7) conjugate (Wyeth, Andover, 
Massachusetts) and the rotavirus (RV) (GlaxoSmithKline, Rixensart, Belgium) vaccine. The 
roll-out of PCV7 had occurred after the commencement of this study resulting in only a few 
infants receiving the prescribed vaccination as outlined in the schedule. Although the IgG 
levels for the vaccine was determined for all infants at each visit, only the presumed 
maternal antibody levels at 2 and 6 weeks will be reported. As the mothers of the infants in 
this study did not receive the described vaccination, the maternally derived antibody levels in 
these infants will thus be due to natural exposure to Streptococcus pneumoniae. 
Based on preliminary data generated from post-vaccination responses and haematological 
data at earlier time points (discussed in following chapters), we then investigated specific 
cellular markers of immune activation on CD4+ T, CD8+ T, CD19+ B and CD20+ B cells as 
well as cellular markers of apoptosis and regulation on the same cell types. A functional 
assay was designed and optimised to measure the expression levels of cellular marker of 
early apoptosis, Annexin V, on both CD4+ T and CD20+ B cells after observing minimal 
expression during in vitro staining of cells.  Furthermore, we investigated the expression of 
the cellular marker of B cell memory (CD27+) on both CD19+ and CD20+ B cells. In 
addition, we assessed a  cellular marker that plays a role in the function of homing of naive 
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T-cells to peripheral lymph nodes (CD62L+) on CD20+ B cells as well as the expression of 
CD127 (IL-7 receptor) on CD4+ T cells that serves to control pro-T cell growth and 
maturation (See Table 4-5 for list of marker functions). Data generated from the investigation 
of these various biomarkers was completed for the 18 and 24 month time point only. 
4.1.2 Ethical Aspects 
The study was conducted according to the Helsinki declaration, as well as the guidelines 
from the Medical Research Council (MRC) and the Institute of Child Health (ICH). Ethical 
approval for the broader pilot and sub-study was granted by the Committee for Human 
Research, University of Stellenbosch (Faculty of Health Sciences).  Informed consent was 
obtained from mothers by a suitable study nurse in the participants’ home language before 
they were included in the study and at any point in time, mothers could withdraw consent 
and exclude their infants from further participation. Blood was collected in a pleasant 
environment and in a manner that is least painful for the study participants. The area of 
venepuncture was treated with EMLA® local anaesthetic cream (lidocaine 2.5% and 
prilocaine 2.5%) 10-20 minutes before the procedure to minimise pain during blood 
collection. Mothers who withdrew their infants from the study were under no circumstances 
deprived of medical care and infants who underwent seroconversion due to failed PMTCT 
(an estimated 5% of enrolled participants) received full medical treatment and all mothers 
had access to HIV counselling.  
All babies received regular health check-ups by a qualified doctor experienced in paediatric 
medicine and the mothers’ travel expenses for study visits were reimbursed. The same total 
volume (5ml) of blood was collected from both the HEU and UE infants. Phlebotomy was 
performed by qualified staff at the KIDCRU (Children’s Infectious Diseases Clinical Research 
Unit) clinical Facilities at Tygerberg Hospital.  
All participant information was handled in a confidential manner at all times and reference to 
the infant and his/her clinical information was restricted to the use of a subject number. 
4.1.3 Sample Size and Method of Sampling 
4.1.3.1 Study population 
The characteristics of the enrolled study participants are listed in Table 4-1 below. A total of 
57 participants were enrolled which included 27 HEU infants and 30 UE control infants.  
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Table 4- 1: Characteristics of enrolled population from 2 week time point 
Characteristics 
HIV-Infected 
Women and 
Exposed Infants 
(HEU) 
HIV-Uninfected 
Women and 
Unexposed (UE) 
Controls 
P-value n 
General Maternal Characteristics 
Maternal age at 
delivery (median, 
range) 
25.00 (18.0-41.0) 26.00 (18.0-41.0) 0.63a 
n=27 HEU 
n=30 UE 
Maternal 
primgravidity (%) 
7 (26%) 9 (31%) 0.40b 
n=27 HEU 
n=29 UE 
Infants delivered 
by normal vaginal 
delivery (NVD) 
(%)  
26 (96%) c 29 (100%)d 0.64e 
n=27 HEU 
n=29 UE 
Social Characteristics 
Household lives 
in informal 
structure (%) 
16 (59%) 5 (17%) 0.002b 
n=27 HEU 
n=30 UE 
Households that 
have inside 
access to running 
water (%) 
11 (41%) 26 (87%) 0.0001b 
n=27 HEU 
n=30 UE 
People in same 
household as 
infant (median, 
range) 
3.5 (1.00-10.00) 
SD (2.40) 
5.5 (2.00-10.00) 
SD (2.13) 
0.0075a 
n=26 HEU 
n=30 UE 
People sleeping 
in the same room 
as infant 
(median, range) 
2.00 (1.00-5.00) 
SD (1.12) 
3.00 (1.00-6.00) 
SD (1.46) 
0.0059a 
n=26 HEU 
n=29 UE 
Maternal HIV Diagnosis 
During pregnancy 
(%) 
14 (52%) N/A 
0.96f n= 27 HEU 
Prior to 
pregnancy (%) 
13 (48%) N/A 
Gestational age 
when therapy 
started-PMTCT  
(median, range), 
weeks 
30 (8-35) 
SD (8.15) 
N/A - n= 13 HEU 
Mothers on 
HAART (%) 
4 (15.4%) N/A - 
n=26 HEU Mothers on Dual 
Therapy (%) 
19 (73.1%) N/A - 
No PMTCT (%) 3 (11.5%) N/A - 
Maternal CD4 Count (extracted from patient files) 
2 weeks (median, 
range) 
337 (131-673) 
SD (150.83) 
N/A - 
n=23 HEU 
6 months 394 (150-620) N/A - n=21 HEU 
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(median, range) SD (122.63) 
12 months 
(median, range) 
433 (200-757) 
SD (132.48) 
N/A - 
n= 18 HEU 
18 months 
(median, range) 
444 (178-800) 
SD (161.97) 
N/A - 
n=15 HEU 
24 months 
(median, range) 
460.50 (203-609) 
SD (142.09) 
N/A - 
n= 14HEU 
Infant Birth Characteristics 
Gestational age 
at birth (median, 
range), weeks  
38 (30-41) 
SD (2.74) 
38 (33-42) 
SD (2.40) 
0.65a 
n=24 HEU 
n =29 UE 
Birth Weight 
(median, range), 
kg 
2.980 (1.90-3.82) 
SD (0.42) 
3.12 (2.08-4.10) 
SD (0.51) 
0.11a 
n=27 HEU 
n= 30 UE 
Gender 
Females (%) 20 (74%) 15 (50%) 
0.09g 
n=27 HEU 
n=30 UE Males (%) 7 (26%) 25 (50%) 
Ethnic Grouping 
African (Xhosa) 
(%) 
19 (70%) 8 (27%) 
<0.001g n=27 HEU 
n= 30 UE 
Coloured (%) 5 (19%) 21 (70%) 
African 
(Zimbabwean) 
(%) 
 1 (4%) 0 
African 
(Malawian) (%) 
2 (7%) 0 
White (%) 0 1 (3%) 
Exclusive Breastfeeding 
Birth (%) 1 (4%) 28 (97%) <0.001 
n=26 HEU 
n=29 UE 
2 weeks (%) 2 (7%) 24 (86%) <0.001 
n=27 HEU 
n=28 UE 
6 weeks (%) 1 (4%) 17 (63%)h <0.001 
n=27 HEU 
n=27 UE 
12 weeks (%) 1 (4%) 11 (44%) <0.001 
n= 27 HEU 
n=25  UE 
Weight over time 
 2 weeks (mean, 
range), kg 
3.28 (2.10-4.37) 
SD (0.52) 
3.34 (2.16-4.50) 
SD (0.50) 
0.64a 
n=28 HEU 
n= 29 UE 
 6 weeks (mean, 
range), kg 
4.38 (3.27-5.4) 
SD (0.60) 
4.31 (2.90-5.30) 
SD (0.66) 
0.66a 
n=28 HEU 
n= 27 UE 
12 weeks (mean, 
range), kg 
5.69 (4.30-7.06) 
SD (0.74) 
5.40 (3.60-7.32) 
SD (0.86) 
0.30a 
n=28 HEU 
n= 26 UE 
6 months (mean, 
range), kg 
7.72 (6.04-9.57) 
SD (1.29) 
7.20 (5.60-10.20) 
SD (1.08) 
0.09a 
n=25 HEU 
n= 22 UE 
12 months 
(mean, range), kg 
9.50 (7.65-11.70) 
SD (1.29) 
8.33 (6.45-11.40) 
SD (1.242) 
0.12a 
n=23 HEU 
n= 21 UE 
18 months  
(mean, range), kg 
11.19 (8.90-14.30) 
SD (1.69) 
10.06 (7.25-12.90) 
SD (1.4068) 
0.03a 
n=18 HEU 
n= 21 UE 
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24 months  
(mean, range), kg 
12.46 (9.50-16.10) 
SD (2.06) 
11.20 (9.00-13.80) 
SD (1.30) 
0.03a 
n=17 HEU 
n= 20 UE 
a
 Student’s t-Test 
b
 Pearson Chi-Square 
c
 In the HEU group, one infant was born via C-section.  
d
 Mode of delivery for one infant in the control group was not documented 
e 
Fisher exact, one tailed test 
f 
Two way ANOVA 
g 
A Pearson Chi-Square analysis was followed using a cross-tabulation form of analysis 
h 
One infant in the UE group were breast fed from two different women. Infant was thus not counted 
as part of exclusive breastfeeding criteria 
4.1.3.2 PMTCT 
During the study period, all HIV-positive women were assessed according to the WHO 
clinical staging guidelines as part of routine care. As soon as the women were confirmed to 
be HIV positive, CD4 counts were measured.  
As part of the clinical guidelines for routine care, mothers with a CD4 count greater than 200 
cells/µl followed the PMTCT regimen. This consisted of dual therapy for both mother and 
infant and involved the initiation of zidovudine at 28 weeks or more gestation, followed by 
zidovudine for 1 month to the infant, as well as a single dose of NVP to both infant and 
mother.  
Mothers, who were in WHO clinical stage 4 with a CD4 count less than 200 cells/µl, were 
eligible for Highly Active Antiretroviral Therapy (HAART). Of the 27 HEU infants who were 
enrolled, 23 maternal CD4 counts were extracted from the patient files. Four of the CD4 
counts were not listed. A total of 6 mothers had a CD4 count below 200 cells/µl. Of these, 3 
mothers were initiated on HAART. One mother with a CD4 count of 293 cells/µl also 
received HAART during pregnancy.  
HIV positive mothers were provided with free infant feeding formula for 6 months. 
All information regarding PMTCT for both mother and infant, including maternal CD4 counts 
were extracted from the patient hospital records and documented if available. 
4.1.3.3 Inclusion and Exclusion Criteria 
Mothers who delivered clinically healthy babies of appropriate birth weight and gestational 
age with no congenital abnormalities were eligible for the study. Selected mothers were 
recruited at Tygerberg Hospital maternity ward postnatally and signed informed consent to 
enrol their infants in the study. Infants with acute illnesses and an HIV positive polymerase 
chain reaction (PCR) at 2 and 6 weeks (suggesting a failed PMTCT programme) were 
excluded from the statistical analysis, but remained part of the study and their health 
followed up at each visit.  
Maternal exclusion criteria included: 
 Mothers that had or were currently undergoing tuberculosis (TB) treatment 
 Unstable or untreated hypertension during pregnancy (including pre-eclampsia) 
 Proteinuria loss greater than 300mg/L/d] 
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 Perinatal pyrexia of more than 38˚C during labour 
 Current infection or undergoing treatment for syphilis 
 Any form of malnutrition or immunodeficiency (other than being HIV positive) 
  Anaemia (haemoglobin levels less than 8g/L) 
4.1.3.4 Sample Collection and Storage 
Enrolment of participants for the pilot study occurred over a period of 4 months (March-June 
2009).  Approximately 95 mothers were recruited for the study shortly after delivery at the 
Tygerberg Hospital Maternity Ward and signed informed consent for enrolment of their 
infants. Patients were referred to the KIDCRU unit and the infants were followed up at 2, 6 
and 12 week and 6, 12 and 18 and 24 month time points. The final study group consisted of 
27 HEU and 30 UE infants. At the 2 week follow-up 4 infants were confirmed HIV PCR 
positive. 
Preparation of Heparinised Syringes for Blood Collection 
Sodium heparin syringes were prepared 1 hour prior to blood collection in a Biosafety Level 
3 (BLS3) laboratory at the Division of Medical Virology, University of Stellenbosch, 
Tygerberg. Five millilitre (5ml) sterile syringes (Neomedic, UK) were primed with sodium 
heparin (Pharmaceutical Partners of Canada) using sterile 23 gage needles (BD 
Biosciences, USA). Approximately 250µl of heparin (10 000 USP Units/ml) was transferred 
into the syringe, which was then capped (BD Biosciences, USA), sealed and left at room 
temperature until used (within 24 hours). 
Blood Collection 
At each time point, a maximum of 4.5 ml of blood was collected into pre-primed sodium 
heparin syringes and about 500µl was collected into paediatric EDTA tubes (BD 
Biosciences, USA). Blood was collected by venepuncture of a peripheral vein in the cubital 
or external jugular vein in the neck. Plasma for antibody studies was collected from sodium 
heparin blood by centrifugation at 3200 rpm for 5 minutes (with brake). About 5 aliquots of 
plasma (approximately 400µl in each tube) were collected into Eppendorf tubes and frozen 
at -80˚C. Three hundred and fifty microlitres (350µl) of whole blood was allocated at the 18 
and 24 months time point for flow cytometric biomarker analysis. For each flow panel, 
consisting of four florochromes, 50µl of whole blood was allocated. Innate immune analysis 
was completed at the 2 and 6 weeks, as well as at the 6, 12 and 24 months time points 
respectively. 
Confirmation of immunisation 
Infant immunisation status was documented on Road to Health Cards (RTHC) by 
appropriate clinic nurses after the administration of the vaccine. RTHC’s were then collected, 
copied and certified at each time point. Only infants with confirmed vaccination dates formed 
part of the analysis.  
Clinical Assessment 
Mothers and their infants were referred to KIDCRU at each visit where a full clinical 
assessment was completed and the information documented on a data capture form. Infants 
were examined by a medical doctor experienced in paediatric medicine for infections and 
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abnormal health. Information concerning growth, feeding regimens, demographics, 
medication, hospitalisations and maternal health was documented at each time point. 
4.1.4 Routine Laboratory Tests 
4.1.4.1 HIV Polymerase Chain Reaction (PCR) Analysis  
An HIV PCR was done for all infants on the study at 2, 6 and 12 weeks and 24 months of 
age. Approximately 75µl of EDTA whole blood was dispensed onto dried blood spot paper 
(DBSP), which was labelled with the patient number and date. The dried blood spots were 
sent to the Division of Medical Virology, NHLS Tygerberg for analysis. 
A qualitative AMPLICOR HIV-1 DNA test, version 1.5 (Roche Molecular Systems Inc, 
Branchburg, New Jersey) was performed on the DBSs from infants at 2 and 6 weeks, after 
which the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative HIV-1 DNA test using 
AMPLILIMK Software, version 3.2 Series (Roche Molecular Systems Inc, Branchburg, New 
Jersey) was employed for the 12 week and 24 month time points. The latter method allowed 
for greater sensitivity (98.8%) and specificity (97.1%) with a positive predictive value of 
90.9% and a negative predictive value of 99.6%. 
AMPLICOR HIV-1 DNA test, version 1.5 
This test was based on four key procedures: (1) Sample preparation, (2) PCR amplification 
or target DNA using HIV-1 specific complementary primers, (3) hybridisation of the amplified 
products to oligonucleotide probes specific to the target DNA and (4) the detection of the 
probe-bound amplified products by calorimetric determination.  
An area of the DBS was punched after which 1ml of Amplicor BLD wash solution was added 
and rotated for 20 minutes. The supernatant was then discarded.  
A working extraction mix was prepared and transferred to a 15ml conical tube. Eighty 
microlitres (80µl) of the HIV-1C reagent also added to the tube. The positive and negative 
HIV-1 controls (50µl of each) were prepared separately.  Two hundred microlitres (200µl) of 
the working mix was added to each pellet including the control tubes. Samples were then 
incubated on a heating block at two intervals of 30 minutes at 60˚C and 100˚C.  
After incubation, 50µl of each sample was added to the analogous working mastermix tubes 
after which amplification was done using the Perkin Elmer 9600 PCR machine. Amplicons 
were then denatured by the addition of 100µl of DN solution.  
Amplicon detection involved the addition of 100µl of HIV-1 HYB to each well in the source 
plate. Twenty-five microlitres (25µl) of the denatured and control amplicon samples were 
added to the plate and mixed until a colour change from blue to yellow was noted. 
Subsequent to incubation (37˚C for 1 hour), the plate was washed using AMPLICOR HIV-1 
wash buffer. One hundred microlitres (100µl) of AV-HRP was added to each well and 
incubated for 15 minutes at 37˚C. The wells were washed and 100µl of substrate, prepared 
by mixing 2.0ml of SUB A and 0.5ml of SUB B, was added to each well. A colour reaction 
was allowed to develop by incubating the plates in the dark at room temperature for 10 
minutes. One hundred microlitres (100µl) of Stop solution was added. The absorbance was 
read at 450nm using the Anthos Reader (Biochrom Ltd, UK). Results were either negative or 
positive. Inconclusive and positive test results were repeated.   
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COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative HIV-1 DNA test 
This is mainly an automated procedure and involves 4 key processes: (1) Sample pre-
extraction and incubation, (2) Sample preparation to isolate HIV-1 target nucleic acids, (3) 
Reverse transcription of the target RNA to generate complementary DNA and (4) 
Simultaneous amplification of target cDNA or proviral DNA by PCR and detection of cleaved 
dual-labelled oligonucleotide detection probe specific to the target.  
The COBAS instrument was loaded with the necessary reagents for processing. Control 
standards, HIV-1 QUAL CS1 were placed on a specific reagent rack of which HIV-1 QUAL 
CS2, HIV-1 QUAL CS3 and HIV-1 QUAL CS4 was placed onto a separate reagent rack.  
One thousand one hundred microlitres (1100µl) of SPEX was then added to each tube 
containing 12mm punched DBSs. Vials for the CTM negative and HIV-1L positive control 
were vortexed and 1000ul transferred to tubes placed at position 1 and 2. 
Sample tubes were placed in an Eppendorf Thermomixer Comfort at 56˚C with continuous 
shaking at 1000 rpm for 10 to 30 minutes in to lyse blood clots. After incubation samples 
were then loaded in corresponding positions and the machine instructed to process samples. 
The analyser automatically determines the presence of HIV-1RNA or proviral DNA and HIV-
1C RNA in the samples and controls. During this analysis, the cycle threshold value as well 
as fluorescence intensity is determined for either the HIV-1 RNA or proviral DNA and the 
HIV-1C RNA of both sample and controls. The analyser also determines if HIV-1L positive 
and CTM negative controls are valid. Should controls fall out of the predicted range, a FLAG 
is generated and samples were repeated. 
Samples that are indicated as positive and have a cycle threshold value greater than 32 or 
an AFI value less than 5 were repeated for confirmation.  
4.1.4.2 Lymphocyte Count (CD3/CD4/CD8) 
Routine lymphocyte analyses were completed for all patients at each time point by the 
Division of Medical Virology, University of Stellenbosch at the Faculty of Health Sciences, 
Tygerberg. In summary, 50µl of whole EDTA blood was incubated with an aliquot of 20µl 
MultiTest™ (BD Bioscience, USA) monoclonal antibody mixture (CD3-FITC/CD4-APC/CD8-
PE/CD45-PerCP) in a TruCount beads tube for 15 minutes at room temperature in the dark 
due to the light sensitive characteristic of the monoclonal antibodies. After the first 
incubation, 450µl of FACS Lysing solution (FACSLyse, BD Bioscience, San Jose, USA) was 
added and cells incubated at room temperature for a further 15 minutes. Samples were 
subsequently analysed on a flow cytometer (FACSCalibur, Becton Dickinson) using the 
automated MultiSet™ software. The CD3, CD4 and CD8 results as well as the CD4:CD8 
ratio of each sample analysed were reported as percentages of each subset, as well as 
absolute values. These results were determined using the beads of known concentration in 
each tube specific to the batch number.   
4.1.4.3 Full and Differential Blood Counts 
At each time point, full and differential blood counts were performed on all infants enrolled 
into the study. Collected EDTA blood samples were sent to the Division of Haematology, 
NHLS Tygerberg Hospital for analysis.  
The Advia 2120 Haematology Analyser® (Siemens Healthcare Diagnostics, USA) is a fully 
automated diagnostic instrument which employs the principles of flow cytometry and 
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involves cytochemical reactions. Cell classification, counts, size and haemoglobin levels are 
measured by the conversion of cytometric data into recognisable results.  
Paediatric tube specimens were run via a manual open tube sampler (OTS). Two hundred 
microlitres (200µl) of the sample was passed through the system for measurement of 
various parameters. For the measurement of haemoglobin, modified cyanmethaemoglobin, a 
surfactant, lyses the red cells and releases haemoglobin. When the protein is denatured, 
haem combines with cyanide and the product is read in the colorimeter. Red blood cells 
were lysed, fixed and stained in the peroxidise chamber. A precipitate containing peroxidises 
and a chromogen is added together with hydrogen peroxide. In lymphocytes and large 
unstained cells (LUC), perioxidase is absent; these cells are identified when moving past a 
pair of detectors in a tungsten light-based optics chamber. The cell types described above 
are characterised in combination with their size (scatter) and peroxidase activity.  
A manual differential count was performed on both study groups to further classify LUC that 
were often noted in automated counts, particularly the HEU group. 
The optimal staining of cellular elements was done using a Romanowsky stain, which assists 
in the identification of abnormal cells, as well as mature and immature leukocytes, which 
may be the result of underlying disorders.   
4.2 VACCINE SPECIFIC ANTIBODY RESPONSES 
The quantitative determination of specific antibody levels to pertussis, tetanus, Hib and 
pneumococcus was performed by the use of standard commercial ELISA assays. Analysis 
was performed within a South African National Accreditation System (SANAS) accredited 
Immunology routine diagnostic laboratory, NHLS, Tygerberg Hospital, using validated 
methods as specified by the kit instructions for the determination of antibody levels. All 
ELISA procedures were done under the supervision of a senior Medical Technologist. The 
external quality assurance for the ELISA laboratory falls under the Royal College of 
Pathologists of Australasia (RCPA) programme.  
4.2.1 Instrumentation and Reagents 
The Bio-Rad PhDTM system (Bio-Rad Laboratories, Inc., Hercules, USA), a robotic liquid 
handling method was employed. Quantitative IgG plasma antibody levels were measured 
according to the manufacturers’ instructions provided by commercial ELISA kits. 
All lines of the ELISA Analyser (Bio-Rad PhDTM) were decontaminated and primed with 
distilled water and appropriate wash buffer before use as part of the daily quality control. 
Specific IgG levels to pertussis and tetanus were evaluated using SERION ELISA classic 
kits (ESR120G and ESR108G Serion Immunodiagnostica GmbH, Würzburg, Germany) in 
accordance with the manufacturers’ guidelines.  
Hib capsular polysaccharide and PCP specific IgG were measured using VaccZyme™ 
Human Anti-Hib and Anti-PCP ELISA kits (MK016 and MK012; The Binding Site Ltd, 
Birmingham, England). Microwells in the pneumococcal assay were  pre-coated with PCP 
antigens 1-5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F 
and 33F.  
All kits were stored at 4°C and brought to room temperature before use. Controls and 
standards provided as part of each kit were included with the samples in all runs.  
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All samples were frozen and batched thawed on the day of analysis. Each thawed batch was 
processed immediately. Samples were not run in duplicate due to limited sample volume.  
4.2.2 Quantitative IgG Measurement for Pertussis and Tetanus 
Samples with positive and negative controls (controls provided with kits) were diluted 1:100 
in dilution buffer (phosphate buffer with protein and Tween 20). One hundred microliters 
(100µl) were dispensed in pre-coated microtiter plates for pertussis and tetanus toxoid. The 
sample-antigen complex was then incubated for 60 minutes at 37˚C to ensure optimal 
binding of antibodies to antigen (solid phase). Microwells were then washed four times with 
300µl of concentrated washing solution (sodium chloride containing Tween 20 and 30mM of 
Tris) to ensure removal of all unbound antibodies and proteins. Thereafter, 100µl of the 
APC-conjugate solution (anti-human-IgG, IgA, IgM from polyclonal goat antibodies 
conjugated to alkaline phosphatase and stabilised with protein stabilisation solution) was 
added to the immune complex and incubated for 30 minutes at 37⁰C. A second washing step 
was done to ensure removal of all unbound conjugate. Addition of 100µl of pNPP-substrate 
solution (para-nitrophenylphosphate, solvent free buffer) resulted in a formation of a 
coloured product which was due to a reaction with the conjugate after 30 minutes of 
incubation at 37˚C. A STOP reagent (1.2N sodium hydroxide) was added to halt the enzyme 
reaction which subsequently resulted in the formation of a yellow coloured product relative to 
the amount of specific antibody bound. The optical density (OD) was measured 
spectrophotometrically at 405nm within 60 minutes of adding the STOP solution against the 
substrate blank with a reference wavelength between 405nm and 620nm. SERION easy 
base 4PL-Software was used to calculate the antibody concentration in IU/ml from the OD 
obtained. 
4.2.3 Validation and Interpretation of Test Results for Pertussis and Tetanus 
Results were valid if the substrate blank had an OD of <0.25. The negative control should 
always represent a negative concentration for pertussis (calculated by the software 
programme) and for tetanus it should be less than 0.1IU/ml. The positive control value must 
be within the validity range specified on the LOT specific quality control (QC) certificate. 
Tetanus values below 0.1IU/ml were regarded as lower than the detection limit. 
Tetanus antibody levels were classified as providing sufficient protection if more than 
0.1U/ml.  
The normal (protective) ranges for antibodies to pertussis, defined by the manufacturer is 
listed in Table 4-2 below.  
Table 4- 2: References ranges for pertussis antibody levels defined by the manufacturer  
Concentration Evaluation of vaccination titres 
>30 FDA U/ml Normal Protector Ranges 
20-30 FDA U/ml Equivocal 
<20 FDA U/ml None 
 
The WHO classifies tetanus antibody levels greater than 0.1 IU/ml providing sufficient 
protection (WHO, 2006)  
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The SERION ELISA kit further classifies the antibody levels to tetanus as described as in 
Table 4-3 below. The significance of these test results were evaluated against several 
parameters, including age, vaccination history and clinical history.  
 
Table 4- 3: Reference ranges for tetanus toxoid antibody levels defined by the manufacturer 
Concentration Evaluation of vaccination titres 
<0.01 IU/ml 
no immunity, depending on vaccination history: booster shot or 
basic immunisation 
0.01-0.1 IU/ml no safe immune protection, booster shot recommended 
0.11-0.5 IU/ml sufficient immune protection 
0.51-1.0 IU/ml sufficient immune protection, booster shot not necessary 
1.1-5.0 IU/ml long term protection, titre control after 5-10 years 
>5.0 IU/ml long term protection, titre control after 10 years 
 
4.2.4 Quantitative Antibody Levels to Hib and PCP 
Patient samples and six calibrators provided in the kit were diluted 1:100 in dilution buffer 
specific for Hib and PCP and added to each of the pre-coated anti-Hib or anti-PCP microtitre 
wells (solid phase). The sample-antigen complex was then incubated for 30 minutes at room 
temperature to ensure optimal binding of antibodies contained in patient serum (mobile 
phase). Microwells were washed three times with 300µl of wash buffer to ensure all unbound 
antibodies and proteins within patient sera were removed. After washing, 100µl of conjugate 
solution (purified peroxidise labelled antibody to human IgG) was added to the immune-
complexes and incubated for 30 minutes at room temperature. A second washing step was 
carried out to ensure all unbound conjugate were removed. Addition of 100ul of substrate 
solution (3,3,,5,5, tetramethylbenzidine (TMB)) was added and allowed to react, which 
resulted in a blue coloured product. After the addition of the substrate solution, 100µl of 
STOP reagent (3M phosphoric acid) was added to each of the wells. This latter step ensured 
that the enzyme-substrate reaction was terminated, resulting in the formation of a yellow 
colour, which is relative to the amount of specific antibody bound.  
The OD was measured spectrophotometrically at 450nm within 30 minutes of adding the 
STOP solution. A calibration curve was constructed for both anti-Hib IgG and anti-PCP 
antibody with concentration on the log scale against the OD on the linear scale for each 
calibrator. The accuracy of the curve is limited by the sensitivity below 0.33mg/L. 
4.2.5 Validation and Interpretation of Test Results for Hib and PCP 
The values for controls (high and low controls) were specified on the QC certificate of the 
respective kits. The standard curve was constructed using known concentrations indicated in 
the kit. The generated curve of the test run was compared to that of the QC certificate for 
further verification of a valid test run. 
Anti-Hib antibody titres of more than 1.0mg/L were regarded as protective (Agbarakwe et al., 
1995).  
There has been no defined level of protective immunity for the collective response to 
pneumococcal serotypes indicated for the PCV7 vaccine.  
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4.2.6 Validation of Plasma Samples for the use of Hib and PCP kits   
Virion Serion kits are validated for use of both plasma and serum.  However, according to 
the manufacturing guidelines for the MK016 and MK012 kits (The Binding Site Ltd, 
Birmingham, England), plasma samples were not validated to be used with these kits. A 
subsequent in-house comparative validation assay was done to compare and correlate the 
results found with plasma and serum for Hib and PCP kits. For this validation, 10 adult 
samples were collected in sodium heparin (for plasma) and serum-separating tubes (SST) 
(for serum). Samples were centrifuged at 4500 rpm to separate the plasma and serum from 
the red blood cells and then analysed according to the methods described above under all 
specified laboratory conditions. Results showed no difference between the two sample 
types. Statistical methods were employed to compare the results. An intra-class correlation 
(ICC) analysis was used to determine if any differences between the two sample types 
exists. Results for the Hib kit showed an ICC value of 0.967 (SEM 0.697) and for the PCP kit 
an ICC value of 0.999 (SEM 3.165) was calculated. An ICC value close to one is indicative 
of the similarity in the methods used. Based on the statistical outcomes, we therefore 
concluded that there were no significant differences between the results obtained for serum 
and plasma.  
4.3 CELLULAR MARKERS OF IMMUNE ACTIVATION, APOPTOSIS AND B CELL 
MEMORY 
4.3.1 Experimental Design of Study 
This part of the study was designed to investigate the levels of immune activation, apoptosis 
and regulation on adaptive immune cells (CD4+ T, CD8+ T, CD19+ B and CD20+ B cells) in 
HEU and UE infants at 18 and 24 months of age. In addition, a functional assay was 
developed and optimised to evaluate the concept of spontaneous apoptosis by measuring 
the expression of the early apoptotic marker, Annexin V, on CD4+ T and CD20+ B cells at 
16 and 24 hours. At the 24 month time point, the expression of Annexin V was only 
measured at 16 hours.   
In addition, this part of the study was also aimed at investigating whether adequate B-cell 
memory is generated by HEU infants, in comparison to UE infants. Therefore, the 
expression of cellular markers of memory (CD27) on CD20+ and CD19+ B cells was 
measured.  
For comparing various cellular markers of immune activation, apoptosis and B cell memory, 
and each subject had four polystyrene round bottom non-pyrogenic falcon tubes (BD 
Bioscience, USA) labelled panel 1-7. Table 4-4 below describes the various panels and 
cellular markers with appropriate function. After sample processing and staining, acquisition 
was conducted using a four colour flow cytometer (BD™ FACSCalibur).  
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
55 
 
Table 4- 4: Summary of cellular markers investigated in HEU and UE infants at 18 and 24 months of 
age (on which markers were measured is highlighted in blue) 
PANELS FLOROCHROMES MARKER MEASURED FUNCTION 
PANEL 1 
PE FasL 
Expressed on activated T cells, signalling pathway for 
apoptosis 
FITC Fas 
Expressed on T cells, initiates a signalling cascade 
leading to cell death 
PERCP CD69 Expressed on activated T cells involved in signalling 
APC CD4 Class II MHC restricted T cell, signalling and adhesion 
PANEL 2 
PE CD80 
Expressed on activated B cells, co-stimulator for T cell 
activation 
FITC Annexin V Measure early apoptosis on B and T cells in this panel 
PERCP CD20 
Expressed on all B cells, Involved in B cell activation 
(general B cell marker) 
APC CD4 Class II MHC restricted T cell, signalling and adhesion 
PANEL 3 
FITC Fas 
Expressed on B cells, initiated a signalling cascade 
leading to cell death 
PERCP CD20 
Expressed on all B cells, Involved in B cell activation 
(general B cell marker) 
APC CD62L 
Expressed on B-cells, homing of naive T cells to 
peripheral lymph nodes 
PANEL 4 
PE CD10 Expressed on mature B cells 
PERCP CD20 
Expressed on all B cells, Involved in B cell activation 
(general B cell marker) 
APC CD27 
Memory B cell marker, mediates co stimulatory signals 
for T and B cell activation 
PANEL 5 
PE CTLA-4 
Expressed on cytotoxic T lymphocytes, involved in the 
regulation of the immune system by transmitting inhibitory 
signals to T cells  
FITC CD127 
Marker of late pro-T cell growth, proliferation and 
maturation, IL-7 receptor 
PERCP CD4 Class II MHC restricted T cell, signalling and adhesion 
APC CD40L 
Expressed on activated T cells and involved in promoting 
B cell proliferation 
PANEL 6 
PE PD-1 
Involved in cell regulation during activation, extended 
member of CTLA-4 family of proteins 
FITC CD69 B cell activation marker 
PERCP CD19 B cell co-receptor subunit 
APC CD27 
Memory B cell marker, mediates co stimulatory signals 
for T and B cell activation 
PANEL 7 
PE FASL 
Expressed on activated T cells, signalling pathway for 
apoptosis 
PERCP CD8 Expressed on cytotoxic T cells (MHC class I receptor) 
APC CD38 
Well described marker of immune activation in HIV, 
expressed on T cells  
 
Spontaneous apoptosis was measured by analysing the expression of cellular apoptotic 
marker, Annexin V, using two polystyrene round bottom non-pyrogenic falcon tubes (BD 
Biosciences, USA) each, labelled 16 and 24 hours. After sample processing and staining 
acquisition was conducted using the Becton Dickinson BD™ FACSCalibur. 
4.3.2 Study Subjects and Blood Collection 
The subjects involved in this segment of the study included infants that formed part of the 
larger pilot study and arrived for the 18 and 24 month visit. Analysis for panels 1-7 listed 
above was completed for a total of 98 infants.  
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At 18 months, a total of 41 infants (18 HEU, 21 UE and 2 HIV positive) were analysed for 
cellular markers listed in panel 1-4. During later stages of the 18 months time point, 
additional panels (5-7) were added and analysed for 18 infants (9 HEU and 9 UE). The 
measurement of Annexin V as part of the spontaneous apoptosis assay (also initiated later 
in the time point), was completed for a total of 15 infant samples which included 6 HEU, 8 
UEs and 1 HIV positive infant.  
At the 24 month time points, a total of 39 infants were analysed (17 HEU, 20 UE and 2 HIV 
positives) for panels 1-7 including the measurement of Annexin V expression at 16 hours 
only.  
Four hundred and fifty microlitres (450µl) of the total 5ml of collected blood (described 
above) was allocated for this part of the study.  
4.3.3 Reagents and Buffers 
Reagents 
a) Monoclonal antibodies: CD4-APC (Clone: OKT4-Biolegend, USA), Fas- 
 FITC (Clone: DX2-BD Biosciences, USA), FasL-PE (Clone: MFL3-  
 eBioscience, UK), CD69-PerCP (Clone: FN50-BD Biosciences, USA),  
 Annexin V-FITC (BD Biosciences, USA), CD20-PerCP (Clone: L27-BD  
 Biosciences, USA), CD80-PE (Clone: L307.4-BD Biosciences, USA), CD62L-
 APC (Clone: Dreg56-BD Biosciences, USA), CD10-PE (Clone: HI10a-BD  
 Biosciences, USA), CD127-FITC (Clone: HL-7R-M21-BD Biosciences, USA), 
 CD27-APC (Clone: 0323-eBioscience, UK) CD4-PerCP (Clone: SK7-BD  
 Biosciences, USA), CTLA-4-PE (Clone: BNI3-BD Biosciences, USA), CD40L-
 APC (Clone: TRAP1-BD Biosciences, USA), CD19-PerCP (Clone: HIB19- 
 Biolegend, USA), PD-1-PE (Clone: MIH4-BD Biosciences, USA), CD69-FITC 
 (Clone: FN50-BD Biosciences, USA), CD8-PerCP (Clone: SK1-BD  
 Biosciences, USA), CD38-APC (Clone: HIT2-eBioscience, UK) and FasL-PE 
 (Clone: MFL3-eBioscience, UK) 
b) Antibody cocktails: prepared according to each panel listed in Table 4-4. 
 For each panel an antibody cocktail was made using equal volumes of each 
 monoclonal antibody. The volume of antibody cocktail alliquoted to each tube 
 is described below. The optimisation (by use of titration and Fluorescence-
 minus-one experiments) of required volume was determined by ongoing  
 projects within the laboratory.   
Buffers and Solutions 
a) 10% FACS lysing solution: working solution was prepared by diluting the 
 10X concentrate (BD Biosciences, USA) in MilliQ water. The solution  
 was used to lyse red blood cells and suspend white blood cells. The  
 solution was stored at 4˚C and brought to room temperature before  
 use.  
b) Staining buffer: this solution was prepared by adding 1.25ml of heat  
 inactivated (56˚C for 1 hour) Foetal Bovine Serum 10106 (FBS;   
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 Gibco®, Invitrogen, New Zealand) to 498.75ml of Dulbecco’s   
 Phosphate Buffered Saline 14190 (DPBS; Gibco® Invitrogen, New  
 Zealand). This buffered salt solution was used during washing stages  
 of cell preparation. Solution was stored at 4˚C and brought to room  
 temperature before use.  
c) Cell culture media: media for spontaneous apoptosis assay was   
 prepared using sterile endotoxin-free RPMI 1640 (Lonza, Biowhittaker,  
 USA) with 10% heat inactivated FBS. Cell culture media was stored at  
 4˚C and was warmed up in a 37˚C incubator an hour before use.  
4.3.4 Cell Preparation and Staining 
Daily maintenance and quality control of flow cytometer 
The basic daily maintenance of the flow cytometer includes start-up and shut-down 
procedures. The start-up procedure includes switching on the flow cytometer, followed by 
the computer at least 15 seconds later to ensure connectivity. The sheath container is filled 
with FACSFlow® (sheath fluid) and the waste container emptied and filled with 200ml of 
FACSClean®. The system is then pressurised using the vent valve. Air within the sheath filter 
is released by using the bleed tube. Two primes are performed to ensure that the flow 
chamber contains no bubbles. About 4ml of distilled water is run through the machine on Hi 
for 5 minutes to ensure effective cleaning of the system. 
After cleaning procedures, calibration and colour compensation of the flow cytometer is 
followed.  
Colour compensation is done using FACSComp® beads. For four colour compensation and 
time delay calibration, two tubes were set up using one drop of unlabelled CaliBRITE® (BD 
Biosiences) beads and one drop of APC-labelled CaliBRITE® beads in 1ml of sheath fluid 
(FACSFlow®). In the tube used for colour compensation, 1 drop of each unlabelled FITC, 
PE, PerCP and APC labelled CaliBRITE beads in 3ml of sheath fluid was added. By use of 
the FACSComp® programme, the machine is monitored for its performance in automated 
time delay calibration and colour compensation. 
As part of the daily shut-down procedure, FACSRinse® is run through the machine with the 
support arm in the un-engaged position. Once the machine aspirates about 2ml of 
FACSRince®, the support arm is placed in the engaged position and continued to run for 
5minutes. The same procedure is followed for FACSClean® and distilled water. On 
completion of this process, the sheath container is de-pressurised by releasing the vent 
valve and selecting the standby mode.  
Staining for markers of immune activation, regulation, apoptosis and B cell memory 
The process for staining cells for the list of markers in Table 4-5 include pipetting 50µl of 
whole blood into four polystyrene round bottom non-pyrogenic falcon tubes labelled panel 1-
7. Five microliters (5µl) of the pre-made antibody cocktail as described above was then 
added to each one of the four panels. Contents were gently mixed by small vortex pulses 
and incubated for 20 minutes in the dark at room temperature.  
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After incubation, 500µl of BD FACSLysing SolutionTM (1X) was added to lyse the red blood 
cells and was thereafter vortexed. Further incubation for 20 minutes in the dark at room 
temperature followed. Subsequently, 500µl of staining buffer was added, vortexed and 
centrifuged for 5 minutes at 1300 rpm also at room temperature.  
After centrifugation, 750µl of the supernatant was removed and the pellet gently re-
suspended. Three hundred and fifty microlitres (350µl) of the staining buffer was added to 
the pellet, which was then stored in the dark at 4˚C until measured on a flow cytometer.  
Staining for Annexin V as cellular marker for spontaneous apoptosis 
One hundred microliters (100µl) of subject whole blood was added to two polystyrene round 
bottom non-pyrogenic falcon tubes and mixed with 100µl of RPMI 1640 + 10% foetal calf 
serum (FCS) (cell culture media).  Samples were thereafter incubated at 37°C (5% CO2) for 
16 and 24 hours respectively. The time points (16 and 24 hours) were chosen based on 
optimisation protocols, were samples were previously incubated at 4 and 16 hours. It was 
concluded that 4 hours was insufficient time for the measurement of spontaneous apoptosis 
and 16 hours seemed to be optimal.  
At 16 and/or 24 hours, samples were removed from incubation and centrifuged at 1300 rpm 
for 5 minutes at room temperature. One hundred and fifty microlitres (150µL) of the 
supernatant was removed in order to leave a volume of 50µl of whole blood.  
The staining procedure for Annexin V then followed which included incubation in the dark at 
room temperature for 20 minutes with 5µl of pre-made antibody cocktail, which included 
monoclonal antibodies, Annexin V-FITC, CD4-APC and CD20-PerCP (BD Biosciences, The 
Scientific Group, South Africa).    
After incubation, 500µl of BD FACSLysing SolutionTM (1X) was added to lyse the red blood 
cells and vortexed thereafter. Further incubation for 20 minutes in the dark at room 
temperature followed. Subsequently, 500µl of staining buffer was added, vortexed and 
centrifuged for 5 minutes at 1300 rpm also at room temperature.  
After centrifugation, 750µl of the supernatant was removed and the pellet was gently re-
suspended. Three hundred and fifty microlitres (350µl) of the staining buffer was then added 
to the pellet which was then stored in the dark at 4˚C until measured on the flow cytometer.  
4.3.5 Flow Cytometric Analysis  
Prepared samples were acquired on a flow cytometer (Becton Dickinson BD™ 
FACSCalibur). CellQuest™ software was used for the acquisition and the threshold was set 
on forward scatter (FSC) to exclude cell debris. A total of 20,000 events in gate 1 (as shown 
in Figure 4-1 below) were acquired. During both 18 and 24 month time points, a panel of 
unstained cells were acquired. The analysis of these unstained panels served as negative 
controls and assisted in the visualisation of the negative population as well as defining 
populations of interest.   
Defining Lymphocyte Population (Gating strategy) 
A dot plot of forward scatter (FSC), which is an indication of cell size and side scatter (SSC), 
an indication cell granularity, was constructed for each sample. Three cell populations were 
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noted with the dot plot. Neutrophils represent the highest population of cells with the highest 
FSC and SSC. Monocytes have similar FSC as neutrophils and intermediate SSC. 
Lymphocytes are located at the bottom of the plot and have the lowest SSC and FSC, 
implying that they are smaller in size and have the least complexity.  
Figure 4-1 below indicates the distinct population groups that exist, as well as the gating 
strategy for lymphocytes.  
 
  
Figure 4- 1:  Definition of lymphocyte and other cell types indicated by a dot plot. Lymphocytes, 
monocytes and neutrophils were identified and gated according to their different characteristics of size 
and granularity. 
 
The lymphocyte gating strategy was employed during the acquisition of each of the seven 
panels.  
A dot plot was constructed for each panel after which the quadrant statistics was used to 
determine the percentage of cells with marker expression on T and B subpopulations (See 
figures 4-2 to 4-8 below).  
 
 
 
Neutrophils 
Monocyte
ss 
Lymphocytes
Gate 1 
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Figure 4- 2: For panel 1, dot plots visualised above were created to measure dual populations (top 
right quadrants) for each of the parameters indicated by A, B and C. (A) dot plot created to measure 
the expression of FAS-FITC on CD4-APC. (B) Dot plot created to measure expression of FASL-PE on 
CD4-APC. (C) Dot plot created to measure expression of CD69-PerCP on CD4-APC. 
 
  
Figure 4- 3: For panel 2, dot plots visualised above were created to measure dual populations (top 
right quadrants) for each of the parameters indicated by A, B and C. (A) dot plot created to measure 
the expression of Annexin V-FITC on CD4-APC. (B) Dot plot created to measure expression of CD80-
PE on CD20-PerCP. (C) Dot plot created to measure expression of Annexin V-FITC on CD20-PerCP. 
 
             
Figure 4- 4: For panel 3, dot plots visualised above were created to measure dual populations (top 
right quadrants) for each of the parameters indicated by A and B. (A) dot plot created to measure the 
expression of FAS-FITC on CD20-PerCP. (B) Dot plot created to measure expression of CD62L-APC 
on CD20-PerCP. 
 
 
A B C 
A B C 
A B 
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Figure 4- 5: For panel 4, dot plots visualised above were created to measure dual populations (top 
right quadrants) for each of the parameters indicated by A and B. (A) Dot plot created to measure 
expression of CD10-PE on CD20-PerCP. (B) Dot plot created to measure expression of CD27-APC 
on CD20-PerCP. 
            
 
Figure 4- 6: For panel 5, dot plots visualised above were created to measure dual populations (top 
right quadrants) for each of the parameters indicated by A, B and C. (A) dot plot created to measure 
the expression of CD127-FITC on CD4-PerCP. (B) Dot plot created to measure expression of CTLA-
4-PE on CD4-PerCP. (C) Dot plot created to measure expression of CD40L-APC on CD4-PerCP. 
 
 
Figure 4- 7: For panel 6, dot plots visualised above were created to measure dual populations (top 
right quadrants) for each of the parameters indicated by A, B and C. (A) dot plot created to measure 
the expression of CD69-FITC on CD19-PerCP. (B) Dot plot created to measure expression of PD-1-
PE on CD19-PerCP. (C) Dot plot created to measure expression of CD27-APC on CD19-PerCP. 
 
A B 
A B C 
A B C 
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Figure 4- 8: For panel 7, dot plots visualised above were created to measure dual populations (top 
right quadrants) for each of the parameters indicated by A and B. (A) Dot plot created to measure 
expression of FasL-PE on CD8-PerCP. (B) Dot plot created to measure expression of CD38-APC on 
CD8-PerCP. 
Measurement of Spontaneous Apoptosis 
The determination of Annexin V binding was also performed on the FACSCalibur™ flow 
cytometer. A total of 20 000 events were acquired using CellQuest™ software. The gating of 
lymphocytes for this section was the same as described previously (Figure 4-1 above). The 
binding of Annexin V on CD4+ T cells and CD20+ B cells was determined by constructing a 
dot plot and defining quadrant statistics. Figures 4-9 to 4-11 below show dot plots of Annexin 
V binding for T and B cells before and after ex vitro stimulation. Stimulation occurred at 16 
and/or 24 hour time points. 
 
   
Figure 4- 9: Unstimulated expression of Annexin V on CD4-APC cells (A) and CD20-PerCP (B) cells. 
There is no indication of dual populations for both CD4-APC and CD20-PerCP. 
 
A B 
A B 
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Figure 4- 10: Expression of Annexin V after 16 and 24 hour stimulations. (A) The generation of a dot 
plot indicates the expression of Annexin V-FITC on CD4-APC (dual population in the top right 
quadrant) after 16 hours. (B) The generation of a dot plot indicates the expression of Annexin V-FITC 
on CD4-APC (dual population in the top right quadrant) after 24 hours.  
 
   
Figure 4- 11: Expression of Annexin V after 16 and 24 hour stimulations. (A) The generation of a dot 
plot indicates the expression of Annexin V-FITC on CD20-PerCP (dual population in the top right 
quadrant) after 16 hours. (B) The generation of a dot plot indicates the expression of Annexin V-FITC 
on CD20-PerCP (dual population in the top right quadrant) after 24 hours.  
4.4 DATA COLLECTION AND PROCESSING  
Data was collected using Microsoft Excel software (2007) spreadsheets. Basic descriptive 
statistics was done using the same programme. Further statistical analysis was performed 
by the Centre for Statistical Analysis, University of Stellenbosch using Statistica version 10 
software. All data sets were analysed for normality. Data that represented a non-normal 
distribution were log transformed and appropriate statistical methods employed for analysis. 
All comparisons were pre-defined except for the comparison of the 18 and 24 month cellular 
makers over time for the two groups, which was post-hoc. Missing data points were removed 
from all analysis.  
Confidence intervals of 95% were used during analysis and p values less than 0.05 (p<0.05) 
and 0.01 (p<0.01) were considered as statistically significant and highly significant 
respectively.  HIV positive infants (n=4) were excluded from all analysis. 
B 
A B 
A 
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4.4.1 Population Characteristics 
The population characteristics were divided into categorical and numerical data.  
Categorical data included mode of delivery, gender, racial group, housing structure, access 
to running and maternal HIV diagnosis (before or after pregnancy). Numerical data included 
gravidity, maternal age, number of people living in the same household as infant, number of 
people sleeping in the same bed as infant, gestational age, birth weight and weight over 
time.  
Other categorical (PMTCT regime and breastfeeding) and numerical data (gestational age 
when PMTCT therapy started and maternal CD4 count) were listed but not statistically 
analysed due to these factors being related to only one group (HEU) or showed vast 
differences amongst the groups (e.g breastfeeding).   
The Student’s T test was employed for the analysis of all numerical data. All data 
represented normal distribution.  
A non parametric Pearson Chi-Square test was employed for categorical data representing 
housing structure and access to running water and a Fisher’s exact one tailed test p-value 
(for the comparison of proportion) was recorded for mode of delivery. Pearson Chi-Square 
cross tabulations was also used for the analysis of contingency tables presented for gender 
and racial groups. Maternal HIV diagnosis (only for the HEU group) was analysed using a 
two-way Analysis of Variance (ANOVA).  
The minimum and maximum ranges were also displayed for each numerical data set.  
4.4.2 Antibody data 
The antibody levels to specific vaccines (pertussis, tetanus, Hib and pneumococcus) at each 
time point for both groups (HEU and UE) were compared by repeated measures ANOVA 
using a mixed model approach which compensated for infants who missed follow-up visits. 
Data was log transformed to compensate for non-normal distribution. Results were displayed 
graphically using Type III decomposition vertical bars with 95% confidence intervals. The p-
values were calculated using by comparing the Least Square (LS) means of the HEU and 
UE groups at the specific time points.  
HEU and UE subjects were categorised from the 12 week blood draw into groups according 
to vaccination doses given. These groups were stratified and analysed by use of log 
transformation and the employment of ANOVA analysis (report of the F-test p-value) to 
determine the effect of the administration of 1 or 2 doses on the IgG levels to pertussis, 
tetanus and Hib. Median days from vaccination to blood draw was calculated at 12 weeks, 6, 
12 and 18 months of age. Infants who did not receive the required dose(s) by the time of the 
specific blood draw were removed from the analysis. Those infants who received “catch-up” 
vaccinations were included in subsequent analysis. The median days from vaccination to 
blood draw were then re-calculated accordingly.   
Spearman correlations were employed to show a relationship between the specific vaccine 
IgG responses at various time points with maternal age, gravidity, housing structure, gender, 
birth weight, racial group, number of household members and access to running water.  
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4.4.3 Flow cytometry cellular markers 
Differences in the expression of the various cellular markers between the two groups were 
compared by employing a one-way ANOVA analysis. An F-test (which assumes normality) 
p-value was reported of which the non parametric Mann-Whitney U test was used as a 
confirmatory tool to test the hypothesis that stipulates a difference between the two groups. 
In cases where the Mann-Whiney U and F-test showed differing outcomes, data was log-
transformed and the F-test reported. The 18 and 24 month time points were compared 
separately and then over time by using a two-way ANOVA.  
The evaluation of the functional “spontaneous apoptosis” assay at 18 months for the 
comparison of expression of Annexin V at three time points (ex vivo, 16 and 24 hours) were 
compared by using a repeated measures ANOVA analysis. Results were displayed 
graphically using Type III decomposition vertical bars with 95% confidence intervals. The p-
values were calculated by comparing the LS means of the HEU and UE groups at the three 
time points. 
At 24 months, the comparison of the expression of Annexin V at two time periods (ex vivo 
and 16 hours) was compared by using a one-way ANOVA analysis. Results were displayed 
graphically using Type III decomposition vertical bars with 95% confidence intervals. The p-
values were calculated by comparing the LS means of the HEU and UE groups at the two 
time points. 
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5.1 STUDY POPULATION 
5.1.1 Overview  
In this study, children born to HIV positive and negative mothers were assessed 
longitudinally (2 weeks to 24 months) for vaccine-specific IgG responses to pertussis, 
tetanus, Hib and pneumocccus. The 2 and 6 week time points indicated the presumed 
maternally derived antibody levels and thereafter subsequent time points (12 weeks, 6, 12, 
18 and 24 months) represented the post-vaccination response as scheduled according to 
the EPI-SA. Although the IgG levels for the pneumococcal vaccine were determined for all 
infants at each visit, only the presumed maternal antibody levels at 2 and 6 weeks will be 
reported.   
In addition, various specific cellular markers of immune activation, apoptosis, regulation and 
B cell memory on CD4+ T, CD20+ B, CD19+ B and CD8+ T cells were assessed at 18 and 
24 months. Furthermore, we evaluated cell susceptibility to undergoing spontaneous 
apoptosis at 18 and 24 months through the development of a functional ex vivo assay and 
subsequent staining procedures for Annexin V.   
5.1.2 Characteristics of Study Population 
In this longitudinal comparative pilot study, a total of 95 mothers were recruited for 
participation after delivery. Of these, 43 were HIV positive (45%) and 52 were HIV uninfected 
(55%). The study also included 3 sets of twin births, all in the HEU group. 
At the 2 week time point, a total of 61 participants were followed up, which included 27 HEU 
(44%), 30 (49%) UE controls and 4 (7%) HIV positive (PCR confirmed at 2 weeks) infants. 
During the time of recruitment and the 2 weeks visit (first time point), 34 patients were lost-
to-follow-up (LTFU) or excluded from the study. Of these 34 mothers, 22 were HIV negative 
and 12 were HIV positive. See Table 5-2 for reasons of exclusion.  At the final time point (24 
months), a total of 39 participants were followed up and included 17 HEU, 20 UE and 2 HIV 
positive babies (See Tables 5-1 and 5-2 for participant retention and attrition). HIV positive 
babies were excluded from statistical analysis; however, remained part of the study and 
were clinically followed up. 
There were 2 infant deaths during the course of this study. One from the UE group who died 
before the 6 month visit (died of a disseminated adenovirus infection) and an HIV positive 
infant who died before the 12 week visit (was admitted to Red Cross Children’s Hospital and 
died of pneumonia).  
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Table 5- 1: Summary of patient visits (retention) from 2 weeks to 24 months 
 
According to the patient files from the HIV positive mothers (n=27), 52% were diagnosed 
during pregnancy. The majority of these (73.1%) received dual therapy, 15.4% were on 
(HAART) and 11.5% did not receive any form of PMTCT care during pregnancy. A total of 23 
maternal CD4 counts were extracted from the patient records at 2 weeks, which produced a 
median value of 337 cells/µl (SD 150.83). All except one (4%) of HIV infected mothers 
(n=26) selected exclusive formula feeding at birth and one mother in the UE group chose to 
formula feed (n=29).  
Time point Status Number Total and % Retention from last visit 
2 weeks 
HEU 
UE 
HIV POS 
27 
30 
4 
61 (64% of recruited population retained 
for follow-up) 
6 weeks 
HEU 
UE 
HIV POS 
27 
28 
4 
59 (97%) 
12 weeks 
HEU 
UE 
HIV POS 
27 
27 
3 
57 (97%) 
6 months 
HEU 
UE 
HIV POS 
25 
22 
3 
50 (88%) 
12 months 
HEU 
UE 
HIV POS 
23 
21 
3 
47 (94%) 
18 months 
HEU 
UE 
HIV POS 
18 
21 
2 
41 (87%) 
24 months 
HEU 
UE 
HIV POS 
17 
20 
2 
39 (95%) 
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The characteristics of the study population are outlined in Table 4-2 (Chapter 4).   
Table 5- 2: Summary of patient attrition 
Number of patients Maternal HIV Status Reason 
28 
18 HIV negative 
10 HIV positive 
Refused further participation 
1 HIV positive Relocation 
1 HIV negative 
Mother diagnosed with 
hypertension 
1 HIV negative 
Mother diagnosed with 
anaemia  
1 HIV negative 
Under-age (17 years) 
Recruitment required consent 
from parents or guardian 
1 HIV positive Late recruitment 
1 HIV negative 
Missed 2 week visit and 
arrived for 6 weeks 
 
5.2 PRESUMED MATERNALLY DERIVED SPECIFIC ANTIBODY LEVELS  
Results will be graphically presented using type III vertical bar graph (95% confidence 
intervals). Time-group interaction vs. LS means for both HEU and UE groups will be used to 
present the IgG specific responses at different time points. The x-axis on the graph depicts 
the time points and the y-axis depicts the specific IgG concentration (Figures 5.1 to 5.4). 
Mean values, standard deviation (SD) and p-values for the specific IgG responses at 
different time points will be summarised in Tables 5.3 to 5.6.  Statistical significance is 
indicated when p < 0.05.  
5.2.1. Pertussis IgG levels at 2 and 6 weeks 
A total of 84 samples were evaluated for IgG levels against pertussis toxin at 2 and 6 weeks 
of age. At 2 weeks, a total of 22 samples in the HEU and 23 samples in the UE groups were 
processed and at 6 weeks, a total of 19 HEU and 20 UE samples were analysed 
respectively. Infants who received the 6 weeks vaccination before or on the blood draw day 
were removed from the analyses. 
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TIME POINT*STATUS; LS Means
Current effect: F(1, 30)=4.7327, p=.03760
Type III decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 5- 1: Comparison of pertussis IgG levels (FDA U/ml) from 2 to 6 weeks of age. The time group 
effect is shown to be significant (p=0.03760). 
 
HEU infants displayed lower mean IgG levels to pertussis (20.80 vs. 38.01 FDA U/ml at 2 
weeks and 13.72 vs. 25.05 FDA U/ml at 6 weeks). The differences between the HEU and 
UE groups reached statistical significance at 2 weeks only. In addition, the lower mean 
levels of IgG in the HEU group at 2 and 6 weeks corresponded with decreased levels of 
protection (protective pertussis levels >30 FDA U/ml). However, in the UE group, the mean 
level at 2 weeks was considered protective, but decreased to non-protective levels at 6 
weeks of age (38.00-23.40 FDA U/ml).  
 
At 2 weeks only 5 HEU infants had levels deemed to be protective (22.7%) in comparison to 
9 infants in UE group (39.1%). At 6 weeks, no infant in the HEU group had protective levels 
for pertussis compared to the UE group where a total of 5 infants (25%) had protective 
levels. Both groups showed a 1.5 fold decrease in the maternal antibody levels from 2 to 6 
weeks of age.  
 
Table 5- 3: Pertussis IgG levels at 2 and 6 weeks of age.  
PERTUSSIS IgG 
Group n Time point 
Mean 
(FDA U/ml) 
SD P-value 
HEU 22 
2 weeks 
20.80 21.43 
0.0237 
UE 23 38.01 39.72 
HEU 19 
6 weeks 
13.72 6.45 
0.1579 
UE 20 25.05 23.51 
  
5.2.2.  Tetanus IgG levels at 2 and 6 weeks 
A total of 84 samples were evaluated for IgG levels against tetanus at 2 and 6 weeks of age. 
At 2 weeks a total of 22 samples in the HEU and 23 samples in the UE groups were 
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processed and at 6 weeks, a total of 19 HEU and 20 UE samples were analysed 
respectively. Infants who received the 6 weeks vaccination before or on the blood draw day 
were removed from the analyses. 
 
TIME POINT*STATUS; LS Means
Current effect: F(1, 30)=8.0525, p=.00807
Type III decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 5- 2: Comparison of tetanus IgG levels (IU/ml) from 2 to 6 weeks of age. The time group effect 
is shown to be significant (p=0.00807). 
 
HEU infants had lower mean levels for tetanus IgG antibodies compared to UE controls 
(0.08 vs. 0.53 IU/ml and 0.05 vs. 0.21 IU/ml). A statistical difference between the two groups 
was noted at both 2 weeks of age. At both time points, HEU infants displayed non-protective 
mean levels for tetanus IgG (protective tetanus levels >0.1 IU/ml) compared to the UE group 
that showed protective mean levels at both 2 and 6 week time points.  
 
At 2 weeks only 5 HEU infants had levels deemed to be protective (22.7%) in comparison to 
13 infants in UE group (56.5%). At 6 weeks, 3 infants in the HEU group (15.8%) had 
protective levels for tetanus compared to the UE group where a total of 8 infants (40%) had 
protective levels. The HEU group showed a 1.8 fold decrease in the tetanus levels from 2 to 
6 weeks compared to the UE group that had a 2.5 fold decrease. 
 
Table 5- 4: Tetanus IgG levels at 2 and 6 weeks of age.  
TETANUS IgG 
Group n Time point 
Mean 
(U/ml) 
SD P-value 
HEU 22 
2 weeks 
0.08 0.12 
0.000394 
UE 23 0.53 0.62 
HEU 19 
6 weeks 
0.05 0.05 
0.100574 
UE 20 0.21 0.31 
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5.2.3.  Hib IgG levels at 2 and 6 weeks 
A total of 84 samples were evaluated for IgG levels against Hib at 2 and 6 weeks of age. At 
2 weeks a total of 19 samples in the HEU and 20 samples in the UE groups were processed 
and at 6 weeks, a total of 24 HEU and 27 UE samples were analysed. Infants who received 
the 6 weeks vaccination before or on the blood draw day were removed from the analyses. 
 
TIME POINT*STATUS; LS Means
Current ef f ect: F(1, 30)=.18638, p=.66903
Ty pe III decomposition
Vertical bars denote 0.95 conf idence interv als
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Figure 5- 3: Comparison of Hib IgG levels (mg/l) from 2 to 6 weeks of age. The time group effect is 
shown to be non-significant (p=0.66903).  
 
HEU infants displayed lower mean values for IgG against Hib at both time points (1.21 vs. 
2.01 mg/l and 0.70 vs. 1.34 mg/l). The differences between the two groups, however, did not 
reach statistical significance for either of the time points. At 2 weeks both groups showed 
protective mean levels for Hib (protective Hib levels >1.0mg/l), however at 6 weeks, the 
mean levels for the HEU group decreased to below 1.0mg/l and the UE group remained 
protective.  
At 2 weeks, only 4 HEU infants had levels deemed to be protective (18.2%) in comparison to 
9 infants in UE group (39.1%). At 6 weeks, 2 infants in the HEU group (10.1%) had 
protective levels for Hib compared to the UE group where a total of 6 infants (30%) had 
protective levels. The HEU group showed a 1.7 fold decrease in the Hib levels from 2 to 6 
weeks compared to the UE groups who had a 1.5 fold decrease. 
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Table 5- 5: Hib IgG levels at 2 and 6 weeks of age.  
HIB IgG 
Group n Time point 
Mean 
(mg/l) 
SD P-value 
HEU 22 
2 weeks 
1.21 3.53 
0.09664 
UE 23 2.01 3.61 
HEU 19 
6 weeks 
0.70 1.61 
0.2206 
UE 20 1.34 1.96 
 
5.2.4. PCP IgG levels at 2 and 6 weeks 
A total of 79 samples were evaluated for IgG levels against PCP at 2 and 6 weeks of age. At 
2 weeks, a total of 22 samples in the HEU and 23 samples in the UE groups were processed 
and at 6 weeks, a total of 16 HEU and 18 UE samples were analysed respectively. Infants 
who received the 6 weeks vaccination before or on the blood draw day were removed from 
the analyses. 
TIME POINT*STATUS; LS Means
Current effect: F(1, 30)=7.5581, p=.01002
Type III decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 5- 4: Comparison of PCP IgG levels (mg/l) from 2 to 6 weeks of age. The time group effect is 
shown to be significant (p=0.01002).  
 
HEU infants displayed lower mean values for IgG against PCP (31.67 vs. 80.77 mg/l and 
11.47 vs. 23.31 mg/l). The differences between the two groups at 2 weeks were statistically 
significant. There are no levels listed for protective immunity for the collective response to 
pneumococcal serotypes.  
Both groups displayed a 2.8 fold decrease in maternal PCP levels from 2 to 6 weeks of age.  
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Table 5- 6: PCP IgG levels for HEU and UE infants at 2 and 6 weeks of age.  
PCP IgG 
Group n Time point 
Mean 
(mg/l) 
SD P-value 
HEU 22 
2 weeks 
31.67 53.19 
0.003330 
UE 23 80.77 107.49 
HEU 16 
6 weeks 
11.47 14.10 
0.097388 
UE 18 23.31 25.15 
 
5.3 POST-VACCINE LEVELS OF SPECIFIC ANTIBODIES 
5.3.1 Vaccination Dose 
At the 12 week time point, a total of 54 samples were analysed for IgG levels to the specified 
vaccines. Of these 54 samples, a total of 36 infants (18 HEU and 18 UE) had received 2 
doses to the combined pertussis, tetanus and Hib vaccine. The median days from the first 
dose to the second dose was 41.5 in the HEU group and 40 in the UE group. The median 
days from the second dose to the 12 week blood draw was 13 in the HEU and 11.5 in the 
UE group respectively. Thirteen (8 HEU and 5 UE) infants received one dose of the vaccine 
(median day in HEU was 40 and UE group was 36) and a total of 5 infants (1 HEU and 4 
UE) did not receive any doses. 
These groups were stratified and statistically analysed by use of log transformation and the 
employment of an ANOVA analysis, to determine the effect of the administration of 1 or 2 
doses on the IgG levels to pertussis, tetanus and Hib. The analysis (by means of noted the 
F-test p-value) showed that dosage did not have an effect on the pertussis IgG levels 
(p=0.61) at 12 weeks.  It however, did have an effect on the IgG levels to tetanus (p<0.01) 
and Hib (p=0.04).  
Based on these findings, infants who did not receive both dosages at the time of the 12 
week blood draw were excluded from the analysis. All HEU and UE infants included in the 
subsequent analysis (6 and 18 months included) received the required vaccination doses as 
scheduled. Infants who received a vaccination after the specified blood draw were noted and 
included in subsequent time points.  
At the 6 month follow-up visit, a total of 47 infant samples were analysed for vaccine specific 
antibodies. Of these, 40 infants (22 HEU and 18 UE) received all 3 required vaccination 
dosages. The median days from the various doses are listed in Table 5-7 below. A total of 3 
infants (2 HEU and 1 UE) received only 2 doses at the time of blood draw and one UE infant 
received only one dose. Three infants (1 HEU and 2 UE) received no vaccinations prior to 
the blood draw. Infants who received less than 3 doses were excluded from the analyses. At 
this time point, 11 infants (7 HEU and 4 UE) received catch-up vaccinations. 
Table 5- 7: Median days from various doses for HEU and UE groups at 6 month visit 
GROUP 
Median day 
from 1
st
 dose to 
2
nd
 dose 
Median day from 
2
nd
 dose to 12 
week blood draw 
Median day from 3
rd
 dose 
to 6 month blood draw 
HEU 41.5 14 77.5 
UE 41 13.5 85 
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At the 12 month follow-up visit, a total of 42 samples were analysed for vaccine specific 
antibodies. Thirty six babies (20 HEU and 16 UE) received all 3 required vaccination 
dosages. A total of 2 babies (1 HEU and 1 UE) received only 2 doses at the time of blood 
draw and one UE infant received only one dose. Three babies (1 HEU and 2 UE) received 
no vaccination doses prior to the blood draw.  Babies who received less than 3 doses were 
excluded from the analysis. At this time point there had been no documentation of any catch-
up vaccinations given to any babies in our study.  
At the 18 month follow-up visit, a total of 39 samples were analysed. Of these, 35 (17 HEU 
and 18 UE) received all 4 required vaccination dosages. The median days from the various 
doses are listed in Table 5-8 below. One UE baby received only 3 doses and a total of 3 (1 
HEU and 2 UE) received no vaccinations prior to the blood draw. Babies who received less 
than 4 doses were excluded from the analysis. At this time point, 3 babies (1 HEU and 2 UE) 
received catch-up vaccinations. 
 
Table 5- 8: Median days from various doses for HEU and UE groups at 18 month visit 
GROUP 
Median day 
from 1
st
 
dose to 2
nd
 
dose 
Median day 
from 2
nd
  dose 
to 12 week 
blood draw 
Median day from 
3
rd
 dose to 6 month 
blood draw 
Median day from 
4
th
 dose to 18 
month blood 
draw 
HEU 41 14 118 29 
UE 40 13.5 85.5 14 
 
At the final 24 month follow-up, a total of 37 samples were analysed. Thirty four babies’ 
infants (16 HEU and 18 UE) received all 4 required vaccination doses and one UE baby 
received only 3 doses. A total of 2 babies (1 HEU and 1 UE) did not receive any vaccinations 
prior to the blood draw time point. Babies who received less than 4 doses were excluded 
from the analysis. At this time point none of the babies received catch-up vaccinations.  
The median vaccine-to-blood draw time in days for each time point is represented for both 
groups in Figure 5-5 and Table 5-9 below.  
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Figure 5- 5: Bar graph representation of the number of days after vaccination on which blood was 
drawn for the measurement of vaccine specific antibody response. The x-axis depicts the number of 
days after vaccination and the y-axis represents the various time points at which blood was taken. 
The median ranges were calculated from the days measured for both groups collectively.  
 
Table 5- 9: Summary of median days from vaccination to blood draws for both groups.  
Dose 
number 
Group 
status 
Median 
days 
Median days for 
both groups 
Number of infants 
1 HEU 42 
41 
18 
 UE 40 18 
2 HEU 13 
12 
18 
 UE 11.5 18 
3 HEU 77.5 
82 
22 
 UE 85 18 
4 HEU 15 
14 
17 
 UE 14 18 
 
Results for post-vaccination responses will be graphically presented using type III vertical 
bar graph (95% confidence intervals). Time-group interaction vs. LS means for both HEU 
and UE groups will be used to present the IgG specific responses at different time points. 
The x-axis on the graph depicts the time points and the y-axis depicts the specific IgG 
concentration (Figure 5.6 – 5.8). 
Mean values, SD and p-values for the specific IgG responses at different time points will be 
summarised in Tables 5.10  to 5.12.  Statistical significance is indicated when p < 0.05.  
5.3.2 Post-vaccine IgG levels to Pertussis 
A total of 181 samples were evaluated for post-vaccine IgG levels against pertussis toxin at 
the 12 weeks, 6, 12, 18 and 24 month time point.  
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TIME POINT*STATUS; LS Means
Current effect: F(4, 123)=2.7326, p=.03203
Type III decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 5- 6: Comparison of pertussis IgG levels (FDA U/ml) from 12 weeks to 24 months. The time 
group effect is shown to be significant (p=0.03203).  
 
The HEU group displayed higher mean levels when compared to the UE group at each of 
the time points except at 24 months of age. These differences were statistically significant at 
6, 12 and 18 months. Apart from the 12 week time point, these significantly higher levels 
also corresponded with protective levels in the HEU group. At 12 weeks and 12 months of 
age, the UE group presented with non-protective mean IgG levels (13.302 and 9.425 FDA 
U/ml). 
At 24 months, both groups had lowered mean IgG levels compared to the 18 month time 
point. The HEU mean levels were lower compared to the UE; however the difference 
between the groups did not reach statistical significance. Furthermore, the levels in both 
groups were considered protective.   
A summary of statistical data is shown in Table 5-10 below. 
Table 5- 10: Summary of pertussis IgG levels for HEU and UE groups from 12 weeks to 24 months  
PERTUSSIS IgG 
Group n Time point 
Mean 
(FDA U/ml) 
SD P-value 
HEU 18 
12 weeks 
19.044 1.484 
0.876 
UE 18 13.302 1.273 
HEU 22 
6 months 
155.487 200.462 
0.00134 
UE 18 63.729 119.023 
HEU 20 
12 months 
26.539 17.252 
0.000003 
UE 16 8.501 8.435 
HEU 17 
18 months 
1658.947 1386.499 
0.0362 
UE 18 792.027 882.172 
HEU 16 
24 months 
263.181 232.464 
0.1549 
UE 18 557.867 1747.278 
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The outcomes of pertussis IgG in both groups at each time point was not influenced by 
maternal age. No significant correlations were associated with housing structure, gender, 
birth weight, racial groups or number of individuals in a household or access to running 
water.  
5.3.3 Post-vaccine IgG levels to Tetanus 
A total of 181 samples were evaluated for post-vaccination IgG levels against tetanus at 12 
weeks, 6, 12, 18 and 24 month time point respectively.  
 
TIME POINT*STATUS; LS Means
Current effect: F(4, 123)=.93176, p=.44793
Type III decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 5- 7: Comparison of tetanus IgG levels (U/ml) from 12 weeks to 24 months. The time group 
effect is shown to be non-significant (p=0.44793).  
 
At 12 weeks, 6, 12 and 18 months the HEU group had slightly higher mean levels to tetanus 
compared to the UE group. However, no statistical differences were noted between the 
groups at any of the four time points. At each time point, both groups showed protective 
levels for tetanus IgG. 
At 24 months, both groups had lowered mean IgG levels compared to the 18 month time 
point. The HEU mean levels however remained higher than the UE group and this difference 
was statistically significant (p=0.037). In addition, the levels in both groups were considered 
protective.   
A summary of statistical data is shown in Table 5-11 below. 
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Table 5- 11: Summary of tetanus IgG levels from 2 weeks to 24 months  
TETANUS IgG 
Group n Time point 
Mean 
(IU/ml) 
SD P-value 
HEU 18 
12 weeks 
1.484 0.723 0.394 
 UE 18 1.273 0.986 
HEU 22 
6 months 
2.587 1.395 
0.512 
UE 18 2.331 1.529 
HEU 20 
12 months 
0.568 0.419 
0.549 
UE 16 0.475 0.364 
HEU 17 
18 months 
5.845 2.710 
0.452 
UE 18 5.424 3.596 
HEU 16 
24 months 
3.277 2.606 
0.018 
UE 18 1.697 1.617 
 
The outcome of tetanus IgG in both groups at each time point was not influenced by 
maternal age, gravidity or gender. However, at 2 weeks of age, UE infants living in informal 
housing structures had increased levels of tetanus IgG compared to those living in formal 
structures (p=0.02267). Infants who had higher birth weight also had increased IgG levels at 
12 weeks of age (p=0.04). In addition, the number of individuals in a household was 
positively correlated with an increase in tetanus levels at 2 and 6 weeks of age (p=0.01 and 
p<0.01).  
5.3.4 Post-vaccine IgG levels to Hib 
A total of 181 samples were evaluated for post-vaccine IgG levels against Hib at 12 weeks, 
6, 12, 18 and 24 month time point respectively.  
TIME POINT*STATUS; LS Means
Current effect: F(4, 123)=.50027, p=.73557
Type III decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 5- 8: Comparison of Hib IgG levels (mg/l) from 12 weeks to 24 months. The time group effect 
is shown to be non-significant (p=0.73557). 
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The HEU group displayed slightly lower mean values to Hib compared to the UE group at 12 
weeks. However at 6, 12 and 18 months, the mean Hib levels were slightly higher in the 
HEU group compared to the UE group. At each of these time points described, no statistical 
significance was noted. Both groups showed protective levels for Hib at each of the four time 
points. 
At 24 months, HEU babies had slightly higher mean values to Hib compared to the UE 
group, however this difference did not reach statistical significance. The Hib levels in each 
group were considered protective.  
Summary of statistical data is shown in Table 5-12 below. 
Table 5- 12: Summary of Hib IgG levels from 12 weeks to 24 months  
HAEMOPHILUS INFLUENZAE B 
Group n Time point 
Mean 
(mg/l) 
SD P-value 
HEU 18 
12 weeks 
9.313 12.017 
0.494 
UE 18 10.089 12.562 
HEU 22 
6 months 
11.867 17.490 
0.437 
UE 18 8.453 12.883 
HEU 20 
12 months 
2.113 3.795 
0.567 
UE 16 1.357 2.588 
HEU 17 
18 months 
41.798 31.817 
0.372 
UE 18 34.812 29.734 
HEU 16 
24 months 
7.200 5.968 
0.682 
UE 18 5.647 4.286 
  
An increase in maternal age and gravidity was associated with increased Hib IgG levels at 
12 weeks of age (p<0.01 and p=0.03). No significant correlations were found between were 
associated with housing structure, access to running water or gender.  
5.3.5  Summary of Antibody Response Results  
In this section of the study the IgG responses to specific vaccines namely; pertussis, 
tetanus, Hib and pneumococcus were evaluated from 2 weeks to 24 months age in two 
infant groups, HEU and UE controls. The 2 and 6 week time points represented the 
presumed maternal antibody transfer and the subsequent time points, represented post-
vaccination levels.  
The HEU group had decreased mean levels for all measured antibodies at 2 and 6 weeks 
compared to UE controls. At 2 weeks statistical significance was reached for pertussis, 
tetanus and pneumococcus, while at 6 weeks, statistical significance was reached only for 
tetanus and pneumococcus.   
IgG levels for pertussis was significantly higher in the HEU group compared to the UE group 
at 6, 12 and 18 months time points. The response to tetanus was similar in both groups at 12 
weeks, 6, 12 and 18 months of age. However at 24 months, the HEU group had significantly 
higher IgG levels to tetanus compared to the UE group. There were no significant 
differences between the two groups for Hib IgG levels, however higher mean levels were 
noted for the HEU group only at 6, 12, 18 and 24 months. At 12 weeks, HEU infants had 
lower mean levels compared to the UE group.  
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The HEU group showed robust IgG responses mainly to protein vaccine antigens (pertussis 
and tetanus) at various time points.  
The next set of results examines the levels of immune activation, regulation and apoptosis 
and B cell memory in the HEU and UE groups at 18 and 24 month follow-up visit.  
5.4 CELLULAR IMMUNE MARKERS OF ACTIVATION, APOPTOSIS AND B CELL 
MEMORY AT 18 MONTHS  
5.4.1 Cellular markers on CD4+ T cells at 18 months time point 
 
 
Figure 5- 9: Bar graph (Error bars with SD) representation for cellular markers on CD4+ T cells. The 
X-axis represents the cellular marker types (Fas, FasL, CD69, Annexin V, CD127, CTLA-4 and 
CD40L). The Y-axis represents the percentage of marker expression.   
 
The evaluation of cellular markers of activation/proliferation (CD69, CD127 and CD40L) and 
apoptosis/regulation (FAS, FASL, Annexin V and CTLA-4) on CD4+ T cells was determined 
at the 18 months time point. A total of 39 samples were analysed for cellular markers FAS, 
FASL, CD69 and Annexin V and a total of 19 samples were analysed for cellular markers 
CD127, CTLA-4 and CD40L (Figure 5-9 and Table 5-13).  
As depicted in Figure 5-12 and summarised in Table 5-13 below, compared to the UE group, 
the HEU group displayed an increased mean value for markers of activation (CD69 [3.04 vs. 
2.70%], CD127 [26.47 vs. 18.40%] and CD40L [2.50 vs. 1.01%]) on CD4+ T cells. Although 
an increase in activation markers may be consistent with HIV exposure, a statistical 
difference between the two groups was only noted for the expression of CD127.  
The increase in mean values for markers of activation in the HEU population may possibly 
correspond with the increase mean values for markers of apoptosis (FAS [12.137 vs. 
11.18%] and FASL [3.20 vs. 1.57%]), however these differences did not reach statistical 
significance.  
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Annexin V expression in both groups was minimal and the percentage mean was similar 
between the two groups (HEU [0.14%] and UE [0.15%]. The expression of Annexin V was 
measured after 16 and 24 hour incubation periods in both groups. Results are listed in 
Section 5-6 below.) 
The expression of CTLA-4 was similar between the two groups (HEU [1.17%] and UE 
[1.04%]; but no statistical significance was reached.  
Table 5- 13: Summary of cellular markers on CD4+ T cells.  
Group n Marker 
Mean 
(% gated) 
SD p-value 
HEU 18 
FAS 
12.13722 3.453801 
0.39 
UE 21 11.18143 3.450505 
HEU 18 
FASL 
3.198333 8.635765 
0.41 
UE 21 1.567143 1.983734 
HEU 18 
CD69 
3.041111 1.327921 
0.20 
UE 21 2.700476 2.519797 
HEU 18 
ANNEXIN V 
0.144444 0.167901 
0.83 
UE 21 0.153810 0.105474 
HEU 10 
CD127 
26.47300 8.970801 
0.03 
UE 9 18.40111 5.213915 
HEU 10 
CTLA-4 
1.174000 0.799669 
0.69 
UE 9 1.042222 0.614609 
HEU 10 
CD40L 
2.499000 2.424213 
0.09 
UE 9 1.008889 0.563393 
 
5.4.2 Cellular markers on CD20+ B cells at 18 months time point 
 
Figure 5- 10: Bar graph (Error bars with SD) representation for cellular markers on CD20+ B cells. 
The X-axis represents the cellular marker types (Annexin V, CD80, Fas, CD62L and CD27). The Y-
axis represents the percentage of marker expression. 
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The evaluation of cellular markers of activation/proliferation (CD80, CD62L and CD10), 
apoptosis (Annexin V, Fas) and memory (CD27) was determined at the 18 month time point. 
A total of 39 samples were analysed for each described marker.  
As depicted in Figure 5-10 and summarised in Table 5-14 below, when compared to UE 
controls, the HEU group displayed increased mean values for certain markers of 
activation/proliferation on CD20+ B cells (CD80 [2.99 vs. 2.28%]; CD62L [18.25 vs. 
17.01%]). However, statistical significance between the two groups was only reached for the 
cellular activation marker, CD80. The expression of CD10 was similar between the groups 
(4.23 vs. 4.10%).  
The HEU group also showed an increase in mean percentage of the apoptotic marker, FAS 
(4.04 vs. 3.44%) compared to the UE controls. However, the expression of Annexin V was 
lower in the HEU than UE groups (0.18 vs. 0.21 %). The expression of the described 
apoptotic markers did not reach statistical significance between the two groups. 
Annexin V expression in both groups was minimal. Therefore, the expression of Annexin V 
was measured after 16 and 24 incubation periods (“stressed conditions”) in both groups. 
(Results listed in Section 5-6 below) 
The cellular marker for B cell memory (CD27) was similar in both HEU and UE groups (4.22 
vs. 4.10 %).   
Table 5- 14: Summary of cellular markers on CD20+ B cells.  
Group n Marker 
Mean 
(% gated) 
SD P-value 
HEU 18 
CD80 
2.986111 1.360744 
0.03a 
UE 21 2.279048 1.938845 
HEU 18 
CD62L 
18.24778 7.882515 
0.63 
UE 21 17.01762 8.043571 
HEU 18 
CD10 
9.875556 4.238405 
0.63 
UE 21 9.162381 4.730180 
HEU 18 
FAS 
4.037222 3.857614 
0.54 
UE 21 3.438571 1.971523 
HEU 18 
ANNEXIN V 
0.180000 0.087313 
0.44 
UE 21 0.214286 0.168213 
HEU 18 
CD27 
4.225556 1.959361 
0.85 
UE 21 4.100476 2.106394 
 aMann-Whiney U test p-value reported which was used a confirmatory tool to the F-test which was non-
 significant 
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5.4.3 Cellular markers on CD19+ B cells at 18 months time point 
 
Figure 5- 11: Bar graph (Error bars with SD) representation for cellular markers on CD19+ B cells. 
The X-axis represents the cellular marker types (CD69, PD1 and CD27). The Y-axis represents the 
percentage of marker expression. 
 
The expression of cellular markers of activation (CD69), programmed cell death (PD1) and 
memory (CD27) on CD19+ B cells was determined in 19 subjects. 
HEU showed decreased mean values for the expression of CD69 (0.85 vs. 1.19%), PD1 
(0.30 vs. 0.53%) and CD27 (3.37 vs. 4.30 %) compared to UE controls. These differences 
did not reach statistical significance (Figure 5-11 and Table 5-15).  
Evaluating the expression of activation markers on CD19+ B cells in comparison to cellular 
markers described on CD20+ B cells, the expression of certain markers seem to be higher in 
both groups. The expression of the memory marker, CD27, on CD20+ B cells seems to be 
similarly expressed on CD19+ B cells; however the HEU group seems to show greater 
expression of memory on CD20+ B cells as opposed to CD19+ B cells (4.23 vs. 3.37%). In 
UE controls, there was similar expression on both cell types (4.10 vs. 4.30%).   
Table 5- 15: Summary of cellular markers on CD19+ B cells. 
Group n Marker 
Mean 
(% gated) 
SD P-value 
HEU 10 
CD69 
0.851000 0.322506 
0.23 
UE 9 1.190000 0.796335 
HEU 10 
PD1 
0.296000 0.144776 
0.18 
UE 9 0.532222 0.516909 
HEU 10 
CD27 
3.370000 2.192127 
0.35 
UE 9 4.302222 2.055212 
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5.4.4 Cellular markers on CD8+ T cells at 18 months time point 
 
Figure 5- 12: Bar graph (Error bars with SD) representation for cellular markers on CD8+ T cells. The 
X-axis represents the cellular marker types (FASL and CD38). The Y-axis represents the percentage 
of marker expression. 
 
The evaluation of cellular markers of activation (CD38) and apoptosis (FASL) was 
determined at the 18 month time point. A total of 19 samples were analysed for each of the 
two bio-markers described.  
As depicted in Figure 5-12 and summarised in Table 5-16 below, both groups produced 
similar mean values for expression of the activation marker, CD38 (19.72 vs. 19.55%). In 
contrast, the HEU infants group showed lower mean values for the expression of the 
apoptotic marker FASL than the UE controls (1.38 vs. 2.48%). Neither of these markers 
produced any statistical difference between the groups. 
Table 5- 16: Summary cellular markers on CD8+ T cells 
Group n Marker 
Mean 
(% gated) 
SD P-value 
HEU 10 
CD38 
19.72400 6.450415 
0.95 
UE 9 19.55111 6.566196 
HEU 10 
FASL 
1.381000 1.853552 
0.34 
UE 9 2.482222 2.940314 
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5.5 CELLULAR IMMUNE MARKERS OF ACTIVATION, APOPTOSIS AND B CELL 
MEMORY AT 24 MONTHS  
5.5.1 Cellular markers on CD4+ T cells at 24 months time point 
 
Figure 5- 13: Bar graph (Error bars with SD) representation for cellular markers on CD4+ T cells. The 
X-axis represents the cellular marker types (FAS, FASL, CD69, Annexin V, CD127, CTLA-4 and 
CD40L). The Y-axis represents the percentage of marker expression. 
 
The expression of cellular markers of activation/proliferation (CD69, CD127 and CD40L) and 
apoptosis/regulation (FAS, FASL, Annexin V and CTLA-4) on CD4+ T cells was determined 
at the 24 months follow-up. A total of 37 samples were analysed for each described cellular 
marker. 
As depicted in Figure 5-16 and summarised in Table 5-17 below, the HEU group produced 
higher mean values than the UE group for all the markers on CD4+ T cells, except CTLA-4 
(CD69 [6.66 vs. 5.28%], CD127 [12.47 vs. 11.68%] and CD40L [0.94 vs. 0.77%]). These 
differences were not statistically significant (Figure 5-13 and Table 5-17).  
Compared to the 18 months time point, HEU and UE infants showed increased expression 
of CD69. Both HEU and UE groups showed a 2 fold increase in expression of CD69 from 18 
to 24 months, however the change was not statistically significant. CD40L in the HEU group 
decreased by 3 fold compared to the UE group that only showed a 2 fold decrease over the 
same period. Both HEU and UE groups showed similar levels for the expression of CD127 at 
each of the two time points. 
The HEU group showed increased expression of apoptotic markers Fas (12.47 vs. 11.68%), 
FasL (11.53 vs. 6.32%) and Annexin V (2.11 vs. 0.93%). The expression of T cell regulation 
marker, CTLA-4, was similar in both groups (3.78 vs. 3.96%). A significant difference 
between the expression of these markers between the two groups was reached for FASL 
and Annexin V.  
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From 18 to 24 months of age, both HEU and UE groups displayed similar levels of Fas. HEU 
infants showed a 4 fold increase in the expression of FasL whereas the UE group only 
showed a 3 fold increase. The change in both groups from 18 to 24 months was statistically 
significant. The HEU group displayed a statistically significant 15 fold increase in the 
expression of Annexin V, whereas the UE group only showed a non-significant 6 fold 
increase. The HEU group further showed a 3 fold increase in the expression of CTLA-4 from 
18 to 24 months of age, while a statistically significant 4 fold increase was found in the UE 
control group. 
Table 5- 17: Summary of cellular markers on CD4+ T cells at 24 months of age  
Group n 
Markers on 
CD4+ T cells 
Mean 
(% gated) 
SD P-value 
HEU 17 
FAS 
12.47 5.95 
0.69 
UE 20 11.68 6.00 
HEU 17 
FASL 
11.53 7.009 
0.03 
UE 20 6.32 6.544 
HEU 17 
CD69 
6.66 7.47 
0.55 
UE 20 5.28 6.37 
HEU 17 
ANNEXIN V 
2.11 4.46 
0.01 
UE 20 0.93 1.20 
HEU 17 
CD127 
18.09 10.36 
0.20 
UE 20 13.78 9.87 
HEU 17 
CTLA-4 
3.78 6.93 
0.92 
UE 20 3.96 4.04 
HEU 17 
CD40L 
0.94 0.94 
0.50 
UE 20 0.77 0.63 
5.5.2 Cellular markers on CD20+ B cells at 24 months time point 
 
Figure 5- 14: Bar graph (Error bars with SD) representation for cellular markers on CD4+ T cells. The 
X-axis represents the cellular marker types (Annexin V, CD80, FAS, CD62L, CD10 and CD27). The 
Y-axis represents the percentage of marker expression. 
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The expression of cellular markers of activation/proliferation (CD80, CD62L and CD10), 
apoptosis (Annexin V, Fas) and memory (CD27) was determined at the 24 month time point. 
A total of 37 samples were analysed for each described marker.  
As depicted in Figure 5-14 and summarised in Table 5-18 below, compared to UE controls, 
the HEU group displayed higher mean values for the expression of cellular markers CD80 
[4.48 vs. 3.77%]. The HEU group also displayed lower mean values for the expression of, 
CD62L [6.35 vs. 8.55%] and CD10 [8.34 vs. 7.79%]. These differences did not however 
reach any statistical significance.  
Both HEU and UE groups showed a 2 fold increase in the expression of CD80 from 18 to 24 
months of age. The difference between the two time points only proved to be significant for 
the UE group. The HEU group showed a 3 fold increase for the expression of CD23 
compared to the UE group infants who displayed a 2 fold increase. The expression of CD10 
was similar for both groups 18 to 24 months.  
At 24 months, the HEU group displayed higher mean values for the expression of cellular 
marker of apoptosis Fas [4.75 vs. 3.32%] and Annexin V [2.36 vs. 1.36%] than the UE 
group. These differences did not reach statistical significance.  
From 18 to 24 months both groups displayed an increase in the expression Annexin V. The 
HEU group displayed a 13 fold increase, whereas the UE group displayed a 6 fold increase; 
both increases were statistically significant (p<0.05) for both groups. The expression of Fas 
was similar in both groups at both the 18 and 24 month time points.  
The expression of the cellular B cell memory marker, CD27 was similar in both groups (2.66 
vs. 2.72%). Both groups showed a statistically significant 2 fold decrease in the expression 
of CD27 from 18 to 24 months. 
Table 5- 18: Summary of cellular markers on CD20+ B cells at 24 months of age  
Group n Marker 
Mean 
(% gated) 
SD P-value 
HEU 17 
CD80 
4.48 3.55 
0.49 
UE 20 3.77 2.68 
HEU 17 
CD62L 
6.35 4.93 
0.18 
UE 20 8.55 4.84 
HEU 17 
CD10 
8.34 4.65 
0.69 
UE 20 7.79 3.59 
HEU 17 
FAS 
4.75 3.27 
0.19 
UE 20 3.32 3.2 
HEU 17 
ANNEXIN V 
2.36 3.14 
0.42 
UE 20 1.36 2.09 
HEU 17 
CD27 
2.66 1.31 
0.91 
UE 20 2.72 1.98 
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5.5.3 Cellular markers on CD19+ B cells at 24 months time point 
 
Figure 5- 15: Bar graph (Error bars with SD) representation for cellular markers on CD19+ B cells. 
The X-axis represents the cellular marker types (CD69, PD1 and CD27). The Y-axis represents the 
percentage of marker expression. 
 
The expression of cellular markers of activation (CD69), programmed cell death (PD1) and 
memory (CD27) on CD19+ B cells was determined in 35 subjects. Blood was insufficient for 
two subjects (one in each group).  
The HEU group showed increased mean value for the expression of the cellular markers of 
activation (CD69 [5.94 vs. 2.65%]), programmed cell death (PD1 [4.45 vs. 2.09%]) and 
memory (CD27 [4.03 vs. 2.61%]). Statistical significance was only reached for CD69 
expression (p<0.01) (Figure 5-15 and Table 5-19). 
Both groups displayed increased expression of CD69 and PD1 from 18 to 24 months of age. 
However, in the HEU group there was a 7 fold increase compared to a 2 fold increase in the 
UE group for the expression of CD69. Statistical significant was reached for the HEU group 
only. This correlated with a 15 fold increase in the expression of PD1 in the HEU group 
compared to a 4 fold increase in the UE group. Furthermore, the HEU group displayed 
similar expression levels of CD27 from 18 to 24 months of age (3.37 to 4.03%), compared to 
the UE group who conversely displayed a 2 fold decrease in the expression of CD27 (4.20 to 
2.78%). The differences between the expression of CD27 from 18 to 24 months between the 
two groups were not statistically significant.  
Table 5- 19: Summary of cellular markers on CD19+ B cells at 24 months of age  
Group n Marker 
Mean 
(% gated) 
SD P-value 
HEU 16 
CD69 
5.94 7.83 
0.019 
UE 19 2.65 2.82 
HEU 16 
PD1 
4.447 8.17 
0.69 
UE 19 2.09 3.08 
HEU 16 
CD27 
4.03 6.67 
0.54 
UE 19 2.61 1.70 
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5.5.4 Cellular markers on CD8+ T cells at 24 months time point 
 
Figure 5- 16: Bar graph (Error bars with SD) representation for cellular markers on CD8+ T cells. The 
X-axis represents the cellular marker types (FasL and CD38). The Y-axis represents the percentage 
of marker expression. 
 
A total of 37 samples were analysed for each of the two markers represented above.  
As depicted in Figure 5-16 and summarised in Table 5-20 below, both groups displayed 
similar expression of the activation marker, CD38 (18.51 vs. 18.65%). Conversely, the HEU 
group displayed increased expression levels of apoptotic marker FasL when compared to 
the UE group (2.44 vs. 0.86%). Statistical significance was reached for the expression of 
FasL.  
Both groups showed similar levels of CD38 expression at both 18 and 24 months of age.  
Compared to the 18 months time point, the HEU group showed a 2 fold increase in the 
expression of FasL at the 24 month time point, in contrast to the UE group who showed a 3 
fold decrease in expression. The change in levels for FasL from 18 to 24 month of age was 
not statistically significant for either group. 
Table 5- 20: Summary of cellular markers on CD8+ T cells at 24 months of age  
Group n Marker 
Mean 
(% gated) 
SD P-value 
HEU 17 
FASL 
2.44 2.85 
0.03 
UE 20 0.86 1.32 
HEU 17 
CD38 
18.51 8.55 
0.96 
UE 20 18.65 6.96 
 
5.6 MEASUREMENT OF IN VITRO SPONTANEOUS APOPTOSIS   
 To measure the expression of early apoptotic marker Annexin V as an opportunity to explore 
the concept of spontaneous apoptosis, samples were placed under timed (16 and 24 hour) 
incubations at 37˚C in the presence of cell culture media (RPMI + 10% Foetal Calf Serum 
[FCS]) and CO2 (Refer to Chapter 4 for methodology).  
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At 18 months, the expression of Annexin V was measured on CD4+ T and CD20+ B cells at 
both 16 and 24 hour time periods. At 24 months, Annexin V expression was measured only 
at 16 hours on the same cell types. The expression of Annexin V on CD4+ T and CD20+ B 
cells described previously represented the ex vivo (after blood draw) expression.  
5.6.1  Spontaneous apoptosis at 18 months (16 and 24 hour intervals) 
5.6.1.1 CD4+/Annexin V+ 
A total of 13 samples (5 HEU and 8 UE) were analysed for the expression of Annexin V on 
CD4+ T cells at 16 and 24 hour periods. The expression levels measured at these time 
points were subsequently compared to the levels expressed within an hour of blood draw (ex 
vivo).  
STATUS*incubation; LS Means
Current effect: F(2, 22)=.43700, p=.65146
Type III decomposition
Vertical bars denote 0.95 confidence intervals
 STATUS
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 STATUS
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Figure 5- 17: Summary of Type III vertical bar graph (95% confidence intervals) representing the 
time-group interaction vs. Least Square (LS) means for both HEU and UE infants for Annexin V 
expression on CD4+ T cells expression at zero (ex vivo), 16 and 24 hour time points. The x-axis 
depicts the time points and the y-axis depicts the expression percentage of Annexin V (p= 0.65146). 
 
At 16 hours, the HEU group displayed increased levels of Annexin V compared to the UE 
group (0.86 vs. 0.55%). Similarly, at 24 hours, the HEU group also displayed increased 
levels of Annexin V compared to the UE group (0.66 vs. 0.41%). These differences were not 
statistically significant. Both groups however demonstrated an increase in expression from 
ex vivo to 16 and 24 hours. The expression of Annexin V seemed to decrease from 16 to 24 
hours in both groups (HEU [0.86 to 0.66 %] and UE [0.55 to 0.41%]) (See Figure 5-17 and 
Table 5-21).  
In the HEU group, the increase from ex vivo to 16 hours was statistically significant and 
resulted in a 7 fold increase. However, the increase from ex vivo to 24 hours (5 fold 
increase), as well as the decrease from 16 to 24 hours (1.3 fold decrease), did not reach 
statistical significance.  
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In the UE group, the increase from ex vivo to 16 hours represented a 3 fold increase, 
compared to HEU with a 7 fold increase. The fold increase from ex vivo to 24 hours was 2.3. 
The fold decrease from 16 to 24 hours was also 1.3 as displayed by HEU group.  
Table 5- 21: Summary of expression of Annexin V on CD4+ T cells at ex vivo, 16 hour and 24 hour 
time periods at 18 months of age.   
Group 
n 
Factor 
Mean  
(% gated) 
SD p-value 
HEU 5 
EX VIVO 
0.122000 0.043243 
0.892533 
UE 8 0.178750 0.082365 
HEU 5 
16 HOURS 
0.864000 1.429066 
0.459313 
UE 8 0.551250 0.813115 
HEU 5 
24 HOURS 
0.658000 0.778569 
0.560384 
UE 8 0.412500 0.564415 
 
HEU 
5 EX VIVO 0.122000 
 
0.035039 
5 16 HOURS 0.864000 
5 EX VIVO 0.122000 
0.118873 
5 24 HOURS 0.658000 
5 16HOURS 0.864000 
0.539242 
5 24 HOURS 0.658000 
      
UE 
8 EX VIVO 0.178750 
 
0.167745 
8 16 HOURS 0.551250 
8 EX VIVO 0.178750 
0.380375 
8 24 HOURS 0.412500 
8 16HOURS 0.551250 
0.600487 
8 24 HOURS 0.412500 
 
5.6.1.2 CD20+/Annexin V+ 
A total of 13 samples (5 HEU and 8 UEs) were analysed for the expression of Annexin V on 
CD20+ B cells at 16 and 24 hour periods. The expression levels measured at these time 
points were subsequently compared to the levels expressed within an hour of blood draw.  
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STATUS*incubation; LS Means
Current effect: F(2, 22)=.32811, p=.72375
Type III decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 5- 18: Summary of Annexin V expression on CD20+ B cell expression at zero (ex vivo), 16 
and 24 hour time points. The x-axis depicts the time points and the y-axis depicts the expression 
percentage of Annexin V (p=0.72375). 
 
At 16 hours, the HEU group displayed an increased mean value of Annexin V 
compared to the UE group (0.91 vs. 0.58%). Similarly, at 24 hours, the HEU group also 
displayed an increased mean value for Annexin V expression compared to UE (0.58 vs. 
0.43%) on CD20+ B cells. These differences however, did not reach statistical significance. 
Both groups display an increase in expression of Annexin V from ex vivo to 16 and 24 hours. 
In addition, as with the expression on CD4+ T cells, the expression of Annexin V tends to 
decrease from 16 to 24 hours in both groups (HEU [0.91 to 0.58%] and UE [0.58 to 0.43%]) 
(See Figure 5-18 and Table 5-22).  
In the HEU group, a 5 fold increase was displayed for the expression of Annexin V from ex 
vivo to 16 hours. Conversely, the increase from ex vivo to 24 hours resulted in a 3 fold 
increase. As previously noted with the Annexin V expression on CD4+ T cells, a fold 
decrease of 1.6 was noted from 16 to 24 hours.   
In the UE group, the increase from ex vivo to 16 hours resulted in a 2 fold increase 
(compared to HEU with a 5 fold increase). The fold increase from ex vivo to 24 hours was 
1.6. The fold decrease from 16 to 24 hours was also 1.3 as similarly displayed by the HEU 
group.  
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Table 5- 22: Summary of Annexin V expression on CD20+ B cells at ex vivo, 16 hour and 24 hour 
time periods at 18 months of age.  
Group n Factor 
Mean 
(% gated) 
SD p-value 
HEU 5 
EX VIVO 
0.196000 0.046690 
0.886171 
UE 8 0.263750 0.171958 
HEU 5 
16 HOURS 
0.914000 1.419165 
0.484387 
UE 8 0.581250 1.161962 
HEU 5 
24 HOURS 
0.578000 0.722336 
0.758716 
UE 8 0.432500 0.587045 
 
HEU 
5 EX VIVO 0.196000 
 
0.077795 
5 16 HOURS 0.914000 
5 EX VIVO 0.196000 
0.335694 
5 24 HOURS 0.578000 
5 16HOURS 0.914000 
0.395983 
5 24 HOURS 0.578000 
 
UE 
8 EX VIVO 0.263750 
 
0.312015 
8 16 HOURS 0.581250 
8 EX VIVO 0.263750 
0.587875 
8 24 HOURS 0.432500 
8 16HOURS 0.581250 
0.632613 
8 24 HOURS 0.432500 
 
5.6.2  Spontaneous apoptosis at 24 months (16 hour interval only) 
The spontaneous apoptosis assay was repeated at the 24 month time point. However, only 
the ex vivo (after blood draw) versus the 16 hour time periods were assessed. Due to 
sample volume limitations and deterioration in the expression of Annexin V after 16 hours 
(noted previously), the 24 hour time point was not included at this time point.   
5.6.2.1 CD4+/Annexin V+ 
A total of 37 samples (17 HEU and 20 UE) were analysed for the expression of Annexin V 
on CD4+ T cells at 16 hours. The expression levels measured at these time points were 
subsequently compared to the levels expressed within an hour of blood draw (ex vivo).  
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STATUS*time; LS Means
Current effect: F(1, 35)=.27173, p=.60545
Type III decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 5- 19: Summary of Annexin V expression on CD4+ T cell expression at zero (ex vivo), 16 and 
24 hour time points. The x-axis depicts the time points and the y-axis depicts the expression 
percentage of Annexin V (p= 0.6054). 
 
At 24 months of age, the HEU group displayed an increased mean value for the expression 
of Annexin V (ex vivo) on CD4+ T cells compared to the UE group (2.11 vs. 0.93%). These 
differences were not statistically significant. Both infant groups however showed an 
increased mean value from ex vivo to 16 hours (HEU [2.11 to 23.77%] and UE [0.93 to 
0.3.57%]) (See Figure 5-19 and Table 5-23).  
In the HEU group, the mean increase from ex vivo to 16 hours was highly significant 
(p<0.01) with a fold increase of 3. Similarly, in the UE group, the mean increase from ex vivo 
to 16 hour was also highly significant, resulting in a fold increase of 4.   
Table 5- 23: Summary of means, standard deviations (SDs) and p-values for both HEU and UE 
groups for expression of Annexin V expression on CD4+ T cells at ex vivo, 16 hour and 24 hour time 
periods at 18 months of age.  
GROUP FACTOR MEAN SD P-VALUE N 
HEU 
EX VIVO 
2.11 4.46 
0.50 
17 
UE 0.93 1.20 20 
HEU 
16 HOURS 
5.50 9.20 
0.27 
17 
UE 3.57 3.56 20 
 
HEU 
EX VIVO 2.11  
0.002630 
17 
16 HOURS 5.50  17 
UE 
EX VIVO 0.93  
0.00951 
20 
16 HOURS 3.57  20 
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5.6.2.2 CD20+/Annexin V+ 
A total of 37 samples (17 HEU and 20 UE) were analysed for the expression of Annexin V 
on CD20+ B cells at 16 hours. The expression levels measured at these time points were 
subsequently compared to the levels expressed within an hour of blood draw (ex vivo). 
STATUS*time; LS Means
Current effect: F(1, 35)=.80834, p=.37476
Type III decomposition
Vertical bars denote 0.95 confidence intervals
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Figure 5- 20: Summary of Annexin V expression on CD420+ B cell expression at ex vivo, 16 and 24 
hour time points. The x-axis depicts the time points and the y-axis depicts the expression percentage 
of Annexin V (p= 0.37476). 
 
At 24 months of age, the HEU group displayed an increased expression of Annexin V (ex 
vivo) on CD20+ B cells compared to the UE group (2.37 vs. 1.66%). These differences were 
not statistically significant. The HEU group also showed a decreased mean value from ex 
vivo to 16 hours (2.37 to 1.70%). The UE group displayed similar levels of Annexin V from ex 
vivo to 16 hours (1.66 to 1.33%). These differences were not statistically significant for any 
of the groups (See Figure 5-20 and Table 5-24).  
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Table 5- 24: Summary of means, standard deviations (SDs) and p-values for both HEU and UE 
groups for expression of Annexin V on CD20+ B cells at ex vivo, 16 hour and 24 hour time periods at 
18 months of age.  
GROUP FACTOR MEAN SD P-VALUE N 
HEU 
EX VIVO 
2.37 3.13 
0.359 
17 
UE 1.66 2.09 20 
HEU 
16 HOURS 
1.70 2.39 
0.930 
17 
UE 1.63 1.54 20 
 
HEU 
EX VIVO 2.37  
0.210 
17 
16 HOURS 1.70  17 
UE 
EX VIVO 1.66  
0.965 
20 
16 HOURS 1.63  20 
 
5.7 ROUTINE LYMPHOCYTE COUNTS 
Routine lymphocyte counts were carried out as described in previous sections at each of the 
indicated time points. The percentage of CD3/CD4 and CD8 counts are listed and displayed 
in Table 5-25 below. In addition, the CD4:CD8 ratio is shown in the indicated table.   
 
  Table 5- 25: Summary of means, standard deviations (SDs) and p-values for both HEU and UE of 
routine lymphocyte counts (CD3/CD4/CD8 and CD4:CD8 ratio) from 2 weeks to 24 months of age 
Time 
point 
Status 
%CD3 
Mean 
SD 
p-
value 
%CD4 
mean 
SD 
p-
value 
%CD8 
mean 
SD 
p-
value 
CD4:CD8 
Ratio 
SD 
p-
value 
N 
2 weeks 
HEU 74.94 6.94 
0.12 
53.84 54.21 
0.68 
20.72 20.75 
0.10 
2.84 2.88 
0.11 
24 
UE 71.48 7.40 52.91 53.04 17.94 17.64 3.32 3.38 28 
6 weeks 
HEU 63.23 8.55 
0.84 
43.42 43.28 
0.45 
18.56 18.64 
0.22 
2.77 2.77 
0.55 
25 
UE 62.78 7.34 45.14 45.04 16.47 16.33 2.96 2.98 27 
12 weeks 
HEU 56.95 9.76 
0.09 
39.74 39.84 
0.74 
15.27 15.28 
0.02 
2.97 2.99 
0.08 
25 
UE 60.67 7.69 40.49 40.22 19.13 19.15 2.44 2.44 27 
6 months 
HEU 56.56 10.79 
0.09 
36.68 37.00 
0.16 
18.06 17.72 
0.70 
2.30 2.39 
0.74 
25 
UE 60.43 7.34 39.97 39.52 18.73 18.65 2.42 2.40 23 
12 
months 
HEU 61.16 8.04 
0.60 
38.26 38.91 
0.86 
20.79 20.39 
0.30 
2.11 2.19 
0.63 
23 
UE 62.39 7.44 37.84 36.90 22.67 22.85 1.96 1.86 21 
18 
months 
HEU 61.19 7.70 
0.44 
38.46 40.78 
0.50 
20.10 19.33 
0.04 
2.006 2.25 
0.41 
18 
UE 63.11 6.60 36.89 35.95 24.05 24.38 1.72 1.63 21 
24 
months 
HEU 63.45 8.96 
0.58 
35.97 3.71 
0.75 
24.70 24.12 
0.33 
1.54 1.31 
0.73 
17 
UE 64.84 6.48 35.18 34.70 26.57 26.80 1.43 1.36 20 
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Results of the lymphocyte counts show no statistically significant differences between the 
HEU and UE groups respectively over each time point except for the %CD8 counts at 12 
weeks and 18 months of age, where the HEU group presented with decreased %CD8 
counts at each of the indicated time points. 
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6.1 OVERVIEW 
The impact and consequences underlying the effects of in utero HIV exposure on infant 
immune responses have not been extensively characterised. Clinical follow-up of these HEU 
infants reveals increased infectious morbidity and mortality (Filteau, 2009) 
This study aimed to investigate the potential immunological mechanisms for the increased 
incidence of infectious morbidity and mortality in HEU infants in a longitudinal multi-
collaborative pilot study. The various properties of adaptive immune responses were 
explored and evaluated. 
The results investigation highlighted important differences in specific adaptive immune 
responses in the HEU group when compared to their UE counterparts. We show that HEU 
infants acquire significantly fewer antibodies from their mothers to specific vaccine antigens; 
however subsequently mount robust responses to some routine vaccinations.  
This investigation also documents the persistence of adaptive immune differences in HEU 
infants beyond the initial vulnerable phase of the first 6 months of life of acquiring infection. 
Our data showed the upregulation of certain cellular markers of activation and apoptosis in 
both T and B cell components of adaptive immunity. 
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In keeping with our formulated hypothesis, we demonstrate that HEU babies in comparison 
to UE controls, showed differences in both the cellular and humoral arms of the adaptive 
immune system. These observations may thus be related to HIV exposure and possibly 
explain long-term immunological aberrations.  
6.2 IgG SPECIFIC ANTIBODY RESPONSES 
6.2.1 Maternal antibody levels 
The placental transfer of maternal antibodies plays a key role in protecting infants from 
infection during the first stages of life before receiving vaccinations and prior to developing 
their own adaptive immune responses (Mackay, 2006).  
Analyses of our data show that the HEU infant group had significantly lower levels of 
maternally derived antibodies to pertussis, tetanus and pneumococcus at 2 weeks of age 
when compared to the UE group.  The results of this observation were consistent with a 
recent study evaluating the association of maternal HIV infection on uninfected infant 
vaccine specific antibody levels. Jones et al (2011) noted significantly lower levels of 
antibodies to pertussis, tetanus, Hib and pneumococcus at birth in HEU infants compared to 
their UE group. Our evaluation in comparison to this study did not measure the specific 
antibody levels in the mothers. Observations by Jones et al showed that HIV infected 
mothers have significantly lower levels of antibodies to Hib and pneumococcus; however no 
differences were noted for pertussis and tetanus. In contrast to Jones et al., the maternal 
groups for both HIV infected and uninfected mothers in our study were similar for age and 
gravidity characteristics (Jones et al., 2011). 
Studies evaluating viral antigens found similar trends in the deficient transfer of antibodies 
from an HIV infected mother to her infant. A Zambian study evaluated the influence of HIV-1 
exposure on the levels of passively acquired antibodies and showed that infants born to HIV 
positive mothers had lower antibody levels to measles than infants born to HIV negative 
women. Levels were even lower in infants infected with HIV. This suggests that prior to 
vaccination, HEU and HIV infected infants are at greater risk for contracting measles (Scott 
et al., 2005). The findings of this study was further supported by other investigations in 
Kenya and Brazil, who showed a decrease of measles antibodies in cord blood samples of 
infants from HIV positive women (Scott et al., 2005, de Moraes-Pinto et al., 1993). 
In addition to HEU infants receiving lower levels of antibodies from their maternal source, a 
small group of infants received levels deemed to be protective. We also observed that 
despite UE infants receiving higher levels of maternal antibodies compared to HEU infants, 
our data highlighted that more than half of these UE infants did not receive levels that are 
considered protective for pertussis and Hib. A plausible explanation for this may be the fact 
that HIV negative women also do not have sufficient antibody levels to transfer, which may 
be due to their own waning immunity. Our speculation may be supported by similar studies 
that found that HIV uninfected women generally have low levels of specific antibodies and 
hence may lead to the lack of transfer of sufficient levels (Jones et al., 2011, van den Berg et 
al., 2010). 
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In contrast to the findings of Jones et al (2011), the maternal antibody levels to Hib were 
similar between the two groups at the 2 and 6 week time points. Although a significant trend 
at 2 weeks (p=0.09764) was observed. A large proportion of infants in both groups did not 
acquire protective levels to Hib. This could imply that HIV uninfected mothers have deficient 
levels of Hib antibodies also due to waning immunity. Studies investigating the transfer of 
maternal Hib antibodies in infants showed that the maternal levels are generally low, even 
with effective transfer to the infant (de Voer et al., 2009).  
Another possible explanation for the deficient transfer of Hib titres in the absence and 
presence of HIV infection may be related to the mechanism and structural components of 
placental transport of Hib antibodies. Transportation of IgG is dependent on placental 
receptors that are specific for the FcγR region. Fc-γR I and III have a predilection for IgG1 
and IgG3, but show low affinity for IgG2 (Takizawa et al., 2005). This impacts the transfer of 
antibodies to polysaccharide antigens across the placenta. Polysaccharides are likely to 
elicit more IgG2 antibodies in contrast to protein antigens that elicit IgG1 and 3 subclasses 
respectively, which are more favourable to crossing the placenta. Other factors that may 
individually relate to the transfer of antibodies to the infant may be associated to gestational 
age at birth, placental defects, as well as the IgG subclass concentration in the mother 
(Findlow et al., 2006).      
Similarly, a study conducted in the Netherlands, investigated the seroprevalence and 
placental transportation of maternal antibodies specific for Hib, diphtheria, tetanus and 
pertussis. De Voer et al (2009) showed that in contrast to antibodies elicited by proteins, 
such as diphtheria, tetanus and pertussis antigens, antibodies directed to polysaccharides, 
such as Hib, were transferred less effectively. In addition, De Voer et al (2009) also noted 
that even with effective antibody transfer to the neonate, the antibody concentrations in the 
mothers were relatively low, potentially leaving infants at increased risk of infection before 
vaccination. They observed that almost all diphtheria and tetanus titres in cord blood serum 
samples were above the generally expected protection level of 0.01 IU/ml (de Voer et al., 
2009). 
A number of studies have alluded to the decreased level of passively transferred antibodies 
from an HIV infected mother to her infant. However, very few studies have addressed the 
immunological mechanism responsible for this. A possible explanation may be due to lower 
maternal antibody levels or impairment in the transfer from an HIV infected mother (Scott et 
al., 2007, Jones et al., 2011). Jones et al found a 23% reduction in the placental transfer of 
antibodies for Hib, 40% for pertussis and 27% for tetanus, but they could not show any 
association between maternal CD4 count or HIV viral load and placental transfer. This goes 
in contrast to a study by Farquhar et al., who showed a positive correlation with maternal 
viral load and reduced transfer of maternal antibodies (Farquhar et al., 2005). It is therefore 
still unclear whether HIV viral load may interfere with the mechanism of transfer. 
A further possible explanation for the decreased efficacy of transfer may be related to the 
concentration of HIV-1 specific antibodies such as gp41 circulating in maternal blood during 
the final trimester. These HIV-1 specific antibodies may block hFcRn receptors and inhibit 
the transport of specific antibodies (such as measles) from the mother to infant. Therefore, it 
can be hypothesised that severity of maternal HIV disease may place infants at risk of 
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contracting diseases despite being HIV uninfected. Based on these observations, it could be 
suggested that the effective control of maternal viral load by initiation of early antiretroviral 
therapy preceding the period when the bulk of IgG is transferred from the maternal source (4 
weeks of gestation), may play a role in the transfer of antibodies from an HIV infected 
mother (Farquhar et al., 2005).  
Polyclonal hypergammaglobulnemia is commonly associated with HIV infection in both 
symptomatic and asymptomatic patients. Brambell, a British medical scientist, was the first 
to associate maternal hypergammaglobulnemia with the transfer of IgG across the placenta 
during the 1960s. It is believed that an excess of immunoglobulin in the mother may cause 
saturation of Fcγ receptors on placental elements, such as syncytiotrophoblasts which may 
limit transfer of antibodies across the placenta (Brambell, 1966, de Moraes-Pinto et al., 
1996, Chucri et al., 2010). This concept was further supported by a Brazilian study that 
showed that maternal HIV infection was associated with reduced placental transfer of 
antibodies to tetanus toxoid, measles and S. pneumoniae. The researchers showed that for 
some antibodies the efficiency of placental transfer decreased as the respective maternal 
levels increased with advancing HIV and related to nonspecific polyclonal antibodies (de 
Moraes-Pinto et al., 1996).  
In addition, a Malawian study showed that maternal HIV infection and 
hypergammagobulneamia was associated with a reduction in transfer of IgG antibodies to S. 
pneumoniae. However, in contrast to our findings, they found no difference in the transfer of 
tetanus toxoid antibodies. Although these infants may be considered protected against 
neonatal tetanus, it has been shown that infection occurs despite having adequate antibody 
level (de Moraes-Pinto et al., 1998). We therefore concluded that the susceptibility of HEU 
infants to tetanus is still unclear. In contrast to the latter study a Brazilian study showed a 
reduction of tetanus IgG levels in neonates which was associated with maternal HIV 
infection (de Moraes-Pinto et al., 1996).  
A study conducted in Kenya in addition showed that maternal HIV infection was associated 
with a 52% reduction of tetanus antibodies in infants after compensating for maternal 
vaccination. The placental transfer was measured using the ratio of levels in cord blood 
serum to that in serum of the mothers i.e. CMR (cord: maternal ratio). They also found that 
5.3% of the mothers and 7.8% of the newborns were classified as being seronegative for 
tetanus. The study concluded that HIV interferes with the transfer of maternal antibodies 
(Cumberland et al., 2007). 
Although several studies have supported the lack in transfer of maternal antibodies in the 
presence of HIV infection, only a few studies have alluded to the rate of decreased levels of 
passively acquired neutralising antibodies during infancy (Cabau et al., 1974).  
At 6 weeks of age the levels between HEU and UE infants in our study were similar, 
although HEU infants still had a lower mean level compared to the UE group. As HEU 
infants initially starting with a lower level of antibodies to various antigens, their levels were 
depleted before those of UE infants. Similar findings were confirmed by Cabau et al who 
reported a significant decay in maternally acquired antibodies to measles and S. 
pneumoniae in a HEU population (Cabau et al., 1974).  
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The time spent in utero may also affect the levels of passively acquired antibodies. 
Investigations have shown that the level of transport of IgG from the placenta is dependent 
on the gestation period. A study evaluating the transport of IgG maternal antibodies to 
pertusiss, diphtheria, tetanus, Hib and Neisseria meningitis C showed that levels in preterm 
infants born at a gestational age less than 32 weeks had significantly lower levels of 
maternal antibodies to the above listed antigens (van den Berg et al., 2010). 
In our cohort, 4 infants with prematurity had a gestational age less than 34 weeks (3 HEU 
and 1 UE). At 2 weeks of age, 2 of these infants had non-protective levels to pertussis (one 
presented with borderline levels). None of the infants had protective levels to tetanus and 
only one infant displayed protective levels to Hib.  
In a review compiled by Cáceres et al (2000), gestational age was directly linked to the 
degree of placental antibody transfer, with prematurity having an adverse effect. Hence they 
questioned whether the increased frequency of lower gestational age births often 
documented in developing countries contributes to a number of newborns with decreased 
levels of antibodies (Caceres et al., 2000). 
Our observation, along with documentation by other researchers, showed that infants may 
have decreased levels of maternally derived antibodies, irrespective of HIV exposure and 
should be addressed. Maternal re-immunisation should be considered in addition to defining 
good predictors for correlates of protection. Previous studies have shown direct correlations 
between antibody concentrations in mothers and infants who had increased levels due to 
maternal history of pertussis or pertussis immunisations (Van Rie et al., 2005). These 
authors also emphasised the difficulty in determining the proportion of infants that are born 
protected to pertussis, because of the absence of definite serological correlates of 
protection. 
There is a great need to evaluate effective interventions to increase maternal and neonatal 
immunity. An approach towards neonatal immunisation in all infant populations should 
perhaps be considered in order to prevent infections in early life.  
The possibility of protecting young infants against diseases by immunising their mothers 
during the third trimester of pregnancy has been investigated since the 1930s. Vaccination 
during pregnancy may be considered as an effort to limit maternal and infant morbidity; 
however, this raises a number of concerns with regard to impairment of infant vaccination 
responses (Siegrist, 2001).  
A study by Englund et al showed that mothers immunised with conjugated Hib vaccines at 
some stage in the third trimester of pregnancy, conveyed higher levels to their infants than 
those mothers that were not immunised. Pregnant mothers, immunised at 32 weeks 
gestation, transferred 82% of antibodies compared to a 92% transfer in mothers immunised 
at 36 weeks gestation (Englund et al., 1995b). More recent studies have indicated that the 
efficiency of placental transfer depends on a number of factors,  that include the integrity of 
the placenta, concentration of IgG, type of vaccine and gestational age (Englund, 2007). 
Polysaccharide vaccines, such as Hib and S. Pneumoniae, are generally considered safe 
and immunogenic during pregnancy (Healy and Baker, 2006).  
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Other studies support the need for maternal immunisation against pertussis, as higher 
concentrations of maternally derived antibodies to pertussis were related to a weaker 
pertussis toxin antibody response to whole cell pertussis vaccine, but not cellular pertussis 
vaccines (Edwards, 2003). Further studies showed that after maternal immunisation, 
concentrations of pertussis antibodies in infants ranged from 50% of maternal titres to equal 
titres in both mother and infant pairs (Van Rie et al., 2005).  
Rich and Abbud concluded that infants who received protective antibody titres to Hib were 
born to mothers that received a constant low-dose of Hib. Furthermore, they suggested that 
adequate binding capacity of the Fc receptor in the placenta is associated with antibody 
affinity and low avidity complexes which are achieved by low-dose. Similar effects are found 
with infection. These complexes can be effortlessly cleaved by the reticuloendothelial system 
and can thus be more readily available for transport via the Fc receptors (Rich, 1996). 
Additional plans to prevent infection during the neonatal period include strategies such as 
“cocoon” immunisation. This is the process whereby the individuals who are in contact with 
the neonate, are vaccinated. Neonatal immunisation would be of a great advantage and 
some of the benefits would include high vaccination coverage as more healthcare contacts 
are available at birth and offering earlier protection prior to the exposure to pathogens (Wood 
and Siegrist, 2011). 
With the increasing number of infants born to HIV infected mothers, assessing the efficiency 
and effect of maternally derived antibodies is essential for determining the factors that may 
be related to the increased infectious morbidity in the HEU population. The evaluation of our 
comparative study showed that HEU infants derive lower levels of maternal antibodies when 
compared to UE infants. This highlights their potentially related susceptibility to contracting 
severe diseases at an early age. In addition, we also documented that despite UE infants 
receiving higher levels of antibody from their HIV uninfected maternal source, in a large 
portion of these cases, levels were still not considered protective. This indicates that both 
HEU and UE infants in our group may be vulnerable to infection. Furthermore, our data 
suggests that HEU infants may need to be vaccinated earlier than their unexposed 
counterparts. Currently the vaccination schedule is not differentiated for HEU and UE 
infants. Despite the high levels of maternally derived antibodies to pneumococcus in our 
cohort, a number of infants are diagnosed with pneumonia in early infancy.  
Lastly, our study, along with others illustrated the need for determining the mechanisms that 
may be responsible for the defective transfer of IgG antibodies to infants with maternal HIV 
infection. Through this understanding of potential factors that influence the passage of 
transfer during gestation we could subsequently be able to devise preventative measures for 
vulnerable infants of disadvantaged communities and improve protection against infections.  
6.3 POST-VACCINATION LEVELS 
A number of factors influence the quality and quantity of an infant’s antibody response to 
vaccination, some of which include the stage of development of their immune system, the 
type of vaccine administered along with its immunogenicity, the number of doses and 
intervals between doses and lastly the effect of maternal antibodies (Wood and Siegrist, 
2011). 
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Based on these characteristics of vaccination, our aim was to further assess whether HEU 
infants mount effective immune responses to vaccinations of the EPI-SA programme when 
compared to UE control infants.  
6.3.1 Vaccination response to pertussis 
After the second pertussis vaccine dose measured at 12 weeks of age, both HEU and UE 
control infants displayed similar responses and only a few produced levels that were 
considered protective. However, after the third vaccination HEU infants mounted significantly 
higher antibody levels to pertussis compared to the UE control group. Our observation is 
consistent with a South African study that showed significantly higher IgG levels of pertussis 
in HEU infants after 3 vaccine doses (Jones et al., 2011). We further showed that this 
significant increased level persisted until 18 months of age after the receipt of the booster 
dose. At 24 months of age, the levels in the HEU group were lower than those of the UE 
group; however, all the HEU infants displayed protected levels compared to 89% in the UE 
group.  
The observed increased response to the pertussis vaccine may potentially be related to the 
decreased maternally derived antibodies in HEU infants seen at both 2 and 6 weeks of age. 
A number of studies have alluded to the potential interference of maternal antibodies with 
the infant’s vaccination response (Scott et al., 2007). There is limited understanding around 
how maternal antibodies inhibit vaccine responses in infants. However, is believed to be 
related to the maternal antibody to vaccine antigen ratio during the time of immunisation 
which subsequently results in epitope masking. Epitope masking refers to the concept 
whereby maternal antibodies “disguise” vaccine antigenic epitopes, therefore preventing the 
binding of infant B cells. In addition, it is suggested that a potential means of avoiding such 
immunological conditions would be to increase the dose of vaccine antigens (Siegrist, 2003). 
Similar studies have described maternal antibody interference with infant vaccine responses 
to measles and tetanus vaccines (Sarvas et al., 1992, Albrecht et al., 1977)  
Jones et al (2011) found that higher maternal antibodies had influenced the infants’ 
response to the first vaccination dose, but played no role in the response to subsequent 
doses (Jones et al., 2011). However, despite this observation by Jones et al (2011) we 
observed that some infants in the control group with relatively high maternal antibody levels 
at 2 and 6 weeks still mounted a lower response after the third vaccination dose than infants 
who had a relatively low maternal antibody level. Further research in support of the study by 
Jones et al confirmed that increased maternal antibody levels did not inhibit the infants’ 
response to specific vaccines, such as tetanus and Hib after the second dose (Kurikka et al., 
1996, Saffar et al., 2007). Both the studies by Jones et al and Kurrika et al is contradicted by 
a Danish study that showed an inhibitory effect of maternal antibodies on infants response to 
vaccination (Sarvas et al., 1992). We did however; observe that UE infants mounted an 
adequate response only after the fourth dose (booster). This corresponds with the findings of 
Glezen (2003) who observed that during early infancy, passively acquired antibodies 
suppressed antibody response to active immunisation, but did not affect priming for later 
boosting (Glezen, 2003). Therefore, some studies suggest that maternal antibodies have no 
effect after the administration of the first and second vaccination. We have however noted 
that in UE infants the potential interference of maternal antibody levels seems to diminish 
only upon the administration of the fourth vaccine dose.  
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Considering that maternal antibodies play no role in the infants’ immune response after the 
second dose does not explain why after the third and fourth dose, HEU infants still mount an 
antibody response that is significantly greater than the UE group for pertussis. Perhaps the 
reason for the increased pertussis levels noted in HEU may potentially be due to a certain 
degree of immune activation of T and B cells upon the administration of immunisation. This 
concept was explored by Obaro et al., however during the evaluation of the immunogenicity 
of childhood vaccines in HIV infected children. The concern was around immunisation and 
its effects on the proliferation of T cells and subsequent release of cytokines (Obaro, 2004). 
The same activation of the immune system may occur in HEU infants given the fact that they 
have been exposed to a highly antigenic environment. However, unlike the HIV positive 
infants addressed by Obara et al., immunisation does not lead to viral replication in HEU 
infants, thereby limiting adverse impairment of the immune response. A study by Bunders et 
al., investigating the impact of maternal HIV infection on immunoglobulin levels in HEU 
children, showed a significant impact of maternal HIV infection on the B cell compartment of 
the HEU immune system, which further suggests that it may be due to HIV exposure. 
Researchers documented that hyperglobulinaemia is a common feature in HIV infection, 
which also persists in HEU infants until at least 24 months of age. They further concluded 
that infants born to HIV positive mothers have an altered humoral response (Bunders et al., 
2010). 
An effective immune response to vaccination should result in the effective priming of both T 
and B cell compartments of the immune system. Responses to whole cell pertussis and the 
influence of maternal antibodies are determined specifically by B cells and do not influence 
the infant’s T cell responses. Neonates mount weak cytotoxic and T cell responses and the 
help for B cell differentiation is limited. Pertussis antibody-secreting as well as memory cells 
are produced despite immunisation of neonates mounting a rapid antibody response 
(Siegrist, 2003).  
Early findings related to vaccination with pertussis indicated that giving the vaccine at birth 
produced a decreased immune response. However, studies using the mouse model found 
that the temporary dampened immune response observed in neonates is antigen specific 
(type of vaccine administered) and that the underlying reason behind the reduced response 
may be due to the immaturity of the neonatal immune response along with the inhibitory 
effects of competing maternal antibodies. Infants immunised with whole-cell pertussis 
seemed to have lowered antibodies in relation to having increased maternal antibodies. 
However, in infants immunised with acellular pertussis vaccine, maternal antibodies did not 
confer interference, thus indicating the vaccination with acellular pertussis allows for a better 
immune response and may be explained by evaluating T-cell mediated immunity (Van Rie et 
al., 2005). Similar studies have observed a decrease in antibody response of up to 56% in 
infants immunised with whole- cell pertussis vaccine as opposed to acellular pertussis 
(Glezen, 2003).  
Only one out of the three HIV positive infants in our study displayed non-protective levels to 
pertussis after receipt of the primary vaccination. At 12 months of age, none of the HIV 
positive infant’s maintained levels deemed to be protective. However, after the fourth 
vaccination dose given at 18 months of age, HIV positive infants had increased levels of IgG 
to pertussis, which was maintained at 24 months of age. A study by Tejiokem et al showed 
that after 3 doses of the whole-cell pertussis vaccine, only 19% of HIV positive children and 
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48% of HEU children possessed detectable antibodies. The initial antibody response was 
much lower in HIV-infected infants than exposed infants; however, it is unclear whether HIV-
infected children may be at risk of severe or more frequent pertussis disease relative to HEU 
infants (Tejiokem et al., 2009). 
There was one documented pertussis infection in a control infant in our study. At 2 weeks of 
age the infant had a maternal antibody level of 50.94 FDA U/ml and at 6 weeks of age this 
level decreased to 21.0 FDA U/ml. After 3 doses of the pertussis vaccine this infant did not 
mount any response and at 12 months of age, had the lowest documented level of 0.9 FDA 
U/ml. At the 18 month time point the levels increased significantly to 327.16 FDA U/ml. At 24 
months the child did not have protective levels to pertussis (24 FDA U/ml) of which during 
this period was diagnosed with pertussis. It is likely that due to receiving high maternal 
antibodies, this infant could not respond adequately to vaccination due to maternal antibody 
interference. The heightened response to the vaccine at the 18 months may have resulted 
due to diminished maternal antibody levels. It is interesting to note, that even after infection 
the infant did not display pertussis levels that were considered protective even after one 
month of natural infection. These observations may suggest primary immunodeficiency and 
indicate the need for further evaluation (Gaspar and Conley, 2000). 
In South Africa the efficacy of both whole-cell and acellular pertussis vaccines have been 
shown to be in the ranges of 83-98%. However, it is mentioned that the extent of the immune 
response to pertussis is proportionate to the number of doses administered (SAVIC, 2009b). 
Our findings suggest that infants in both the HEU and UE groups mount the highest 
response to pertussis after the fourth vaccination dose. Similar studies have confirmed this 
finding  (Torbicka et al., 1995). UE infants in our study mounted the highest protective 
response to pertussis only after the fourth dose where 94% of infants had protective levels. 
Our findings are in contrast to a study conducted in Taiwan were infants vaccinated at 2, 4 
and 6 months showed protective antibody titres against pertussis at each of these time 
points (Lin et al., 2003).   
A study in Finland observed the effects of genetic divergence between whole-cell and 
acellular pertussis vaccines. It was stated that B. pertussis population undergoes continuous 
and rapid changes, however despite this molecular observations, it was concluded that both 
types of vaccines still offered protection against pertussis. The study advised administering 
the vaccination as early as possible, and furthermore highlighted the importance of booster 
immunisation (Elomaa et al., 2009). 
No correlates of protection for pertussis have thus far been established. It is suggested that 
protection induced against pertussis may depend on a number of immunological factors 
relating to the humoral and cell-mediated responses. Bearing in mind the decay of maternal 
antibodies, a definitive vaccine response represents a 4-fold increase in antibody 
concentration between the pre- and post-vaccination samples (Godfroid et al., 2004). 
Similarly, Capeding et al (2008) described pertussis seroconversion as a four-fold increase 
in antibody titres that occurred in 95.3% of their study population (Capeding et al., 2008).  
There is much concern regarding the re-emerging profile of pertussis. The effects of adapted 
epidemiology show increased incidences in infants, adolescents and adults, which may be 
due to a number of reasons including increased efficacy of diagnostic techniques. Other 
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factors, such as demographic changes, waning immunity, changes in vaccine coverage and 
perhaps a decrease in vaccine efficacy due to drifts in isolates and strains, may all be 
related to the increase in incidence rates. Studies have shown that immunisation and 
infection during childhood are not producing sufficient immunity (Edwards and Freeman, 
2006, Cherry, 2005, Bamberger and Srugo, 2008, Campins-Marti et al., 2001). A Brazilian 
study has confirmed that immunity in infants immunised with 3 doses of whole-cell pertussis 
produced high levels of antibodies. The researchers concluded that the vaccine induces 
effective immunological memory that may only last for 2 years subsequent to the completion 
of the immunisation schedule (Pereira et al., 2010). A study conducted in France showed 
that infants produced an adequate response to pertussis whole-cell vaccines, but these 
responses diminished without a booster dose. However, 6 years after vaccination, 
responses increased suggesting exposure to infected persons and persistence of pertussis 
strains with unfamiliar circulating strains. The researchers highlighted that infection is more 
likely to occur within 6 years of receiving their last vaccination.  
These findings therefore support the need to further evaluate the disease causing isolates in 
more detail and promote the implementation of additional booster vaccinations, either in 
children at pre-school age and/or adolescents to prevent the possibility of an outbreak.  
6.3.2 Vaccination response to Clostridium Tetani 
After the second vaccination dose, both HEU and UE infant groups responded adequately to 
the tetanus vaccine and both groups produced 100% antibody protection. After the third 
vaccination dose, infants were still able to maintain adequate levels to tetanus. There 
seemed to be no difference in the antibody levels in HEU and UE infants from 12 weeks to 
18 months of age. Our data follows that of Jones et al., who showed no differences in the 
vaccine responses in HEU and UE after receiving the third dose (Jones et al., 2011). Despite 
receiving significantly low maternal antibody levels at birth, there was no increase in the 
antibody response to the vaccine after 2, 3 or 4 doses. Our longitudinal data show that 
differences in HEU and UE infants appear to emerge at 24 months of age. Despite HEU 
infants having an increased IgG level to tetanus at 24 months, infants in both groups 
displayed protective levels.  
Protective responses are based on both the levels of IgG antibodies, which are mainly IgG1 
responses, as well avidity aspects. A study conducted in Gabon measured the IgG levels in 
a group of children originating from rural and urban areas respectively. Researchers showed 
increased level of Ig1 anti-tetanus antibodies were present in rural children after vaccination 
when compared to semi-rural children. The avidity was similar amongst the two groups (van 
Riet et al., 2008). It could be speculated that the increased IgG specific antibodies to tetanus 
in the HEU group at 24 months may be due to our HEU group (compared to our UE group) 
differing significantly with regards to social characteristics. More infants in the exposed group 
live in informal housing structures thus may be pre-exposed to tetanus antigens that may be 
contained in soil. In addition, may be due to exposure to unhygienic environments. This may 
have resulted in the heightened response represented at the 24 months time point.  
There is some speculation with regards to the correlates of protection for tetanus. There 
have been a number of tetanus infections where individuals presented sufficient levels 
expected to confer protection (Borrow et al., 2003). Therefore, despite having adequate 
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levels to tetanus in both HEU and UE groups after vaccination, does not imply that these 
infants are not susceptible to infection.  
A recent Brazilian study evaluating the vaccine response in HEU infants to a number of 
antigens including tetanus, reported that although HEU infants had lower mean IgG levels to 
tetanus in comparison to UE infants, a statistically significant difference between the two 
groups was not achieved (Abramczuk et al., 2011) which is in keeping with our findings. The 
median age however in the HEU group was just over 7 months. There were no reports on 
the tetanus levels prior to the 7 month time point. Abramczuk et al found that a large portion 
of HEU infants were non responders to Hepatitis B vaccine and concluded that HIV infection 
is not largely associated with failure to respond to tetanus or diphtheria, but more likely to be 
associated with aberrant Hep B responses. Based on this speculation, we have observed 
that all HIV positive infants in our study had protective levels to tetanus and therefore 
support no association with HIV exposure or infection with different responses to tetanus and 
further speculate that the increased response is possibly due to environmental antigen 
exposure. Another study showed that 75% of their HIV positive cohort responded to the 
tetanus vaccination (Melvin and Mohan, 2003). Therefore, the significantly higher response 
depicted in HEU infants at 24 months of age in our study might not directly be due to HIV 
exposure but perhaps rather to greater antigenic exposure.  
Abramczuk et al (2011) also found no association between infant CD4 counts and IgG levels 
to tetanus, which corresponded to another study that showed similar responses in HEU 
individuals with lower CD4+ T cell responses (Gesner et al., 1994). Based on these 
observations, it is believed that the differing humoral immune responses in HEU infants be 
due to functional changes in T lymphocytes and aberrant functional abilities related to 
antigen presentation (Abramczuk et al., 2011) 
It is unlikely that maternal antibody levels would have had an influence on the heightened 
response observed for HEU infants at 24 months of age. According to Kurika et al., maternal 
antibody interference to tetanus IgG levels in infants are diminished after the second dose 
(Kurikka et al., 1996). 
6.3.4 Vaccination response to Haemophilus Influenzae b 
In contrast to the protein vaccines described above, HEU infants showed no significant 
differences compared to the UE group at each of the post-vaccination time points. At 12 
weeks of age, they still had lower levels of Hib IgG compared to UE control infants and only 
67% of these infants had protective levels in comparison to 100% of infants in the UE group. 
After 3 vaccine doses, measured at the 6 months time point, both HEU and UE infants 
displayed similar levels antibodies and protection.  
Our findings are consistent with Jones et al., who found similar responses in both HEU and 
UE infant groups after 3 doses of the Hib vaccine (Jones et al., 2011). Researchers 
observed that HEU infants do not demonstrate robust (but similar) response to the Hib 
vaccine in comparison to UE infants. This finding may be related to the lack of competing 
maternal antibodies as both infant groups (HEU and UE) seem to inherit limited amounts of 
maternal antibodies. The findings of Jones et al showed that HEU infants had significantly 
lower levels to Hib at birth however still did not mount a significantly higher response to the 
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vaccine after 3 doses compared to other vaccines, such as pertussis and pneumococcus. 
This may indicate other potential reasons for why HEU infants have similar responses to the 
Hib conjugate vaccine.  
Our data shows that, despite having relatively high levels of protection after the third vaccine 
dose, a small percentage of infants in both HEU and UE groups were able to maintain these 
levels at 12 months of age. Although the levels in the HEU group seemed faintly higher than 
the controls, they were only able to maintain 30% of their protective levels to Hib. In addition, 
only 25 % of the UE infants had levels deemed to be protective. This implies that at 12 
months of age, both HEU and UE infants in our cohort were susceptible to the major causes 
of diseases, such as meningitis and pneumonia due to Hib.  
In 2010, a total of 82 cases of Hib were reported amongst children less than 5 years of age. 
According to the GERMA-SA audit, a total of 91 Hib disease cases were reported in South 
Africa of which the Western Cape represented the third highest (21 cases). The highest 
incidence was in the Eastern Cape, followed by Gauteng (GERMS-SA, 2010). There had 
been no documented incidence of Hib related infections in our cohort even during the 
vulnerable period at 12 months when the levels of protection was relatively low.  
A study by Goldblatt et al demonstrated an increase in Hib levels after 3 doses of the 
vaccine. This seemed to be effective in inducing immunological memory; thus, with the 
primary schedule sufficient memory associated with long term protection would be generated 
upon infection even though the circulating antibody titres are low (Goldblatt et al., 1998). 
This observation can therefore be related to the incidence in both HEU and UE control 
infants having decreased levels to Hib, which according to Goldblatt et al., does not make 
them vulnerable to infection due to the initiation of long-term memory associated with Hib 
conjugate vaccines. In addition, infants in our study who received only 3 doses of the Hib 
vaccine still maintained protective IgG levels at 18 and 24 months of age.  
A review by Plotkin outlined the importance of defining correlates of protection and 
highlighted the underlying mechanism of protection may not be related to the mechanisms 
involved in the recovery of infection. Rather, Plotkin states that correlates of protection differ 
both in quantity and quality and thus depends on the purpose of wanting to prevent infection 
(systemic or mucosal) or to prevent disease (Plotkin, 2010). For pathogens such as Hib, 
protection should be defined by opsonophagocytic or bactericidal antibodies (functionality), 
however antibody binding is considered as useful substitutes. The protective ranges relating 
to antibody concentration differ amongst countries and research groups. Three important 
points that have emerged with regards to adequate protection against Hib: (1) Antibodies 
should be present at the time of exposure (2) those antibodies must demonstrate higher 
levels of avidity to propose protection and (3) protein conjugates reduce T cell dependent 
responses and protection may be offered by lower levels of antibody (Plotkin, 2010). 
Hib IgG levels subsequent to 12 months were similar between the two groups and both HEU 
and UE infants displayed protective levels above 80%. By the age of 2 years both groups 
had adequately protective levels to Hib. However, four infants in our study (2 HEU and 2 UE) 
displayed IgG levels <0.1µg/ml. Only one of these four infants mounted an adequate 
response to the first two doses of the Hib vaccine. After the third vaccine dose all infants 
mounted adequate levels to Hib. At 12 months of age, only one of the 4 infants had levels 
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>0.1µg/ml. This same infant did not mount a response to the booster vaccination at 18 
months, compared to the other three who had levels deemed to be protective. A common 
trend that seems to be emerging with this group of infants is that after each vaccination, 
most of these infants were not able to maintain protective levels.  
There is a relative amount of debate regarding the immunological response related to 
capsular polysaccharide elicited by B cells. It is often reported that the response is carried 
out independent of T cell help; however increasing evidence suggests a potential role for 
CD4+ T cells. Suggestions indicate that the conjugation of bacterial polysaccharides to a 
carrier protein provides foreign peptide antigens that are presented to the immune system 
and subsequently recruits antigen specific CD4+ T cells (Siegrist, 2001, Clerici et al., 2000). 
Matos outlined however that the response to conjugated vaccines is known to be T cell 
independent. Molecules such as PRP are T cell independent antigens that can activate only 
mature B cells and prevent infants from producing antibodies against polysaccharide 
epitopes. T-independent mechanisms develop over age. Due to this a number of conjugated 
vaccines have been developed to enhance the immune response to PRP, some of which 
include the conjugation to diphtheria toxoid, tetanus toxoid and the outer membrane protein 
of Neisseria meningitis (Matos et al., 2009).  
There are some concerns surrounding the efficacy of vaccines used in combination with 
others. Despite having many advantages, such as lowered cost, few injections given and 
better conformity, concerns have been raised about the increased reactogenicity and 
interfering immunogenicity. In our cohort, Hib was given in combination with diphtheria, 
tetanus and pertussis (DTP-Hib; Sanofi Pasteur). Studies evaluating the effect of 
combination vaccines found similar responses to all vaccines given in combination or 
individually. Even newer combination vaccines, such as DTaP-IPV//Hib, induce protective 
antibody titres against all antigens covered in the vaccine (Lin et al., 2003). Other studies 
have found lower antibody levels to combination vaccines in comparison to separate 
vaccinations, but thereafter concluded that functional characteristics were similar and 
resulted in adequate immunological memory (Poolman et al., 2001). 
In a Brazilian study designed to evaluate the functional activity of Hib antibodies elicited in a 
group of infants immunised with the diphtheria-tetanus-pertussis vaccine combined with Hib, 
it was found that a strong anti-PRP response (≥ 1.0µg/ml) was generated. It was further 
observed that 97% of the infant’s immunised with DTP-Hib produced high levels of PRP IgG 
antibodies that were considered to be a serological substitute of long-term protection. 
Antibody levels of 0.15µg/ml of anti-PRP were considered as being the minimum level for 
eliciting short-term protection (Matos et al., 2009). 
In a Nigerian study, the response to the Hib vaccine varied in different population groups 
according to age at which immunisation was administered, the type of conjugate vaccine 
given, whether the vaccine was administered in the same syringe, pre-existing antibodies 
and even nutritional elements. Despite these factors 86% of the infants in their study 
achieved antibody levels >1.0µg/ml four weeks after two or three does of the vaccine and 
95% of their cohort maintained these levels until 9 months of age (Campagne et al., 1998). 
HIV-infected individuals have a 6-8 fold increased risk of invasive Hib disease. The initial 
immunological response in HIV-infected individuals is 54% as opposed to 90% in uninfected 
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individuals and by 15 months of age there is sequential loss of memory to a protective 
efficacy of just 30% (Jeena, 2008). HIV positive infants in our study were able to mount 
adequate responses to Hib after the second vaccine dose, however out of the 3 HIV positive 
infants in our study, only 2 were able to mount an effective response to Hib after the third 
vaccine dose. At 12 and 18 months of age, all HIV positive infants had protective levels to 
Hib, however only 1 infant retained protective levels at 24 months.  
Madhi et al (2005) investigated both the quantity and quality of the Hib conjugate vaccine in 
both HIV-infected and uninfected infants. In this study only a few HIV positive infants were 
likely to have antibody concentrations above the indicated protective levels and were also 
lower compared to uninfected infants. In addition, a limited proportion of HIV infected infants 
had antibody levels considered to be functional. The concentration of antibody required for 
50% killing of Hib bacteria was much higher in HIV infected infants. The risk for vaccine 
failure was much higher for HIV infected infants than HIV uninfected infants (Madhi et al., 
2005). In contrast, Read et al showed no correlation between antibody levels to Hib and viral 
load (Read et al., 1998). However, similar studies have shown that robust responses to Hib 
were associated with higher CD4+ T cell counts (Steinhoff and Goldblatt, 2003). In the same 
study by Madhi et al (2005), 95.3% of HIV uninfected infants produced antibody levels 
greater than 0.1µg/ml after the third dose. Similarly, the findings in our study showed that 
89% of uninfected infants mounted adequate responses.  
Rustein et al., found that only 46% of HIV infected infants mounted adequate Hib responses 
compared to 79% of infants in their HEU group. After a booster dose at 15 months, the 
differences between the group were no longer comparable (Rutstein et al., 1996). It was 
therefore recommended that HIV infected infants receive a booster dose after 2 years of age 
as Hib is considered a significant pathogen in HIV-infected adults (Mangtani et al., 2010).  
6.3.5 Response to PCV7 vaccination 
Approximately 1 million children under the age of 5 years die of pneumococcal infections 
each year (Scott, 2007). Streptococcus pneumoniae infection is classified as the major 
cause of pneumonia and meningitis (Quiambao et al., 2007). Immune compromised patients 
such as those infected with HIV are more susceptible to contracting diseases, including 
those related to S. pneumoniae infection. 
Two randomised placebo control trials evaluated pneumococcal vaccine (PCV9-CRM) in 
South Africa and Gambia. The South African trial conducted from 1998 to 2001 
demonstrated 65% and 83% efficacy against pneumococcal disease in both HIV infected 
and uninfected children respectively (Klugman et al., 2003). Although a number of studies 
have measured the responses to PCV vaccination in HIV infected infants, a paucity of 
studies have addressed the immunogenicity in HEU infants 
The approval of the pneumococcal vaccination into the EPI-SA schedule occurred during 
April 2009, the same time the recruitment of our cohort commenced. However, due a 
number of delays with the roll-out of the vaccine programme, a number of infants in our 
study did not receive the required vaccine dosage according to schedule. In addition, there 
had been no catch-up programme during the same year. Although the IgG levels to 
pneumococcus were measured for all infants at each at the indicated time points of the 
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study, the data could not be collated due to high variability of missed dosages in the limited 
amount of infants who did receive the vaccine. This section, will therefore only focus on the 
antibody levels of a few infants who received the first vaccine dose according to the 
schedule.  
As most of our infants have not received the vaccine, we can only speculate the impact of 
maternal levels on the infants’ vaccine responses. Jones et al documented robust responses 
to pneumococcal vaccination in HEU infants compared to UE controls who had received 
significantly higher levels of maternal antibodies in comparison to the exposed group (Jones 
et al., 2011). Considering that the population of mothers and infants were from the same 
region and maternal age groups, we assume that the response in our cohort of HEU and UE 
controls would have been similar. Madhi et al (2010) also showed higher IgG antibody 
concentrations after vaccination in HEU infants which was indicative of a more vigorous 
response. Furthermore, Madhi et al also considered the contributing factor of maternal 
antibodies as interference (Madhi et al., 2010). 
At the 12 week visit, 12 or our infants (5 HEU and 7 UE) received one dose of the PCV7 
vaccine. Quantitative measurement of the specific IgG levels show that HEU infants had a 
higher median level of antibodies in comparison to the UE group. These results are 
consistent with the general findings of Jones et al (2011) and furthermore promote the 
reason for robust responses to vaccination in HEU infant’s due to the lack of competing 
maternal antibodies. Infants who received only one dose of the vaccine presented with 
sufficient levels considered to be protective. These findings are consistent with another 
South African study observing the effective immunogenicity of PCVs after one dose 
(Huebner et al., 2004). Other studies have found immunogenicity to only some of the 
pneumococcal serotypes after one vaccine dose whereas different studies documented 
immunogenicity to all serotypes after 3 vaccine doses (Rennels et al., 1998, Leach et al., 
1996). 
A South African study measured both serotype-specific antibody concentrations (quantity) 
and OPA (quality) properties after 3 vaccine doses in a subgroup of infants born to HIV 
positive and negative mothers. Results of this study showed that both HEU and UE infants 
had antibody concentrations greater than 0.35µg/ml for each serotype measured. However, 
HEU infants showed a greater concentration for serotype 6B and in addition required higher 
concentrations of antibody for 50% killing activity against serotype 19F. These findings 
indicate that antibody levels to PCV in its entirety should not be the only determining factors 
of correlates of protection, but evaluation of functionality will serve as better determinants of 
vaccine efficacy. In addition, this functional observation may advocate faint changes in the 
immune response to vaccines in HEU infants which could contribute to increased morbidity 
related to pneumococcal disease in this population (Rodgers and Klugman, 2011, Madhi et 
al., 2010). 
Madhi et al (2010) further highlighted the importance of using OPA as a means of evaluating 
protection against pneumococcal disease in addition to antibody concentrations given the 
fact that serotype-specific antibodies confers protection against disease by opsonising and 
initiating phagocytosis. In addition, Madhi et al states single measurements of IgG levels 
may result in an over-estimation of protection offered by PCV (Madhi et al., 2010). 
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Given that PCV7 contains the most common serotypes known to be resistant to antibiotics, a 
decrease in both antibiotic resistance and treatment has been accepted after routine use in 
immunisation programmes. A large portion of infants in our study, were not vaccinated 
against pneumococcal disease thus potentially leaving them vulnerable to infection. It is 
therefore recommended that extra care be taken to increasing the coverage and 
administration of PCV7 in low-resource settings such as South Africa. In addition, the 
initiation of catch-up programmes would serve well considering the delay in the vaccine roll-
out plan 
On a global level, the implementation of PCV7 into the national immunisation schedule in 
over 50 countries has shown decreased rates of mortality, pneumonia and otitis media. 
Furthermore infection rates have decreased in areas where children are known to be 
affected by HIV (Rodgers and Klugman, 2011).  
6.4 EVALUATION OF SPECIFIC CELLULAR BIOMARKERS ON T AND B 
LYMPHOCYTES BY FLOW CYTOMETRY 
Cellular of immune activation, regulation and apoptosis were investigated in HEU children at 
18 and 24 months of age and compared to UE controls. The aim of this part of the study was 
to evaluate these as possible consequences of HIV exposure and whether they persisted as 
potential long term immunological aberrations.  
HEU infants have differences in immune function that had been shown in their responses to 
vaccination and may not necessarily be linked to the significantly decreased levels of 
maternal antibody acquisition.  
Based on the preliminary findings of vaccine hyper-responsiveness our pilot cohort we 
hypothesised that those infants born to HIV positive may also experience a prolonged state 
of immune activation. 
This could possibly be related to an antigen loaded environment as well as maternal factors 
including ARV therapy. 
6.4.1 Expression of cellular markers of immune activation and regulation on CD4+ and CD8+ 
T lymphocytes 
Uninfected infants of HIV positive mothers showed evidence of antigenic stimulation and 
subsequent immune activation of CD4+ lymphocytes (Clerici et al., 2000). These responses 
have been shown to be HIV specific and appear after birth. In addition, HIV infected women 
are known to be at higher risk of infections than HIV uninfected women, subsequently 
exposing their infants to a larger number of antigens therefore leading to increased immune 
activation in their infants (ter Kuile et al., 2004, Cotton et al., 2008). 
A recent study by Borges-Almeida et al detected several differences in the cord blood 
lymphocyte sub-populations in HEU infants compared to UE controls. Newborns exposed to 
HIV not only showed a decrease in IL-4 production, but more importantly increased levels of 
IFN-. This reflects a skewing towards Th1 responses (more inflamed as such). These 
observations were more profound in infants born to mothers on HAART, thereby indicating 
that the disease stage of an HIV positive mother plays a role in the immunological response 
of their infants, even though HIV negative  (Borges-Almeida et al., 2011). Interestingly, 
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studies have shown that despite adequate antiretroviral therapy, immune activation and 
inflammation persist (Hunt et al., 2011) as determined by the levels of CD38 expression on 
CD8 T cells. This has been attributed to several factors such as ongoing leakage of 
microbial products, such as lipopolysaccharide (LPS) across the gut epithelium (Lee et al., 
2009), reactivation of CMV (Naeger et al., 2010) and response to lymphopenia itself (Lee et 
al., 2009). Therefore, these infants may similarly have been exposed to such pro-
inflammatory stimuli, despite administration of maternal ART.  
HEU infants display significant alterations compared to UE infants due to intrauterine 
exposure to HIV and ARV drugs. Some alterations include mitochondrial dysfunction, 
abnormal haematological features and abnormal maturation of T and B lymphocytes 
(Bunders et al., 2005b). 
During the period of foetal development, HEU infants are exposed to HIV particles and 
proteins. Evidence of exposure to HIV is illustrated by documented levels of immune 
activation, the presence of HIV-specific T cells, increased detection of HIV-specific CD4+ T 
cells and low levels of HIV-specific CD8+ T cells. In addition, treatment with ARV in HIV 
positive women is linked to the inhibition of bone marrow function (Rowland-Jones et al., 
1993, Clerici et al., 2000).  
It is well documented that HIV results in the inhibition of progenitor cell function and causes 
cell apoptosis which leads to immunological and haematological deficiencies (Clark et al., 
2000). In HIV positive women, an imbalance between Th1 and Th2 cytokine expression has 
been described, which results in cytokine imbalances in the infant, leading to abnormal 
immunological functions (Klein et al., 1997).  
A study by Nielsen et al showed that HEU infants have impaired progenitor cell function and 
therefore presented with low CD4 counts. Both numbers of naïve CD4+ T cells and T cell 
receptor circles (TREC) frequency were lower in infants of HIV positive mothers, strongly 
suggesting a reduced thymic output. These researchers hypothesised that impaired 
progenitor cell function in HEU may be due to exposure to HIV particles or HIV proteins 
(Nielsen et al., 2001). 
Several studies have addressed a number of immune abnormalities that persist in HEU 
infants during the neonatal period; however few studies have examined the effects of HIV 
exposure subsequent to this time. Clerici et al., observed composite defects such as 
reduced CD4/CD8 ratios, decreased percentages of both CD4+ and CD8+ naïve T cells as 
well as increased activation on CD8+ T cells on HEU newborns and further concluded that 
such defects persisted over time in older exposed children (Clerici et al., 2000). 
In this study we evaluated the expression of markers of immune activation (CD69 and 
CD40L) and proliferation (CD127) on CD4+ T cells, as well as immune activation (CD38) on 
CD8+ T cells. Analysis of our data showed that HEU babies had increased expression levels 
for CD69, CD127 and CD40L on CD4+ T cells at both 18 and 24 months, although 
statistically significant differences were only reached for CD40L and CD127 at 18 months of 
age.  
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A study by Nielsen et al showed a correlation between lymphocyte proliferation and 
expression of CD69 in a group the HIV positive individuals (Nielsen et al., 1998). These 
finding may relate to our observation seen in HEU infants where an increase in both CD69 
and IL-7 receptor (involved in generation, activation and homeostasis of T cells), CD127 was 
observed. CD69 is classified as an early marker of immune activation, which is up regulated 
in response to antigenic stimulation. Some studies have indicated impairment in the 
expression of CD69 in patients who are in the advanced stages of HIV disease progression. 
These patients do not show increased CD69 expression upon stimulation with an antigen, 
such as Staphylococcus enterotoxin B (Pitsios et al., 2008). The increase in CD69 observed 
in our HEU population at both 18 and 24 months of age may be indicative of chronic 
antigenic stimulation.  
It is interesting to note that an increase in the expression of several markers seems to be 
higher at 24 compared to 18 months in both HEU and UE groups. This may indicate that 
both infant groups have increased antigenic exposure at 24 months in comparison to 18 
months. The higher levels in HEU infants at 24 months may be related to excessive 
exposure. Expression levels in both infant groups at 24 months seem to be within similar 
ranges to adult control patients in the study by Nielsen et al (1998). This would reflect 
maturation in the development of their immune systems  
Reviewing our data on the small group of HIV infected children not included in this study, we 
showed that at 18 months of age, the expression levels of CD69 were closer to those levels 
in the HEU group and further, that at 24 months of age, the activation marker was double 
that seen in both HEU and UE infants. This may have been due to the even greater 
antigenic exposure of their immunodeficiency (HIV infection)  
CD40 ligand is mostly expressed on activated CD4+ T cells and plays a role in B-cell 
proliferation and immunoglobulin class switching. The interaction of CD40 with CD40L is 
also responsible for the activation of the immune response (Romano et al., 2006). Our study 
showed that HEU infants display increased levels of CD40L (CD154) on CD4+ T cells. 
Although these differences were not significant, there seems to be a significant trend for the 
expression of this molecule in the HEU population on CD4 T cells at 18 months of age. 
Ramano et al similarly investigated the expression of the molecule by use of a CD45 
PanLeucogating approach to study a group of HEU infants and were able to confirm an 
increase of the expression CD40L on both CD4 and CD8 lymphocytes. In addition, the initial 
hypothesis of their study was to prove that ARV exposure had a potential immunostimulatory 
effect on the infant’s immune system. Although their study lacked a control population who 
were not subjected to ARV, they did not find a correlation of CD40L expression related to 
maternal viral load or CD4 count, gender, gestational age or feeding methods. Based on this 
they were able to indirectly relate the effect of ART exposure on the increased expression of 
CD40L (Romano et al., 2006). However, it is more likely that the chronic pro-inflammatory 
environment despite ART, promoted the upregulated expression of CD40L and not the drugs 
themselves. 
The positive effects of ARV drugs are not only to reduce viral replication, but also to promote 
antiviral immunity.  Similar observations were made in both HIV and non-HIV cases where 
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anti-virals were administered (Sipsas et al., 2002). In addition, treatment with nucleoside 
analogs was also found to increase the expression of CD40L (Bergamini et al., 2002).  
The binding of CD40L on activated T cells to the CD40 receptor on B cells leads to the 
increased expression of co-stimulatory molecules, such as CD80 on other antigen 
presenting cells (O'Gorman et al., 2001). This may explain the increased expression of 
CD80 on B cells (described below) that significantly increased at 18 months of age in the 
HEU group of our study.  
Altered expression of CD40 ligand can lead to dysfunctions in both the T and B cell 
compartments of the immune system. O’Gorman et al showed that the levels of CD40L were 
aberrantly lower in a group of HIV infected children compared to uninfected HIV exposed 
children. It is hypothesised that this could be due to the loss of a sub-population of T helper 
cells which upregulate CD40L upon stimulation (O'Gorman et al., 2001). Similarly in our 
study, we observed that the two HIV infected children showed lower expression of CD40L at 
24 months of age.  
As with the study by Romano et al., the researchers showed that there was no relationship 
between the viral load and the expression of CD40L, therefore suggesting that children with 
the highest viral loads do not necessarily present with the most impaired levels of CD40L 
(O'Gorman et al., 2001). Further studies are therefore required to describe the reasons 
behind the abnormal expression of CD40L and whether these levels can be restored with 
antiretroviral therapy.  
Ramano et al., furthermore suggests that strategies that support the expression of CD40L on 
expanding CD4+T cells may be helpful in complementing the immunity of the host against 
HIV (Romano et al., 2006).  
According to Clerici et al., immune defects observed in HEU infants may not only be a 
consequence of ARV drug exposure. Similar abnormalities are also observed in older 
children born to HIV infected mothers who were not exposed to ARVs (Clerici et al., 2000).  
CD127 is an interleukin 7 (IL-7) receptor that plays an important role in thymopoiesis (thymic 
development), enhancement of CTL function, promotion of T cell survival as well 
maintenance of T cell homeostasis. IL-7 is also essential for T cell development, 
reconstitution and proliferation through the upregulation of Bcl-2 (Hassan and Reen, 1998, 
Young and Angel, 2011).  
We observed increased levels of CD127 expression at both 18 and 24 months in the HEU 
group, although only significant at 18 months of age. To our knowledge there are currently 
no other studies that have observed the expression of CD127 in HEU infants. However, 
Clerici et al measured the levels of serum IL-7 on ELISA and found increased levels in both 
newborns and older children born to HIV infected mothers. They conclude that the increased 
levels of serum IL-7 are consistent with the impairment of T-cell homeostasis previously 
documented in the same study (Clerici et al., 2000).  
Thymic function is altered during with HIV infection and characterised by dysregulation of the 
thymic epithelial network, reduced thymic output and ultimately an impaired naïve T cell 
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pool. The IL-7 or IL-7 receptor signalling pathway is critical for the maturation and 
differentiation of thymocytes. HIV infection is associated with decreased CD127 expression 
and impaired CD127 signalling (Paiardini et al., 2005). The HIV infected babies in our study 
displayed much lower levels of CD127 at 24 months of age, which is consistent with the 
latter findings. However, a recent study by Young and Angel (2011) found that HIV infection 
alters the activity of IL-7 responses, however not through the down-regulation of CD127. We 
observed a significant increase in the expression of CD127 in the HEU group at 18 months 
of age, but without evaluating levels of IL-7. This would have generated data that is more 
comparable with larger studies. 
For successful clearance of a pathogen, a fine balance between inflammation and control of 
excess immune activation is required. Immune regulatory molecules, such as CTLA-4 or 
CD152, are such regulatory elements of the immune system that control immune activation, 
thereby preventing immunologically mediated damage and exhaustion (Kaufmann and 
Walker, 2009). The expression of CTLA-4 in our cohort was similar in the HEU and UE 
groups. A recent study evaluated the expression of CTLA-4 along with other molecules for 
immune regulation in groups of HIV controllers and HIV progressors in an attempt to 
evaluate mechanisms of viral control.  They found an increase in expression of CTLA-4 
along with a decrease in CD40L (implying prior activation) on CD4+ T cells in the HIV 
progressor group compared to the controllers (Whittall et al., 2011). Our findings show a 
trend (no significance) in the increased expression of CD40L and no upregulation of CTLA-4 
in comparison to UE control group. This may indicate that due to controlled immune 
activation on CD4+ T cells, the expression of CTLA-4 was regulated additionally. Another 
study showed a greater increase in expression of CTLA-4 in an untreated HIV infected group 
rather than the HEU infants (Nqoko et al., 2009). The HIV infected infants in our study 
showed similar levels of CTLA-4 expression to both HEU and UE groups; this may be due to 
adequate immune control by ARV treatment.  
Evidence of exposure to HIV in HEU infants is illustrated by the presence of both HIV-
specific T helper and cytotoxic T cells. It has been suggested that these types of 
observations may be linked to correlates of protection against HIV (Clerici et al., 1993, 
Bernard et al., 1999). 
Clerici et al (2000) further showed an increase in the activation marker CD38 on CD8+ T 
cells in children (approximately 7 years of age) born to HIV positive mothers. This was 
interpreted as further evidence for the persistent immune abnormalities in HEU individuals. 
In contrast to the latter findings, we did not find differing levels for the expression of CD38 in 
our HEU group compared to the UE group. However at both the 18 and 24 months time 
points, the mean CD8+ T lymphocyte counts were also lower in the HEU group compared to 
the UE controls. However, the children in the study by Clerici et al were not on any form of 
ARV treatment, whereas our HEU infants received a minimum of NVP shortly after birth. 
Based on these observations we expect that children born to HIV positive mothers and who 
were treatment naïve may experience increased levels of immune activation than HEU 
children exposed to PMTCT drugs. Although the benefits of ARV far outweigh the side-
effects, ARV exposure may have further disadvantages. Bunders et al (2005) has shown 
that exposure to ART in foetal and infant life is associated with long-standing effects, such 
as decreased levels of CD8 cell counts (Bunders et al., 2005a). Similarly, HEU infants in our 
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study present with decreased CD8 cell counts compared to UE infants from 12 weeks of age 
to 24 months; however these differences were not statistically significant. Importantly, the 
study presented by Bunders et al., was conducted in children of around 8 years of age. 
Further studies are required to evaluate whether this effects of ARV exposure may persist 
later in life to an extent where the differences between HEU and UE individuals would 
become significant.  
The expression of CD38 on CD8+ T cells is a strong predictor of HIV disease progression in 
combination with viral load and CD4 T cell counts. A study evaluating the levels of CD38 in 
HIV positive children showed that children with undetectable viral loads had decreased 
levels of CD38 compared to those with increased levels associated virological failure 
(Resino et al., 2004). Although the levels of CD38 expression were much higher in our HIV 
infected children compared to our HEU infants, the levels were different from those 
described by Resion et al.  HIV positive infants in our study presented with undetectable viral 
loads (but reactive HIV antibodies) at 24 months of age, which may be indicative of 
adequately suppressed viral replication. 
6.4.2 Expression of cellular markers of apoptosis on CD4+ and CD8+ T lymphocytes 
Apoptosis is a process by which cells undergo DNA degradation and subsequent death. Cell 
death is an important component of physiological processes for maintenance of immune 
homeostasis. However, in the case of HIV infection, apoptosis results in the loss of both 
infected and uninfected CD4 T cells, the pathogenesis for this continues to be unclear. Since 
vertical transmission occurs at the time of development of the immune system of the 
exposed infant, , apoptosis could be responsible for the depletion of mature and immature T 
lymphocytes (Hosaka et al., 2000). 
HIV proteins, such as gp120, nef and tat have all been described to induce cell apoptosis. 
Many studies have documented increased levels of apoptosis in HIV infected paediatric 
populations (Debatin et al., 1994, Finkel et al., 1995), but limited studies have addressed 
apoptotic characteristics in the HEU population. Importantly, it has been documented that 
HIV proteins in combination with bound antibodies may result in CD4 anergy and induce 
apoptosis without direct HIV infection of CD4+ T cells (Banda et al., 1992). 
Scruggs and Naylor (2008) suggested that mitochondrial toxicity due to the administration of 
zidovudine may lead to the reduction of mitochondrial DNA, oxidative stress and the 
reduction in L-carnitine levels. These factors collectively or individually activate the apoptotic 
pathway (Scruggs and Dirks Naylor, 2008, Blanche et al., 1999). 
It is plausible that the drug toxicities observed in HIV infected patients occur also in HEU 
individuals exposed to ARVs. HEU patients may also persist with increased apoptotic levels 
and low mitochondrial DNA numbers after the conclusion of prophylactic medication. 
We described the apoptotic characteristics by measuring the expression of death pathway 
markers on CD4+ (Fas, FasL and Annexin V) and CD8+ (FasL) T cells in both HEU and UE 
groups and found increased expression of these markers in the HEU group.  This may be a 
result of HIV exposure, increased antigenic stimulation, ARV exposure or protective 
mechanisms to HIV infection. Our HEU group showed increased levels of expression for 
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death signalling markers, Fas, FasL and the marker of early apoptosis, Annexin V on CD4+ 
T cells and an increased expression of FasL on CD8+ T cells.  
A study by Economides et al (1998) was the first to measure and compare the levels of 
apoptosis in CD4+ and CD8+ T cells of cord blood samples of HIV infected, in HEU 
individuals and UE newborns. They found that HEU newborns showed significantly 
increased apoptosis after one day of in vitro culture than those obtained from UE newborns. 
In comparison to both uninfected groups, the one HIV infected infant in the study, showed 
the highest levels of apoptosis in CD4 and CD8 lymphocytes. 
Studies have suggested that apoptosis may be as a result of immune activation (Hosaka et 
al., 2000). It has been documented that exposure to HIV increases immune activation. In the 
HIV population, a stronger correlation is observed between apoptosis and inflammation 
rather than severity of disease. In addition, studies of HIV infected adults and children show 
that apoptosis also occurs in HIV uninfected cells (Finkel et al., 1995). Other studies have 
found increased apoptosis despite immune activation (Miyamoto et al., 2010) 
To support these observations, the increased levels of apoptotic markers may be linked to 
the increased levels of activation (CD40L and CD69) previously described in our population 
of the HEU group.  
In keeping with the observations of Economides et al (1998) who found the highest level of 
apoptosis in HIV infected individuals, the HIV positive infants in our study also showed the 
highest levels of apoptotic markers (Fas and FasL) on CD4+ T cells. Although the method of 
evaluating apoptosis and sample types differed between Economides et al and our study, we 
show similar findings.  
Hosaka et al (2000), showed a correlation with an increase in soluble Fas/FasL and a 
decline in CD4 counts. In addition, they found a positive correlation with the levels of sFas 
and increase viral load indicating an association with disease progression. The same study 
evaluated these parameters in HEU infants, however found no correlation between CD4 
counts and levels of sFas/FasL.   
Apoptosis has also been described in other forms of viral infection not related to HIV. This 
may be the reason for the inconsistent trend observed in our HEU group who showed 
decreased FasL on CD8 T cells at 18 months and significantly higher expression at 24 
months. It is possible that the increased apoptotic markers seen in the HEU group may be 
due to increased exposure to a number of viral and other infections. In addition, infants in 
our HEU group had significantly higher social morbidity than their unexposed counterparts, 
which could potentially expose them to more environmental pathogens.  
As previously mentioned, exposure to antiretroviral therapy may lead to increased cell death. 
All exposed infants in our study had exposure to ARV’s either during foetal stages, shortly 
after birth or during both time periods. Although this study was not designed to address ARV 
therapy and its effects, it is clinically relevant to add to the context of HIV exposure and the 
association with immunological defects. In contrast to investigations by Scruggs and Naylor 
(2008) who suggested a potential link between increased apoptosis and ARV therapy, 
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another study (Miyamoto et al. 2010) have observed increased activation and apoptosis in 
HEU children and adolescents not exposed to ARV drugs during pregnancy or early infancy. 
Apoptosis has also been described as an immunological mechanism that may assist in 
conferring protection against HIV infection. A study by Velilla et al (2005) suggested that this 
may be supported, considering that they observed higher spontaneous apoptosis in 
monocytes in adults exposed to HIV than the control group. They also measured the in vitro 
spontaneous expression of Annexin V in response to p24 antigens on monocytes and 
PBMCs in three groups consisting of HIV exposed, HIV positive and negative individuals. As 
with the babies in our study, their results indicated that when compared to UE individuals, 
HEU individuals had a higher susceptibility to spontaneous apoptosis in both monocytes and 
PBMCs. In addition, lower p24 levels were found in monocyte cell cultures. Since monocytes 
serve as key targets for HIV infection, exploring HIV resistance by means of apoptosis 
deserves further research bearing in mind that these findings may be applicable to only a 
limited number of HEU individuals (Velilla et al., 2005). 
At 18 months of age, we measured the levels of Annexin V ex vivo and at 16 and 24 hour 
intervals as a means of evaluating levels of spontaneous apoptosis. The expression of 
Annexin V was minimal at baseline (ex vivo): similar levels were found at 18 months of age 
in both our groups. However, after the 16 hour incubation we found a significant increase in 
the levels of Annexin V in HEU infants compared to UE controls. Based on the studies by 
Velilla et al (2005), this may indicate that the CD4 T cells of HEU babies are more 
susceptible to undergoing apoptosis (Velilla et al., 2005). In contrast to these studies, we did 
not measure the expression of Annexin V in the presence of the HIV antigen. We illustrated 
susceptibility to apoptosis by incubating cells in culture medium over time. At 24 hours we 
saw a decreased level of Annexin V, indicating a saturation point of the apoptotic process 
and a subsequent uptake by phagocytes and increase in cell debris.  
At 24 months of age we found an increase in Annexin V expression in both HEU and UE 
groups after 16 hour incubation periods. This observation can be linked to an error in the 
experimental process that did not occur at the 18 months time point. After laboratory 
processing, samples were batched and stored at 4˚C until flow cytometric acquisition. We 
found that samples left for longer than two days at this temperature had increased levels of 
Annexin V expression than those that were left at a shorter period. We conclude that 
because we did not add a fixative to preserve cells, continuous expression of Annexin V had 
occurred. However, considering that our control group was also subjected to same error, we 
additionally found, in keeping with our hypothesis, that the HEU group had higher levels of 
Annexin V expression compared to the UE group.   
6.4.3 Expression of surrogate markers of immune activation on CD19+ and CD20+ B 
lymphocytes 
The in utero development of an infant of an HIV positive mother experiences an environment 
supplemented with viral constituents. In view of the fact that HIV uses CD4 T cells as its 
main targets, it may be expected that immune aberrations are mainly associated with T 
rather than B lymphocytes. Based on this hypothesis set out by Clerici et al (Clerici et al., 
2000), we aimed to explore potential differences in the B cell compartment that may exist in 
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HEU infants, given the fact that we had detected significant variation in vaccine specific 
antibodies compared to UE controls.  
We observed a significant increase in activation markers CD80 and CD69 on CD20+ and 
CD19+ B cells at 18 and 24 months of age.  
A number of B lymphocyte abnormalities have been described in HIV infection, some of 
which include polyclonal B cell activation and hypergammaglobulinemia.  In vitro studies 
have also shown that viral antigens tend to induce differentiation of B cells and have 
inhibitory effects on B cell function through the destruction of CD4+ T cell help (De Milito, 
2004). A study by Bunders et al (2010), showed persistent hypergammaglubulinemia in 
children born to HIV positive mothers. 
We propose that T cell activation, potentially due to HIV exposure, as well as the chronic 
pro-inflammatory milieu, may influence the activation of B cells. In contrast, during HIV 
infection, a decreased expression of CD80 and CD86 has been described. It is believed that 
this down-regulation may thus be responsible for the defective communication between B 
lymphocytes and CD4+ T cells (Malaspina et al. 2003). We noted however an increase in 
CD40L expressed on CD4+ T cells; we presume that this type of activation may lead to co-
stimulation of B cells in an appropriate communication between B and T cells in HEU babies. 
In addition, this may account for the increased antibody responses previously described.  
Another study evaluated the role of T and B cell interactions and its potential relationship 
with increasing HIV viral replication. They showed that CD80 down regulated p24 and TNFα 
production and did not decrease T cell proliferation. In contrast, CD86 was shown to favour 
promote the replication of HIV-1(Krzysiek et al., 1998). 
Other studies have observed changes in B lymphocytes in cord blood of HEU infants born to 
HIV positive mothers on HAART. It was further observed that these abnormalities persisted 
in HEU children up to 2 years of age that related to residual HIV-mediated immune 
abnormalities (Borges-Almeida et al., 2011). 
Our study has also observed an increase (although not significant) in the expression of 
CD10 and CD23 on CD20+ B cells. CD10 expression occurs mainly on B and T cell 
precursors and CD23 is expressed on mature B cells. Studies have shown that an increase 
in the levels of soluble markers of B cell activation, such as CD23, is associated with the 
occurrence of AIDS-associated B cell lymphomas (De Milito, 2004). Other studies have 
associated increased expression of CD10 on immature B cells with the development of 
autoimmune disorders that may be related to the ability of HIV proteins to enhance B cell 
proliferation (Malaspina et al., 2006). A study of HIV positive infants in comparison to HEU 
and control infants showed that HIV positive infants had significantly lower levels of CD23 on 
CD19 B cells compared to HEU and control infants. Also, the levels of CD10 expression was 
both higher in the HIV positive and HEU infants in comparison to the controls. In contrast to 
our findings, this study showed no expression of early activation marker CD69 on B cells in 
any population, however it is worth noticing that their HEU infants were 10 months of age 
and their control group was over 2 years of age (Rodriguez et al., 1996). 
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In comparison to UE children in our study, HEU children showed increased levels of 
expression of CD62L (function in leukocyte adhesion and homing) at 18 months of age, 
however decreased levels at 24 months of age. These differences were not significant.  
Rodriguez et al (1996), showed decreased expression of this marker in HIV positive children 
compared with exposed and controls who showed similar levels. However, CD62L was 
higher in cord blood of HIV positive infants and no differences were noted for HEU and UE 
cord blood samples (Rodriguez et al., 1996). CD62L and CD23 are expressed upon antigen 
stimulation; therefore the increase in CD62L observed at 18 months may be as a result of 
vaccination. Both HEU and UE groups showed a greater increase in CD62L expression at 
18 months in comparison to 24 months (Rodriguez et al., 1996).  
We found discrepant literature surrounding the various markers described above. Reports 
however state that, phenotypic characteristics measured by the expression of cell surface 
markers differ with age and immunological features (Rodriguez et al., 1996).  
6.4.4 Expression of markers of apoptosis on CD19+ and CD20+ B lymphocytes 
Gp120 also binds to uninfected B cells and may cause depletion through a super-antigen 
effect (Weinhold et al., 1989). Another study conducted in South Africa evaluated the 
severity of infections that exist within a group of 8 HEU infants. Researchers observed 14 
episodes of primary infection and 4 nosocomial infections. Interestingly, low CD4+ T cells 
and B-cell depletion were noticed in some of these infants (Slogrove et al., 2009). 
At 18 and 24 months of age, we observed increased levels of expression of Fas on CD20+ B 
cells in HEU infants compared to UE controls, although these differences did not reach 
statistical significance. In addition, we also found that CD20+ B cells in the HEU group 
showed a statistical trend of increased susceptibility to undergoing spontaneous apoptosis 
through the expression of early apoptotic marker Annexin V. 
Observations by Miyamoto et al (2010) similarly reported a higher percentage of B cell 
apoptosis in a group of HEU children compared to UE controls. In addition, when the HEU 
group was separated into groups who had and had not been subjected to ARV exposure 
during gestation, no significant difference was found, although there was a trend towards 
higher lymphocyte apoptosis with ARV exposure.   
As mentioned earlier, Scruggs and Naylor (2008) pointed out the consequences of ARV drug 
exposure, such as zidovudine administration leading to mitochondrial toxicity and depletion. 
Collectively these factors contribute to the induction of apoptosis in the immune system.  
The increased expression of Fas and FasL has been observed in B lymphocytes of HIV 
infected patients thus leading to increased B cell abnormalities (De Milito, 2004)  
There are only a limited number of studies relating to B cell apoptosis in the HEU population. 
Further studies are required to assess the effects of ARV exposure on B cell apoptosis.  
6.4.5 Evaluation of PD-1 expression on CD19+ B cells 
PD-1 is classified as a transmembrane protein which forms part of the immunoglobulin 
superfamily and is related to CD28 and CTLA-4 regulatory proteins. The expression of PD-1 
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on lymphocytes is generally upregulated following antigen binding of the immunoglobulin or 
T cell receptor and its expression is thought to play a role in dampening or limiting 
lymphocyte activation. Thus the expression of PD-1 mainly occurs on activated T and B cells 
and also macrophages (Agata et al., 1996).  
In the presence of PD-1, B and T cell stimulation and subsequent proliferation are 
diminished thereby facilitating decreased responses to antigen stimulation (Nishimura et al., 
1998). PD-1 has also been associated with diminished T cell function during chronic viral 
infections (Barber et al., 2006). In murine models, deficient expression of PD-1 has been 
associated with multiple autoimmune features (Freeman et al., 2000).  
The evaluation of PD-1 expression has mainly been described on T cells in the context of 
HIV infection (Kaufmann and Walker, 2009, Nakayama et al., 2011, D'Souza et al., 2007). A 
recent study evaluated the various factors that contribute to increased T cell activation and 
PD-1 expression in HIV infected children and showed that the increased expression of PD-1 
as well as increased immune activation were related more to the generalised immune 
response to HIV infection rather than specifically to the viral load (Prendergast et al., 2011). 
Another study showed an association of PD-1 expression in HIV infection with T cell 
exhaustion resulting in disease progression (Day et al., 2006). Day et al (2006) reported an 
upregulation of PD-1 on CD8+ T cells which correlated with HIV specific CD8+ T cell 
functioning and in addition, was associated with disease progression. In contrast to 
Prendergast et al (2011), this study showed a positive correlation with the expression of PD-
1 on CD4+ T cells and viral load (Day et al., 2006).  
We evaluated the expression of PD-1 on CD19+ B cells in both HEU and UE infant groups 
at 18 and 24 months of age. To our knowledge, there has been no study to date that has 
evaluated the expression of PD-1 on either T or B lymphocytes in HEU infants or children. 
We showed that the expression of this marker on CD19+ B cells was not statistically 
significant at any of the time points measured, however at 24 months of age, the levels in the 
HEU group were higher than those of the UE group. We speculated therefore that the 
expression of PD-1 is related to the increased expression of cellular activation marker CD69 
on CD19+ B cells and may serve to control or regulate lymphocyte proliferation in response 
to antigenic stimuli. In addition, we found that the expression of PD-1 was decreased in HEU 
infants at 18 months of age which was likely to correspond to the levels of CD69 which were 
also decreased. 
Although PD-1 has been shown to play a role in the regulation of B cell survival in the murine 
model (Nishimura et al., 1998), the knowledge of its role during HIV infection is limited. A 
recent study conducted with Rhesus macaques aimed to investigate the function of the PD-1 
pathway in B cell dysfunction during SIV infection using both in vitro and in vivo experimental 
approaches (Titanji et al., 2010). Researchers of this study found that the highest expression 
of PD-1 occurred mainly on activated memory B cells when compared with the other B cell 
subsets measured. The increased expression of PD-1 on activated memory B cells may 
relate to their intrinsic nature of having the lowest threshold of activation and thus would 
require intense regulation. The fact that their study did not find a loss in activated memory B 
cells expressing PD-1, may relate to the role of these cells in preventing rapid disease 
progression (Titanji et al., 2010). Titanji et al further postulated that individuals with 
increased activated memory B cells may be at risk for rapid disease progression.  
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The findings of the latter study therefore prompted further studies to evaluate PD-1 
expression on B cells as potential predictors of disease progression in human HIV infected 
populations. Furthermore, the study highlighted that the expression of PD-1 on activated 
memory B cells may represent the host response to preventing rapid disease progression. 
Although we did not find a significant difference between HEU and UE groups for the 
expression of PD-1 on CD19+ B cells, we postulated that higher levels may be related to a 
regulatory mechanism and may play a role in preventing autoimmunity.  
6.4.6 Evaluation of cellular markers of B cell memory 
CD27 is important in regulating interactions between B and T lymphocytes and is also 
critically involved in the process of B cell differentiation and antibody production (De Milto 
2004). More importantly, CD27 is a well described marker of B cell memory, which is an 
element in adaptive immunity and the response to vaccination (Carsetti and Tozzi, 2009).  
In adaptive immunity, the importance of serological protection emerges after the exposure to 
pathogens or immunisation. Impairment of the humoral immune response in terms of 
responding to vaccination is a common feature in the HIV infected population. Decreased 
responses to important vaccinations, such as pneumococcus, tetanus and Hib have been 
reported along with decreased memory pools (Hart et al., 2007). In the HIV infected 
population, studies have suggested that memory B cell sub-populations may be a better 
predictor for the risk of being susceptible to diseases, such as pneumococcus (D'Orsogna et 
al., 2007).  
We found that the HEU group had similar expression of CD27 on both CD20 and CD19 B 
cells compared to UE controls. In support of our findings, Miyamoto et al (2010) also found 
the expression of CD27 to be similar in both control and HEU groups. This observation is in 
contrast to the patterns observed during HIV infection. The adequate expression of CD27 in 
the HEU group serves well in the process of responding to immunisation and may explain 
the vaccine-specific robust responses observed in this cohort. Further studies are required to 
address whether these levels of protection will persist in years to come following future 
encounters with specific pathogens.  
Although memory B cells are generally characterised by the expression of cellular surface 
marker CD27, it has also been described as a cell marker linked to B cell activation and 
differentiation. In the context of HIV infection, such characteristics are prominent thus 
according to Moir and Fauci do not represent true memory. It is therefore recommended that 
cellular markers such as CD21 that differentiate between resting memory (CD21hi) and 
activated or differentiated (CD21lo) subpopulations B cells, should be included when 
evaluating B cell memory in the context of HIV. In addition, other features that are observed 
in HIV patients with high viral load is the fact that B cells undergo terminal differentiation 
which leads to the loss of expression of CD20 and are further characterised by decreased 
levels of CD19. Due to this, the levels between patients with high viral loads are similar to 
that of HIV negative patients. In addition, the number of B cells that express CD27 remain 
low during ARV treatment and it is further suggested that ARV treatment may prevent the 
loss of memory B cells (Moir and Fauci, 2008). Based on these observations and 
suggestions, the same principles could be followed when evaluating memory B cell 
expression in HEU infants and children. Furthermore, early ARV exposure in these infants 
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may have contributed to preserving the memory B cell compartment, thus leading to similar 
levels as the UE group.  Perhaps it would also be worth evaluating memory B cell 
characteristics in early infancy where immune activation would be more prominent.  
6.5 SUMMARY AND CONCLUSION: CELLULAR BIOMARKERS 
We observed that HEU infants show variability in the expression of certain markers of 
activation, regulation and apoptosis compared to UE controls on both T and B cell 
populations at 18 and 24 months of age. We showed that HEU infants have increased 
expression of certain markers on both T and B cell compartments; however these 
observations proved to be greater in variance on the T cells. This may be indicative of long-
term effects of either in utero exposure to HIV or possibly exposure to ARV drugs during 
foetal development and early infancy. It is possible that the upregulation of certain markers is 
due to frequent pathogen exposure, based on the differences of social morbidity in the HEU 
cohort, (which results in the up regulation upon repeated encounters with infectious agents), 
in addition to the effects of exposure to an HIV infected mother.  
Although we do not have evidence for the expression of these markers in early infancy, we 
can speculate based on observations of other studies that the effects of HIV exposure 
seems to be continue through to childhood and these children can be distinguished 
immunologically from control individuals even after the period of vulnerability to infection. It is 
therefore not appropriate to classify HEU children with immunologically normal controls.  
A number of studies have alluded to impairments of both CD4+ and CD8+ T lymphocyte 
subsets in early infancy that continue into adolescent years. These observations raise 
concerns that these children may be more susceptible to infection and autoimmune 
conditions.   
We have also observed similar expression of surrogate markers of B cell memory in HEU 
infants in comparison to UE controls. However, further observations are required to 
determine if the same levels persist or decay over time.  
These findings highlight the need for further studies and evaluation of the clinical 
implications related to these observations in the HEU population that seems to be increasing 
in number and age.  
6.6 STUDY LIMITATIONS AND FUTURE RECOMMENDATIONS 
A major limitation of this study was the relatively small sample size of our study population 
that may have influenced the statistical outcomes of the analyses. Despite this we were able 
to observe significant trends in some of the questions we raised. However, further larger 
longitudinal studies are required to confirm our findings.  
We alluded to the presumed maternal antibody transfer in infants.  It would have been of 
greater advantage to measure the levels of specific antibody in the maternal source in order 
to determine the levels of circulating antibodies. In future, it would also be of great value to 
measure the maternal total IgG levels as a marker of disease progression, which could be 
related to the degree of transfer of antibodies to the infant.  
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As this study formed part of a larger cohort study, the primary hypothesis was not to address 
the adaptive immune response of HEU infants, but rather to assess the innate immune 
response. This was thought to be the major contributing factor to the infectious morbidity in 
early life. As a result of this, we did not originally have a standardised method of collecting 
vaccination data and ensuring the receipt of immunisation in infants. Therefore, a large 
proportion of infants were excluded due to non-timely administration of vaccination. Not only 
does this prompt a greater intervention to ensure vaccination in larger studies, but also 
serves to highlight the lack of awareness surrounding immunisation as a preventative tool for 
contracting disease. It would appear that vaccination education would benefit less educated 
communities.  
Owing to the delay in the implementation of the pneumococcal vaccination, a large number 
of infants in our study did not receive the prescribed dosages. The small proportion that 
received the vaccination did not complete the schedule. Thus, we were unable to document 
a response to the pneumococcal vaccination in relation to HIV exposure.  
Based on the findings observed with HEU infant response to vaccination, future studies 
addressing the functionality of these antibodies will ensure better understanding of the 
correlates of protection for vaccine responses. 
To our knowledge this is the only first longitudinal study that evaluates the influence of 
maternal HIV infection in the first 2 years of life.  
A number of limitations with the evaluation of cellular immune biomarkers are also 
acknowledged. We only evaluated these markers at 18 and 24 months and can therefore not 
relate these findings with the expression in early infancy. As a result, we are unable to 
comment on whether the levels of immune activation decreased with age. There is also 
minimal literature on some of these markers, therefore limiting the comparable nature of our 
findings.  
The flow-cytometric analyses for the evaluation of CD38 expression were determined using 
quadrant gates. This may have resulted in inadequate analyses, due to the “dribble-over” 
effect often noted with CD38 cell populations. For future studies, CD38 populations would 
best be represented or quantified using the mean fluorescence intensity (MFI) of which 
accuracy will be valid by using standardised quality controls such as Quantibrite™ beads. 
Similarly to the accurate flow-cytometric analysis for CD38 quantification, CD127 populations 
are not best represented using quadrant gates. For future studies, it is recommended that 
CD127 be characterised as negative, low or high rather than just present or absent. CD127 
is generally expressed on Tregs and thus, Tregs that express FOXP3 have been shown to 
lie in the CD127 low population subset. Therefore, the accurate representation of CD127 
should be shown as a percentage of total CD4 populations.  
Although this study merely aimed to evaluate and observe the levels of expression for 
various cellular markers of immune activation and apoptosis, the direct question of whether 
immune activation correlated with cell death was not addressed. For prospective studies it 
would be of interest to include a flow cytometric panel of both markers of activation and 
apoptosis (e.g. CD69 and Annexin V) after in vitro cell activation with a suitable stimulant.   
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The assessment of the immune regulatory properties of T and B cells were evaluated by 
measuring the cellular expression of specific cellular regulatory markers such as CTLA-4 
and CD127 on CD4+T cells as well as PD-1 on CD19+B cells. Although these markers are 
not extensively evaluated in HEU populations, they are often described during HIV infection 
thus making them ideal for evaluating immune regulation during HIV exposure. Other 
markers of immune regulation such as FOXP3 would serve valuable markers for future 
research. 
Lastly, our infant groups (HEU and UE) were not from similar social backgrounds or ethnic 
groups. These serve as confounding factors for the immunological differences found 
between HEU and UE infants. Due to HEU infants originating from a background of high 
social morbidity, the upregulation of immune markers of activation and apoptosis may be 
due to constant environmental antigenic exposure.  
Furthermore, it has been documented that differences in haematologic parameters are 
related to ethnicity (Lisse et al., 1997). Therefore, it would be of value to match cohorts in 
terms of ethnicity and social backgrounds in order to have comparable data. With that said, 
obtaining matching populations are extremely difficult in a setting where the burden of HIV 
resides in particular groups.  
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CHAPTER 7 
CONCLUSION 
 
This study aimed to evaluate characteristics of the adaptive immune system with the 
proposed hypothesis that HEU infants display different features to those of UE controls.  
Our pilot study longitudinally evaluated and described specific antibody levels in infants born 
to HIV infected and uninfected mothers from 2 weeks to 2 years of age before and after 
routine vaccinations as outlined by the EPI-SA.  
We concluded that infants born to HIV infected mothers received significantly less, and in 
addition, non-protective levels of maternally derived antibodies to specific pathogens. 
Although UE control infants had higher levels of maternally derived antibodies, we showed 
that a large proportion of these antibodies were also not considered protective.  
Larger prospective studies are required to confirm these findings as potential contributing 
factors to increased infectious morbidity in HEU infants. Based on the findings of this pilot 
work we suggest that a targeted vaccine approach be considered in HIV infected women 
and exposed infants. This study also highlighted the need to address re-vaccination of 
adolescents and women of child bearing age to increase their own levels and also the 
transfer of maternal antibodies; however the potential effect of interference of maternal 
antibodies with the infant’s vaccination response has to be evaluated carefully. Therefore, 
the timing and dosage need to be defined. Protective levels for a range of routine childhood 
vaccines, as well as correlates of protection within the South African setting of HIV exposure 
are required.  
We showed that HEU babies mount robust responses to certain vaccine antigens. We 
concluded that this may be due to the lack of maternal competing antibodies or alternatively 
due to the influence of HIV on B cell activation (polyclonal activation), alternatively via 
indirect T cell activation. The functionality of these antibodies and the ability to clear infection 
needs to be investigated. 
In addition, we highlighted that a significant proportion of infants did not receive their 
vaccination according to schedule. A number of vulnerable infants in both HEU and UE 
groups in our cohort did not receive PCV7 according to maternal questionnaire despite a 
relatively high coverage documented. There is also a need to clearly define the levels of 
protection in combination with functionality. Furthermore, assays should be designed more 
effectively to address specific serotypes of PCVs, due to the fact that serotype prevalence 
differs amongst various population groups. 
This pilot study also evaluated the expression of cellular markers of immune activation, 
regulation and apoptosis in both T and B cell compartments of the immune system at 18 and 
24 months of age, after the vulnerable phase for infection which was documented in the first 
6 months of life. We hypothesised that HIV exposure during foetal development adaptive 
immune responses that are different to those infants born to HIV uninfected mothers and 
persist after infancy.  
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We demonstrated that HEU babies displayed increased levels of immune activation and 
apoptosis mainly of the T cell compartment even at 2 years subsequent to in utero exposure. 
Immune activation of the B cells may represent stimulation by T cell interaction. Our 
evaluation is however limited to later time points of infant development and we were unable 
to compare the levels of immune activation prior to 18 and 24 months. We concluded that 
the increased immune activation and apoptosis in HEU infants may either be related to 
persistent activation that may be attributable to prior HIV exposure or due to more rapid 
upregulation in response to excess antigen stimulation of their environment.  
Although these findings could be consistent with a differently primed immune system, larger 
studies are required to confirm these observations in relation to the clinical outcomes and to 
further assess whether these differences persist into later childhood. A confounding factor in 
this study was difference of social background between our two groups. We observed that 
HEU infants came from a more socially disadvantaged environment that may be contributing 
to chronic immune stimulation. 
The implications and consequences of the immunological differences described in this study 
are unknown. Larger cohort studies are required to confirm whether HIV negative children of 
HIV positive mothers are at increased risk of serious infections and whether they suffer long 
lasting impairment of their immune systems. Early priming of their immune systems may in 
fact “equip” HEU infants to upregulate mechanisms of defence long term; however concerns 
are raised about the development of autoimmunity also. Further studies of HEU individuals 
will assist in defining the immunological changes related to exposure and also re-exposure 
to HIV and assist in structuring a more holistic and successful care of children infected with 
and affected by HIV 
HEU infants are ideal candidates for evaluating appropriate models for effective clearance of 
the HIV virus. This study population not only provides insight into immune mechanisms of 
response to HIV exposure but it may serve as a potential study model that is classified as 
being “vaccinated” against HIV.  
“There are data to support the notion that, among infants exposed to HIV in utero, at least 
one-third develop seemingly protective cellular immune responses bodes well for 
development of effective vaccines that could be used among infants.”  
(Kuhn et al., 2002) 
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ADDENDUM B: Ethical approval for extension of larger pilot study (June 2009) 
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